Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

WORLD PATENTS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATIONS PUBLISHED IN 2011



Publication No.: WO2011000063A1  Published: 06/Jan/2011

Title: AQUEOUS SOLUTION OF MULTICOMPONENT INCLUSION COMPOUNDS COMPRISING GENTAMICIN AND IRON IL LACTATE IN CY CLODEXTRINS, PROCESS FOR THE MANUFACTURE THEREOF, USE, METHOD OF THE IMMUNIZATION AND GOOD HEALTH OF DOMESTIC ANIMALS, KIT, AND PHARMACEUTICAL COMP

Applicant/Assignee: SCHERING PLOUGH SAUDE ANIMAL INDUSTRIA E

Application No.: BR2009/000190   Filing Date: 29/Jun/2009

Abstract:The present invention relates to a pharmaceutical composition, as a new aqueous solution, for oral administration of an aminoglycoside antibiotic, a donor of biochemical iron, a drug delivery system and a pharmaceutically acceptable acid or buffer. The present invention also refers to the process for the manufacture of said aqueous solution, the use of the aminogly coside antibiotic, the donor of biochemical iron, the drug delivery system and the pharmaceutically acceptable acid or buffer for preparing the aqueous solution, to the method of the immunization and good health of domestic animals and to the kit comprising the aqueous solution and instructions for using it.

Priority:

Inventor: SENGES LINO ANTONIO CARLOS [BR]


Publication No.: WO2011000095A1  Published: 06/Jan/2011

Title: MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF

Applicant/Assignee: ANGIOCHEM INC

Application No.: CA2010/001014   Filing Date: 30/Jun/2010

Abstract:The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.

Priority: US20090222785P Applic. Date: 2009-07-02; US20090252024P Applic. Date: 2009-10-15

Inventor: DEMEULE MICHEL [CA]; CHE CHRISTIAN [CA]; THIOT CARINE [CA]


Publication No.: WO2011000106A1  Published: 06/Jan/2011

Title: IMPROVED CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS

Applicant/Assignee: PROTIVA BIOTHERAPEUTICS, INC

Application No.: CA2010/001029   Filing Date: 30/Jun/2010

Abstract:The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Priority: US20090222462P Applic. Date: 2009-07-01; US20100295134P Applic. Date: 2010-01-14

Inventor: HEYES JAMES [CA]; PALMER LORNE [CA]; MASLOWSKI MAGDALENA [CA]; MACLACHLAN IAN [CA]


Publication No.: WO2011000108A1  Published: 06/Jan/2011

Title: COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B

Applicant/Assignee: PROTIVA BIOTHERAPEUTICS, INC

Application No.: CA2010/001031   Filing Date: 30/Jun/2010

Abstract:The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Priority: US20090222464P Applic. Date: 2009-07-01; US20100351275P Applic. Date: 2010-06-03

Inventor: LEE AMY C H [CA]; JUDGE ADAM [CA]; ROBBINS MARJORIE [CA]; YAWORSKI ED [CA]; MACLACHLAN IAN [CA]


Publication No.: WO2011000126A1  Published: 06/Jan/2011

Title: PHARMACEUTICAL COMPOSITION OF LIPOSOLUBLE DRUGS, PREPARATION METHOD AND USE THEREOF

Applicant/Assignee:

Application No.: CN2009/000725   Filing Date: 29/Jun/2009

Abstract:A composition of liposoluble drugs, the preparation method and use therof are disclosed. The composition comprises an effective amount of liposoluble drugs, hydrophilic or water-miscible macromolecular materials, hydrophobic macromolecular materials and nonionic surfactants having HLB of 10-20. The composition also comprises a co-stabilizer, such as ethylene glycol monoethyl ether and fatty acid macrogolglyceride.

Priority:

Inventor: LIU YU [CN]


Publication No.: WO2011000208A1  Published: 06/Jan/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING DIMETHICONE/ SIMETHICONE

Applicant/Assignee:

Application No.: CN2010/000857   Filing Date: 13/Jun/2010

Abstract:The present invention provides a pharmaceutical composition containing dimethicone/simethicone, mainly prepared from the following raw materials of portion by weight: acetylcysteine or pharmaceutically acceptable salts thereof 1-1000 portion and dimethicone or simethicone 1-500 portion. The composition can be prepared to form various kinds of pharmaceutically acceptable formulations. The composition can be used as an auxiliary medicine administrated before the gastrointestinal endoscopy and treatment or imaging examination. Compared with using acetylcysteine, dimethicone or simethicone alone at the same dosage, the composition of the present invention has stronger effects of defoaming and eliminating mucus.

Priority: CN20091104243 Applic. Date: 2009-07-03

Inventor: WANG GUOHUA [CN]


Publication No.: WO2011000210A1  Published: 06/Jan/2011

Title: COMPOSITION OF PERMEATION ENHANCER AND USE THEREOF IN TRANSDERMAL DRUG DELIVERY SYSTEM

Applicant/Assignee: RUNBIO BIOTECH CO., LTD

Application No.: CN2010/000935   Filing Date: 24/Jun/2010

Abstract:A permeation enhancer and its use in the transdermal drug delivery system. The permeation enhancer comprises ethers and alcohols which are not C6-C18 fatty alcohols. It may further contains C6-C18 fatty acids or C6-C18 fatty alcohols. The ether compound is selected from dimethyl isosorbide, diethylene glycol monoethyl ether or diethylene glycol monomethyl ether. The alcohol compound is selected from propylene glycol, polyethylene glycol or benzyl alcohol. The permeation enhancer does not comprise DMSO.

Priority: CN20091149880 Applic. Date: 2009-07-01

Inventor: YANG MINGJING [CN]; ZHENG HUIYI [CN]


Publication No.: WO2011000489A2  Published: 06/Jan/2011

Title: NOVEL ESTERS, AND USE THEREOF

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: EP2010/003713   Filing Date: 19/Jun/2010

Abstract:The invention relates to esters of general formula (I) R1-C(=O)-O-R2, (1) where R1 represents a linear alkyl radical comprising 7 to 9 C atoms, R2 represents a linear alkyl radical comprising 9 to 10 C atoms

or (2) where R1 represents a linear alkyl radical comprising 8 to 9 C atoms and R2 represents a linear alkyl radical comprising 8 C atoms

or (3) where R1 represents a linear alkyl radical comprising 7 to 9 C atoms and R2 represents a linear alkyl radical comprising 7 atoms

or (4) where R1 represents an alkyl radical comprising 7 or 8 C atoms and R2 represents an alkyl radical comprising 9 C atoms, under the provision that if R1 represents a linear alkyl radical, R2 represents a branched alkyl radical, or if R1 represents a branched alkyl radical, R2 represents a linear alkyl radical

or (5) where R1 represents an alkyl radical comprising 8 C atoms and R2 represents an alkyl radical comprising 8 C atoms, under the provision that if R1 represents a linear alkyl radical, R2 represents a branched alkyl radical or if R1 represents a branched alkyl radical, R2 represents a linear alkyl radical

or n-octyl-i-octanoic acid ester, n-decyl-i-octanoic acid ester, n-decyl-i-nonanoic acid ester, i-nonyl-n-decanoic acid ester, n-heptyl-n-dodecanoic acid ester, i-nonyl-i-octanoic acid ester.

Priority: DE200910031280 Applic. Date: 2009-06-30; EP20090010268 Applic. Date: 2009-08-08; DE200910055869 Applic. Date: 2009-11-26

Inventor: KAWA ROLF [DE]; BRUENING STEFAN [DE]; MAURER STEFANIE [DE]


Publication No.: WO2011000889A1  Published: 06/Jan/2011

Title: TOPICAL VACCINE FORMULATIONS AND METHODS OF TREATING DRUG ADDICTION USING SAME

Applicant/Assignee:

Application No.: EP2010/059318   Filing Date: 30/Jun/2010

Abstract:Provided herein are topical hapten-carrier conjugate formulations comprising a hapten-carrier conjugate, a lipid, and a surfactant, and uses thereof for the treatment of drug addiction.

Priority: US20090221812P Applic. Date: 2009-06-30

Inventor: HENRY WILLIAM [GB]


Publication No.: WO2011000958A1  Published: 06/Jan/2011

Title: COMPOUNDS TARGETING THE CATION-INDEPENDENT MANNOSE 6-PHOSPHATE RECEPTOR

Applicant/Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -, UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES

Application No.: EP2010/059507   Filing Date: 02/Jul/2010

Abstract:The invention relates to conjugates of products of interest and of compounds targeting the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies.

Priority: EP20090305647 Applic. Date: 2009-07-03

Inventor: GARCIA MARCEL [FR]; MORERE ALAIN [FR]; GARY-BOBO MAGALI [FR]; CERUTTI MARTINE [FR]; EL CHEIKH KHALED [FR]; BASILE ILARIA [FR]; NIRDE PHILIPPE [FR]


Publication No.: WO2011001276A1  Published: 06/Jan/2011

Title: IMMUNOCYTOKINES IN COMBINATION WITH ANTI-ERBB ANTIBODIES FOR THE TREATMENT OF CANCER

Applicant/Assignee: PHILOGEN S.P.A

Application No.: IB2010/001629   Filing Date: 25/Jun/2010

Abstract:This invention relates to the treatment of cancer using anti-ErbB antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.

Priority: US20090221925P Applic. Date: 2009-06-30

Inventor: MANUELA KASPAR [CH]; TRACHSEL EVELINE [CH]


Publication No.: WO2011001440A1  Published: 06/Jan/2011

Title: PHARMACEUTICAL COMPOSITIONS OF VALSARTAN

Applicant/Assignee: HETERO RESEARCH FOUNDATION

Application No.: IN2009/000376   Filing Date: 03/Jul/2009

Abstract:The present invention relates to the stable pharmaceutical composition comprising valsartan or a pharmaceutically acceptable salt thereof with mannitol as a filler and povidone as binder. The present invention also relate to the valsartan or pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or amlodipine or both

and optionally one or more additional excipients.

Priority:

Inventor: PARTHASARADHI REDDY BANDI [IN]; SRINIVAS REDDY MALE [IN]; VENKATESWAR REDDY POTHIREDDY [IN]; VANAJA KUMARI MUPPIDI [IN]


Publication No.: WO2011001634A1  Published: 06/Jan/2011

Title: METHOD FOR IMPROVING BIOAVAILABILITY OF LATANOPROST

Applicant/Assignee: SANTEN PHARMACEUTICAL CO., LTD

Application No.: JP2010/004179   Filing Date: 23/Jun/2010

Abstract:The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic amine, and to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment.

Priority: EP20090397519 Applic. Date: 2009-06-30

Inventor: REUNAMAKI TIMO [FI]; TERVO PAULA [FI]; LOKKILA JUKKA [FI]; PELLINEN PERTTI [FI]; ALAJUUMA PAIVI [FI]; OKSALA OLLI [FI]


Publication No.: WO2011001657A1  Published: 06/Jan/2011

Title: POLYIONIC DENDRIMER AND HYDROGEL COMPRISING SAME

Applicant/Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY

Application No.: JP2010/004267   Filing Date: 28/Jun/2010

Abstract:Provided is a hydrogel which comprises water as the main component at a high water content and has mechanical strength suitable for practical use and which exhibits high transparency and self-healing and shape-retaining properties. Also provided are both a material for the hydrogel and a novel polyionic dendrimer. A polyionic dendrimer which comprises a hydrophilic linear polymer as the core and polyester dendrons attached to both terminals of the linear polymer and in which cationic groups are bonded to the surfaces of the dendrons, said cationic groups being selected from the group consisting of guanidine group, thiourea group, and isothiourea group

a material for a hydrogel, which comprises the polyionic dendrimer and clay

and a hydrogel prepared using the material.

Priority: JP20090156670 Applic. Date: 2009-07-01

Inventor: MYNAR JUSTIN [US]; AIDA TAKUZO [JP]


Publication No.: WO2011001780A1  Published: 06/Jan/2011

Title: METHOD FOR PRODUCING LIPOSOMES BY TWO-STAGE EMULSIFICATION METHOD USING OUTER AQUEOUS PHASE CONTAINING SPECIFIC DISPERSING AGENT, METHOD FOR PRODUCING LIPOSOME DISPERSION OR DRY POWDER THEREOF USING THE METHOD FOR PRODUCING LIPOSOMES, AND LIPOSOME DI

Applicant/Assignee: KONICA MINOLTA HOLDINGS, INC

Application No.: JP2010/059371   Filing Date: 02/Jun/2010

Abstract:Disclosed is a method for producing liposomes, a liposome dispersion or a dry powder thereof by a two-stage emulsification method using an additive (dispersing agent) whereby a liposome dispersion and a dry powder thereof, which ensure the prevention of the leakage of an encapsulated drug or the like from liposomes during prolonged storage and can be stably used over a long period of time, can be obtained. A method for producing liposomes by a two-stage emulsification method, characterized by using, in the secondary emulsification step, an outer aqueous phase containing a dispersing agent (hereinafter referred to as "a specific dispersing agent") which forms no molecular self-assembly or exclusively forms molecular self-assemblies having a volume-average particle diameter equal to or less than 10 nm

and a method for producing a liposome dispersion and a dry powder thereof using the aforesaid production method. The aforesaid specific dispersing agent preferably contains at least one component selected from among, for example, gelatin, albumin, dextran and a polyalkylene oxide-based compound.

Priority: JP20090157626 Applic. Date: 2009-07-02

Inventor: MOTOKUI YASUYUKI [JP]; WADA TAKESHI [JP]; ISODA TAKESHI [JP]


Publication No.: WO2011001869A1  Published: 06/Jan/2011

Title: METHOD FOR PRODUCING NANOSPHERES, NANOSPHERES, EXTERNAL COMPOSITION FOR SKIN CONTAINING SAME, AND COSMETIC PREPARATION

Applicant/Assignee: SHALOM CO., LTD, SCHOOL CORPORATION KANSAI UNIVERSITY

Application No.: JP2010/060630   Filing Date: 23/Jun/2010

Abstract:Disclosed is a method for producing nanospheres, by which fine polymer particles that internally contain either a hydrophilic substance and/or a hydrophobic substance and have a particle diameter of nano order can be produced. In the method for producing nanospheres, a solvent in which either a hydrophilic substance and/or a hydrophobic substance is dissolved, a water-immiscible organic solvent in which an amphiphilic polymer is dissolved, and a water-immiscible organic solvent in which a hydrophobic polymer is dissolved are mixed together, then the thus-obtained primary solution is irradiated with an ultrasonic wave, thereby forming a primary emulsion, then an aqueous solvent in which a hydrophilic polymer is dissolved is added into the primary emulsion, thereby forming a secondary solution, and then the secondary solution is irradiated with an ultrasonic wave, thereby forming a secondary emulsion.

Priority: JP20090157496 Applic. Date: 2009-07-02

Inventor: KON TATSUHIKO [JP]; OHYA YUICHI [JP]; MINAMIGAKI SATOSHI [JP]


Publication No.: WO2011001951A1  Published: 06/Jan/2011

Title: OPHTHALMIC COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: JP2010/061005   Filing Date: 29/Jun/2010

Abstract:Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed oil, sunflower oil, purified lanolin and gel hydrocarbon.

Priority: JP20090154862 Applic. Date: 2009-06-30

Inventor: ODAKA AKITO [JP]; INOUE CHIEKO [JP]; HATTORI MANABU [JP]; TABUCHI NOBUHITO [JP]


Publication No.: WO2011002034A1  Published: 06/Jan/2011

Title: NEEDLE-LIKE MATERIAL

Applicant/Assignee: TOPPAN PRINTING CO., LTD, HISAMITSU PHARMACEUTICAL CO., INC

Application No.: JP2010/061181   Filing Date: 30/Jun/2010

Abstract:A needle-like material comprising a support (23) and protrusions (22) extending from the support (23), wherein each of the protrusions (22) is composed of a material comprising pectin and an alginate.

Priority: JP20090156661 Applic. Date: 2009-07-01

Inventor: KATO HIROYUKI [JP]


Publication No.: WO2011002077A1  Published: 06/Jan/2011

Title: TNF-? GENE THERAPY AGENT CONTAINED IN POLYMERIC MICELLE

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: JP2010/061312   Filing Date: 02/Jul/2010

Abstract:Disclosed is a gene delivery system or the like, which is useful for treatment of intractable cancers including pancreatic cancer and peritoneal dissemination. Specifically disclosed is a pharmaceutical composition contained in a polymeric micelle, said pharmaceutical composition containing an expression plasmid for TNF-a as an active ingredient. The expression plasmid is composed of one of the following block polymers: (1) a block copolymer which has a hydrophilic segment that is composed of a polyethylene glycol or a derivative thereof and a polycationic segment that is composed of a polypeptide

or (2) a block copolymer which has a hydrophilic segment that is composed of a polyethylene glycol or a derivative thereof and a polycationic segment that is composed of a polypeptide, with the hydrophilic segment and the polycationic segment being bonded by a disulfide bond.

Priority: JP20090158282 Applic. Date: 2009-07-02

Inventor: NAKANO KENJI [JP]; KATAOKA KAZUNORI [JP]; NISHIYAMA NOBUHIRO [JP]


Publication No.: WO2011002852A2  Published: 06/Jan/2011

Title: PRO-DRUG COMPLEXES AND RELATED METHODS OF USE

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: US2010/040546   Filing Date: 30/Jun/2010

Abstract:The present invention provides methods, compositions and applications for efficient, site-specific drug delivery using pro-drug complexes comprising therapeutic agents and one or more functional groups (e.g., imaging agents, targeting agents, and trigger agents). In particular, the present invention relates to pro-drug complexes comprising one or more functional groups conjugated with a therapeutic agent (e.g., a chemotherapeutic agent), methods of synthesizing the same, as well as systems and methods utilizing the therapeutic and diagnostic compositions (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.)).

Priority: US20090221596P Applic. Date: 2009-06-30

Inventor: BAKER JR JAMES R [US]; HUANG BAOHUA M [US]; THOMAS THOMMEY P [US]


Publication No.: WO2011003155A1  Published: 13/Jan/2011

Title: BIOPOLYMER HYBRID GEL-DEPOT DELIVERY SYSTEM

Applicant/Assignee: POLYMERS CRC LIMITED

Application No.: AU2010/000883   Filing Date: 09/Jul/2010

Abstract:The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein

a biocompatible phosphate and/or sulphonamide compound

a biologically active agent

an aqueous insoluble alkaline earth metal phosphate

and a biocompatible glycan and/or proteoglycan.

Priority: AU20090903213 Applic. Date: 2009-07-09

Inventor: MAINWARING DAVID EDWARD [AU]; AL KOBAISI MOHAMMAD [AU]; CHUA BRENDON YEW LOONG [AU]; JACKSON DAVID CHARLES [AU]; ZENG WEIGUANG [AU]


Publication No.: WO2011003172A1  Published: 13/Jan/2011

Title: CONTROLLED NITRIC OXIDE DELIVERY FROM AQUEOUS S-NITROSOTHIOL CONJUGATED POLYMERS AND THEIR COMPLEXES

Applicant/Assignee: UNIVERSITY OF TORONTO

Application No.: CA2010/000270   Filing Date: 26/Feb/2010

Abstract:A method of making an aqueous solution of a bio-adhesive, supramacromoIecular nitric oxide generatable polymer complex of the general formula (I): wherein R1 is independently selected from the group consisting of an alkane unsubstituted or substituted with alkoxy groups

R2 is independently selected from the group consisting of C 1-6 alkyl

R3 and R4 are independently selected from the group consisting of optionally substituted aliphatic or aromatic alkyl

W is a hydrogen-bond accepting ftractional group-containing entity

Y is a carboxylic acid ester or amide linkage

R is independently selected peptide linking group

T1, T2, T3 and T4 are independently selected polymer residues

and m1, m2, m3, n1, and n2 are integers greater than 25

and wherein P has a molecular weight of about 1 x 103 to 1 x 107 and Q has a molecular weight of about 1 x 103to 1 x 107

the method comprising (a) covalently linking a S-nitrosothiol compound having an amino linking group with a bio-adhesive, hydrophobic polyanhydride compound to form a nitric oxide donor polymeric conjugate carrier

comprising (i) treating the polyanhydride compound dissolved in an aprotic solvent with an aqueous solution of said S-nitrosothiol compound for an effective period of time and protected from light

(ii) removing the aprotic solvent to produce an essentially aqueous solution of the conjugate carrier

and (b) mixing the solution of the conjugate carrier with an intermolecular hydrogen bond acceptable polymer to produce an aqueous solution of the complex. Solutions are to be used in the treatment of healing wounds. Also provided is the polymeric conjugate carrier for use in the treatment of healing wounds through the release of nitric oxide. The invention is also of value through use of photo irradiation of the conjugate carrier and complex containing systems, to enhance the healing of skin wounds.

Priority: CA20092671595 Applic. Date: 2009-07-09

Inventor: LEE PING I [CA]; LI YAN [CN]


Publication No.: WO2011003240A1  Published: 13/Jan/2011

Title: FORMULATION COMPRISING TERPOLYMER AND ACTIVE SUBSTANCE, AND PREPARATION THEREOF

Applicant/Assignee: BASF (CHINA) COMPANY LIMITED, BASF SE

Application No.: CN2009/072723   Filing Date: 10/Jul/2009

Abstract:A formulation comprising a terpolymer and an active substance and the producing process thereof are disclosed. Said terpolymer comprises 17-60 wt.% of the main chain segment, 20-56 wt.% of the hydrophobic pendent chains, and 20-40 wt.% hydrophilic pendent chains, based on the total weight of the terpolymer. The main chain segment is formed from the monomer which is selected from (meth)acrylic acid, vinyl benzene sulfonic acid or N-isopropyl acrylamide. The hydrophobic pendent chain is derived from hydrophobic vinyl, such as alkyl (meth)acrylate, styrene and/or vinyl acetate. The hydrophilic pendent chain is derived from monomer which is selected from (polyethylene glycol monomethylether) acrylate, acrylamide, vinylpyrrolidone, or N,N-dimethylacrylamide.

Priority:

Inventor: WU QI [CN]; HE WEIDONG [CN]; DREHER JING [DE]; KARDORFF UWE [DE]; ZHANG GUANGZHAO [CN]


Publication No.: WO2011003430A1  Published: 13/Jan/2011

Title: LIQUID PHARMACEUTICAL FORM OF ALKYLPHOSPHOCHOLINE AND METHOD OF PREPARING SAME

Applicant/Assignee: EXPERGEN DRUG DEVELOPMENT GMBH

Application No.: EP2009/004984   Filing Date: 09/Jul/2009

Abstract:The inventions relates to a liquid pharmaceutical form containing an active ingredient alkylphosphocholines and a co-solvent system. The co-solvent system is mixture from hexylene glycol, propylene glycol, diethylene glycol monoethyl ether and water. The pharmaceutical form having a pH value in the range of 4 to 6, which if it is necessary can be achieved by adding a pH adjuster. The composition has a good storage stability and it is suitable for local application on the different organs of the body. The inventions relates also to a method for producing the same pharmaceutical form.

Priority:

Inventor: MENG PAUL [AT]


Publication No.: WO2011003557A1  Published: 13/Jan/2011

Title: A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: EP2010/004051   Filing Date: 05/Jul/2010

Abstract:The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Priority: EP20090164612 Applic. Date: 2009-07-06

Inventor: BRINKMANN ULRICH [DE]; CROASDALE REBECCA [DE]; DORMEYER WILMA [DE]; GEORGES GUY [DE]; HAAS ALEXANDER [DE]; HOFFMANN EIKE [DE]; METZ SILKE [DE]; MUNDIGL OLAF [DE]; SCHEUER WERNER [DE]; STRACKE JAN OLAF [DE]


Publication No.: WO2011003622A1  Published: 13/Jan/2011

Title: METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS

Applicant/Assignee: ABLYNX N.V

Application No.: EP2010/004196   Filing Date: 09/Jul/2010

Abstract:The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.

Priority: US20090270613P Applic. Date: 2009-07-10

Inventor: STALS HILDE [BE]; DE BRABANDERE VERONIQUE [BE]; SCHOTTE PETER [BE]


Publication No.: WO2011003633A1  Published: 13/Jan/2011

Title: PEGYLATED L-ASPARAGINASE

Applicant/Assignee: ALIZE PHARMA II

Application No.: EP2010/054156   Filing Date: 30/Mar/2010

Abstract:Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.

Priority: US20090223320P Applic. Date: 2009-07-06

Inventor: ABRIBAT THIERRY [FR]


Publication No.: WO2011003766A1  Published: 13/Jan/2011

Title: BIODEGRADABLE COPOLYMER COMPRISING AMYLOPECTIN OR GLYCOGEN SUITABLE FOR DELIVERING NUCLEIC ACID MATERIALS INTO CELLS

Applicant/Assignee: UNIVERSITY OF ROSTOCK

Application No.: EP2010/059134   Filing Date: 28/Jun/2010

Abstract:The invention is related to a biodegradable copolymer, which is suitable for delivering nucleic acid materials into cells, and which comprises a amylopectin or glycogen and at least one cationic polymer or cationic monomer having amino functions, which is bound to the amylopectin or glycogen by ester linkage between at least one free hydroxyl group of the amylopectin or glycogen and at least one amino group of the cationic polymer or cationic monomer forming an -O-C=O-NH- bond. The biodegradable copolymer is capable of delivering nucleic acid molecules into the cells in a high efficient way with extremely low cytotoxicity.

Priority: EP20090164764 Applic. Date: 2009-07-07

Inventor: WANG WEIWEI [DE]; LI WENZHONG [DE]; MA NAN [DE]; STEINHOFF GUSTAV [DE]


Publication No.: WO2011003780A1  Published: 13/Jan/2011

Title: BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES

Applicant/Assignee: F. HOFFMANN-LA ROCHE AG

Application No.: EP2010/059243   Filing Date: 30/Jun/2010

Abstract:This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof.

Priority: EP20090164612 Applic. Date: 2009-07-06

Inventor: BRAMLAGE BIRGIT [DE]; BRINKMANN ULRICH [DE]; CROASDALE REBECCA [DE]; DILL SIMONE [DE]; DORMEYER WILMA [DE]; GEORGES GUY [DE]; GROTE MICHAEL [DE]; HAAS ALEXANDER [DE]; HOFFMANN EIKE [DE]; ICKENSTEIN LUDGER MARKUS [DE]; JAHN-HOFMANN KERSTIN [DE]; JOHN MATTHIAS [DE]; METZ SILKE [DE]; MUNDIGL OLAF [DE]; SCHEUER WERNER [DE]; STRACKE JAN OLAF [DE]


Publication No.: WO2011003822A2  Published: 13/Jan/2011

Title: INSULIN PREPARATIONS CONTAINING METHIONINE

Applicant/Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH

Application No.: EP2010/059436   Filing Date: 02/Jul/2010

Abstract:The invention relates to an aqueous pharmaceutical formulation having insulin, an insulin analog, or an insulin derivative, and methionine

and to the production thereof, to the use thereof for treating diabetes mellitus, and to a medication for treating diabetes mellitus.

Priority: DE200910031748 Applic. Date: 2009-07-06; US20090264356P Applic. Date: 2009-11-25; DE201010013134 Applic. Date: 2010-03-27

Inventor: SCHOETTLE ISABELL [DE]; HAGENDORF ANNIKA [DE]; FUERST CHRISTIANE [DE]; HAUCK GERRIT [DE]; SIEFKE-HENZLER VERENA [DE]; KAMM WALTER [DE]; SCHNIEDERS JULIA [DE]


Publication No.: WO2011003858A2  Published: 13/Jan/2011

Title: PHARMACEUTICAL COMPOSITIONS AND SOLID FORMS

Applicant/Assignee: NOVARTIS AG

Application No.: EP2010/059553   Filing Date: 05/Jul/2010

Abstract:The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl- pyrimidin-4-yloxy)-naphthalene-1-carboxyfic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthatene-1-carboxylic acid (3-trifluoromethyI- phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1- carboxylic acid (3-trifluoromethyi-phenyi)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates to specific forms of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-paphthalene-1- carboxyiic acid (3-trifluaromethyl-phenyl)-amide and to the manufacturing and use of such forms.

The present invention also relates to a new process to produce 6-{6-hydroxymethyl- pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide.

Priority: US20090223269P Applic. Date: 2009-07-06

Inventor: BERGHAUSEN JOERG [CH]; HAUG CLAIRE [CH]; HERBIG MICHAEL [CH]; HU BIN [US]; JONAT STEPHANE [CH]; LELETI RAJENDER [US]; MEINGASSNER JOSEF GOTTFRIED [AT]; MONNIER STEPHANIE [FR]; NAPP MATTHIAS [CH]; PRASHAD MAHAVIR [US]; STUETZ ANTON [AT]; THAKUR RANJIT [CH]


Publication No.: WO2011003886A1  Published: 13/Jan/2011

Title: PEGYLATED L-ASPARAGINASE

Applicant/Assignee: ALIZE PHARMA II

Application No.: EP2010/059599   Filing Date: 06/Jul/2010

Abstract:Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.

Priority: US20090223320P Applic. Date: 2009-07-06; WO2010EP54156 Applic. Date: 2010-03-30

Inventor: ABRIBAT THIERRY [FR]


Publication No.: WO2011004010A1  Published: 13/Jan/2011

Title: SOLID LINEAR OLIGO-OR POLY-E-CAPROLACTONE DERIVATIVES

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: EP2010/059901   Filing Date: 09/Jul/2010

Abstract:The present invention relates to linear oligo- or poly-e-caprolactones di-blockcopolymers, in solid form at room temperature, comprising monoalkyl oligoethyleneglycol residues. The present invention further relates to a drug delivery formulation comprising above materials and a process for the preparation of the drug delivery formulation. The oligoethyleneglycol residues are preferably selected from the group consisting of methyl diethylene glycol, methyl triethyleneglycol or methyl tetraethylene glycol. The oligo- or poly-e-caprolactone derivatives are prepared via the reaction of mono-hydroxy-oligoethyleneglycol with e-caprolactone, whereby the mono-hydroxy-oligoethyleneglycol acts as an initiator.

Priority: EP20090165069 Applic. Date: 2009-07-09; WO2010EP54518 Applic. Date: 2010-04-06

Inventor: MIHOV GEORGE [NL]; DRAAISMA GUY [NL]


Publication No.: WO2011004117A1  Published: 13/Jan/2011

Title: METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TRANS-BUCCAL MUCOSA TREATMENT OF POSTPRANDIAL HYPERGLYCAEMIA IN TYPE II DIABETES

Applicant/Assignee:

Application No.: FR2010/051426   Filing Date: 07/Jul/2010

Abstract:The subject matter of the invention is a method and a pharmaceutical composition in the form of an aqueous-alcoholic solution in which at least one hypoglycaemic/insulinotropic active ingredient is stably and completely dissolved, at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for trans-buccal mucosa application in the short-term treatment of postprandial hypoglycaemia in type II diabetes in humans or animals. The invention also relates to a method for preparing this formulation and to the specific use thereof for the short-term treatment of postprandial hypoglycaemia (PPH) in the context of type II diabetes.

Priority: FR20090054819 Applic. Date: 2009-07-10

Inventor: PEROVITCH PHILIPPE [FR]; MAURY MARC [FR]; DUMONTEIX JEAN-PIERRE [FR]


Publication No.: WO2011004293A1  Published: 13/Jan/2011

Title: METHOD FOR PREPARING POLYMERIZED LIPID CONSTRUCTS, RESULTING POLYMERIZED LIPID CONSTRUCTS, AND USES THEREOF FOR ENCAPSULATING ACTIVE AGENTS

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Application No.: IB2010/053022   Filing Date: 01/Jul/2010

Abstract:The present invention relates to a method for preparing polymerized lipid constructs (PLC), characterized in that said method includes the following steps: (a) contacting nanotubes with a lipid solution, said lipids comprising one or two fatty carbon chains, each comprising 6 to 60 carbon atoms and a photopolymerizable dialkyne (-C=C-C=C-) group, said fatty chain(s) being bonded to a neutral or charged hydrophilic polar head

(b) adsorbing the lipids around the nanotubes, said adsorption being carried out by strong sonication or agitation

(c) polymerizing the lipids adsorbed around the nanotubes, said polymerization being carried out by ultraviolet irradiation

then, optionally recovering, by purification, the polymerized lipids around the nanotubes

(e) desorbing the polymerized lipids around the nanotubes through sonication or extraction, said extraction being a cold or hot extraction

and (f) recovering the polymerized lipids thus disassembled from the nanotubes, also known as polymerized lipid constructs (PLC). The invention also relates to the use of PLCs for the application thereof to the encapsulation of cosmetic or pharmaceutical active agents.

Priority: FR20090003321 Applic. Date: 2009-07-06

Inventor: WAGNER ALAIN [FR]; MEUNIER STEPHANE [FR]; THAUVIN CEDRIC [FR]; MORERE ALEXANDRE [FR]


Publication No.: WO2011004379A1  Published: 13/Jan/2011

Title: COMPOSITIONS AND METHODS FOR TREATING CANCER

Applicant/Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD

Application No.: IL2010/000554   Filing Date: 08/Jul/2010

Abstract:A method of killing a cancer cell expressing NCAM and optionally FZD7 is provided. The method comprising contacting the cancer cell with a cytotoxic moiety and an NCAM targeting moiety, thereby killing the cancer cell.

Priority: US20090213757P Applic. Date: 2009-07-10

Inventor: DEKEL BENJAMIN [IL]; PODE-SHAKKED NAOMI [IL]; KESHET GILMOR IRIS [IL]


Publication No.: WO2011004395A1  Published: 13/Jan/2011

Title: MICROEMULSION FORMULATION FOR BIOLOGICALS

Applicant/Assignee: INTAS BIOPHARMACEUTICALS LIMITED

Application No.: IN2010/000447   Filing Date: 02/Jul/2010

Abstract:The present invention provides a stable water-in-oil microemulsion pharmaceutical formulation comprising a continuous oil phase and a dispersed aqueous phase containing a biological. The microemulsion formulation of the present invention is stable under refrigerated conditions, have acceptable organo-leptic properties and improve the absorption of biologicals through mucous membrane.

Priority: IN2009MU01600 Applic. Date: 2009-07-06

Inventor: MODY RUSTOM SORAB [IN]; GUPTA AJAY KUMAR [IN]; PAUL SUMITA [IN]


Publication No.: WO2011004398A2  Published: 13/Jan/2011

Title: PRESERVATIVES FROM CHITIN DERIVATIVES

Applicant/Assignee: CAMLIN FINE CHEMICALS LIMITED

Application No.: IN2010/000458   Filing Date: 07/Jul/2010

Abstract:The invention comprises a process for producing a chitosan derivative, and a product prepared thereby, by activating chitosan or a chitosan precursor chitin in alcohol that contains water from 0% to maximum of about 30% and preparing derivatives by reacting with a reagent to get derivatives that have various uses including an antimicrobial, or a microbiostatic, or an antitranspirant, or an antifungal, or a fruit preservative properties or as carrier of active molecules or functional groups etc. or a combination thereof. Illustrated derivatives include acid, succinic, enzymatically deaceylated, enzymatically hydrolysed by chitinolysis, sugar, formaldehyde, phosphoric acid, hydrochloric acid and copper sulfate derivatives that are obtained by reaction individually or in a combination of consecutive reactions.

A novel class of thermostable proteo-chitinase is also disclosed prepared from Aspergillus niger MTCC 5572 that has molecular weight on SDS PAGE of about 50 Kilo Daltons and optimum hydrolytic activity at pH 2 and 80 DEG C. Compositions for treatments of natural products and methods for retarding ageing, improvement of shelf life and retarding microbiological spoilage of banana and other fruits are also disclosed.

Priority: IN2009MU01605 Applic. Date: 2009-07-07; IN2010MU01643 Applic. Date: 2010-05-28

Inventor: SHENDYE ABHAY PARASHURAM [IN]


Publication No.: WO2011004552A1  Published: 13/Jan/2011

Title: WATER-SOLUBLE DRUG CARRIER AND PROCESS FOR PRODUCTION THEREOF

Applicant/Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Application No.: JP2010/004021   Filing Date: 16/Jun/2010

Abstract:Disclosed are: a drug delivery carrier which has no concern about the leakage of a drug therefrom, can control particle sizes thereof easily, is widely applicable even to drugs other than drugs that do not have high anionic properties, besides water-soluble drugs, can deliver water-soluble substances such as genes and proteins, and can be used as a non-viral gene vector

and a process for producing the drug delivery carrier. The drug delivery carrier is characterized in that a water-soluble drug are double-coated with two types of surfactants 1 and 2. The drug delivery carrier can be produced by a process comprising the steps of: 1) mixing an aqueous phase containing the water-soluble drug with an oily phase containing the surfactant 1 while agitating to form a W/O emulsion in which the aqueous phase containing the water-soluble drug is dispersed in the oily phase

2) removing the inner aqueous phase from the W/O emulsion to form an S/O in which a complex of the water-soluble drug and the surfactant 1 is dispersed in the oily phase

3) mixing the S/O with an aqueous phase containing the surfactant 2 while agitating to form an S/O/W emulsion in which the S/O is dispersed in the aqueous phase

and 4) removing the inner oily phase from the S/O/W emulsion to form an S/W in which a complex of the water-soluble drug, the surfactant 1 and the surfactant 2 is dispersed in the aqueous phase.

Priority: US20090224171P Applic. Date: 2009-07-09

Inventor: GOTO MASAHIRO [JP]; KAMIYA NORIHO [JP]; TAHARA YOSHIRO [JP]


Publication No.: WO2011004799A1  Published: 13/Jan/2011

Title: TABLET HAVING HOLLOW STRUCTURE

Applicant/Assignee: KYORIN PHARMACEUTICAL CO., LTD

Application No.: JP2010/061430   Filing Date: 05/Jul/2010

Abstract:Disclosed is a tablet which has a hollow structure that has a cavity in the central portion, and which contains at least one excipient selected from among sugar alcohols, sugars, cellulose derivatives and starches, and a component having a hydrophobic effect. The tablet is floatable on water.

Priority: JP20090159804 Applic. Date: 2009-07-06; JP20090251715 Applic. Date: 2009-11-02

Inventor: FUKUDA MAMORU; GOTO AKINORI


Publication No.: WO2011005098A1  Published: 13/Jan/2011

Title: PEPTIDE LIGANDS FOR TARGETING TO THE BLOOD-BRAIN BARRIER

Applicant/Assignee: ABBOTT HEALTHCARE PRODUCTS B.V, UNIVERSITEIT LEIDEN, UNIVERSITEIT UTRECHT HOLDING B.V

Application No.: NL2010/050448   Filing Date: 12/Jul/2010

Abstract:The present invention relates to peptides comprising defined amino acid sequences, compositions comprising said peptides and a pharmaceutically acceptable substance, use of said peptides as a central nervous system targeting principle in the treatment, prophylaxis or diagnosis of a central nervous system disorders, combinations of said peptides with pharmaceutically acceptable substances, use of said combinations for the treatment, prophylaxis or diagnosis of a central nervous system disorders, a method of delivery of said peptide and of a pharmaceutically acceptable substance and a nucleic acid sequence encoding for said peptide sequence.

Priority: EP20090165239 Applic. Date: 2009-07-10

Inventor: VAN ROOY INGE [NL]; HENNINK WILHELMUS EVERHARDUS [NL]; MASTROBATTISTA ENRICO [NL]; SCHIFFELERS RAYMOND MICHEL [NL]; DINTER-HEIDORN HEIKE [DE]; BRINKHUIS RENE PASCAL [NL]; VAN HEST JAN [NL]; RUTJES FLORIS PETER JOHANNES THEODORUS [NL]


Publication No.: WO2011005113A1  Published: 13/Jan/2011

Title: COMPOSITION COMPRISING BIOACTIVE AMINO ACIDS AND/OR PEPTIDES AND MARINE OIL IN A STABLE OIL-IN-WATER EMULSION, AND THE USE OF SAID COMPOSITION AS A FUNCTIONAL OR THERAPEUTIC COMPOSITION

Applicant/Assignee: SMARTFISH AS

Application No.: NO2010/000271   Filing Date: 06/Jul/2010

Abstract:The present invention relates to food supplements. Particularly, the present invention relates to a composition comprising marine oil in a stable oil-in-water emulsion, further comprising at least one specific bioactive amino acid or peptide, or derivatives thereof. In addition, the present invention relates to a process for the production of said composition and the use of said composition as a functional or therapeutic composition.

Priority: NO20090002564 Applic. Date: 2009-07-06

Inventor: MATHISEN JANNE SANDE [NO]; MATHISEN HENRIK [NO]


Publication No.: WO2011005270A1  Published: 13/Jan/2011

Title: PERACID/PEROXIDE COMPOSITION, PROCESS FOR ACCURATELY MAKING THE SAME, AND METHOD FOR USE AS AN EVAPORATING FILM ANTI-MICROBIAL SOLUTION AND AS A PHOTOSENSITIZER

Applicant/Assignee:

Application No.: US2009/057695   Filing Date: 21/Sep/2009

Abstract:A method is provided for the microbicidal treatment of a surface such as sanitization, disinfection, sterilization, and decontamination of a surface or object by use of an anti-microbial composition comprising an aqueous solution of peracetic acid and hydrogen peroxide with acetic acid, water soluble polymer containing lactam, and phosphate ester surfactant and little or no stabilizer, and according to the method enhanced microbicidal efficacy is obtained when the composition is applied onto a surface as a thin film wetting the surface so that a shorter contact time for a desired fractional reduction in microbial population is obtained Still further, the compositions comprise photosensitizer for light-activated anti-microbial efficacy.

Priority: US2009-459777 Applic. Date: 2009-07-08

Inventor: GOLDEN JEFFRY [US]; BRISTER PAUL [US]; STADER JOAN [US]; MARTIN CHARLES [US]


Publication No.: WO2011005540A1  Published: 13/Jan/2011

Title: METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS

Applicant/Assignee: BURNHAM INSTITUTE FOR MEDICAL RESEARCH

Application No.: US2010/039539   Filing Date: 22/Jun/2010

Abstract:Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

Priority: US20090219086P Applic. Date: 2009-06-22; US20090249140P Applic. Date: 2009-10-06

Inventor: RUOSLAHTI ERKKI [US]; TEESALU TAMBET [US]; SUGAHARA KAZUKI [US]


Publication No.: WO2011005636A1  Published: 13/Jan/2011

Title: TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS

Applicant/Assignee: MERCK SHARP & DOHME CORP

Application No.: US2010/040704   Filing Date: 01/Jul/2010

Abstract:The present invention is directed to tetrahydronapthyridine and tetrahydropyridopyrazine compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Priority: US20090224314P Applic. Date: 2009-07-09

Inventor: MERCER SWATI P [US]; ROECKER ANTHONY J [US]


Publication No.: WO2011005646A2  Published: 13/Jan/2011

Title: PHARMACEUTICAL COMPOSITION FOR A HEPATITIS C VIRAL PROTEASE INHIBITOR

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: US2010/040734   Filing Date: 01/Jul/2010

Abstract:Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants.

Priority: US20090223507P Applic. Date: 2009-07-07

Inventor: CHEN FENG-JING [US]; SCHWABE ROBERT J [US]


Publication No.: WO2011005756A1  Published: 13/Jan/2011

Title: DELIVERY OF AGENTS TARGETED TO MICROBIOTA NICHES

Applicant/Assignee: PURETECH VENTURES, LLC

Application No.: US2010/041060   Filing Date: 06/Jul/2010

Abstract:Methods for delivery of therapeutic, prophylactic, and diagnostic agents to an animal host, wherein the delivery of the agent is targeted at a bacterial niche present in the host, have been developed. In particular, delivery systems capable of selectively targeting or selectively avoiding bacterial niches, wherein the bacterial niches are identified by the functional role they serve in the host environment, such as metabolism of sugars, amino acids, or xenobiotics, or by their colonization of a given anatomical location of the host, such as the oral cavity, the gut, or the skin, are described. Use of the compositions results in an alteration of a host's microbial composition associated with a condition, a disease state, or a higher risk for a condition or disease.

Priority: US20090223266P Applic. Date: 2009-07-06

Inventor: OLLE BERNAT [US]; PUTNAM DAVID AARON [US]; BEHR JONATHAN ROBERT [US]; MARTUCCI W EDWARD [US]


Publication No.: WO2011005850A1  Published: 13/Jan/2011

Title: LIPIDIC COMPOSITIONS FOR INDUCTION OF IMMUNE TOLERANCE

Applicant/Assignee: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

Application No.: US2010/041196   Filing Date: 07/Jul/2010

Abstract:This invention provides a method for inducing immune tolerance toward an antigen comprising the antigen in lipidic particles or lipidic compositions. The lipidic particles are made up of phosphatidylserine and phosphatidylcholine, or phosphatidylinositol and phosphatidylcholine. The lipidic compositions comprise the antigen and O-phospho-L- serine. Administration of these composition results in inducing immune tolerance to the antigen.

Priority: US20090223521P Applic. Date: 2009-07-07

Inventor: BALU-IYER SATHY V [US]; GAITONDE PUNEET RAJEEV [US]; BANKERT RICHARD [US]


Publication No.: WO2011005853A2  Published: 13/Jan/2011

Title: COMPOSITIONS AND METHODS OF TOPICAL DRUG DELIVERY FOR THE TREATMENT OF CARPAL TUNNEL SYNDROME

Applicant/Assignee: MSK PHARMA, LLC

Application No.: US2010/041199   Filing Date: 07/Jul/2010

Abstract:The present invention generally relates to transdermal drug delivery systems. More particularly, the present invention provides compositions and transdermal drug delivery systems for the treatment and/or relief of symptoms associated with carpal tunnel syndrome or tendonitis.

Priority: US20090223975P Applic. Date: 2009-07-08

Inventor: QIU YONG [US]; KUO JAMES S [US]; KUO GERALDINE P [US]; CHIANG CHIN-CHIH [US]; CHEN PAUL R [US]


Publication No.: WO2011005864A2  Published: 13/Jan/2011

Title: ETHYLENEOXIDE BUTYLENEOXIDE BLOCK COPOLYMER COMPOSITIONS

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: US2010/041218   Filing Date: 07/Jul/2010

Abstract:The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated.

Priority: US20090223599P Applic. Date: 2009-07-07

Inventor: DAVIS JAMES W [US]; KETELSON HOWARD ALLEN [US]; MEADOWS DAVID L [US]


Publication No.: WO2011006029A1  Published: 13/Jan/2011

Title: ARTIFICIAL CELL CONSTRUCTS FOR INDUCING IMMUNOLOGICAL TOLERANCE

Applicant/Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Application No.: US2010/041463   Filing Date: 09/Jul/2010

Abstract:The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.

Priority: US20090224571P Applic. Date: 2009-07-10

Inventor: LITTLE STEVEN R [US]


Publication No.: WO2011006453A1  Published: 20/Jan/2011

Title: COMPOUND LIPID BASED ON PENTAERYTHRITOL, INTERMEDIATES, PREPARATION METHOD AND USE THEREOF

Applicant/Assignee: HARBIN INSTITUTE OF TECHNOLOGY

Application No.: CN2010/075269   Filing Date: 19/Jul/2010

Abstract:Disclosed are compound lipid based on pentaerythritol, intermediates, preparation method and use thereof. The said lipid is prepared by nucleophilic substitution reaction. The lipid has uniform sizes, good stability, and silicate network structure on the surface. The method has simple technology and is suitable for industrialization.

Priority: CN20091072538 Applic. Date: 2009-07-17; CN20091073423 Applic. Date: 2009-12-15; CN20101222232 Applic. Date: 2010-07-09; CN20101222238 Applic. Date: 2010-07-09; CN20101224640 Applic. Date: 2010-07-13

Inventor: DAI ZHIFEI [CN]; LIANG XIAOLONG [CN]; YUE XIULI [CN]


Publication No.: WO2011006504A2  Published: 20/Jan/2011

Title: TREATMENT OF HYPERPROLIFERATIVE CONDITIONS

Applicant/Assignee: VALDERM APS

Application No.: DK2010/050179   Filing Date: 08/Jul/2010

Abstract:The present invention relates to stable pharmaceutical formulations comprising a solubilized lipophilic anthracycline and the uses thereof in the treatment of clinical conditions, wherein hyperproliferation, such as epithelial hyperproliferation, is a primary factor of the pathogenesis. The pharmaceutical compositions comprises i) a lipophilic anthracycline

ii) one or more oil phase carriers

iii) one or more pharmaceutical acceptable solubilizers

iv) one or more co-surfactants

and the composition further comprises an aqueous phase comprising at least one buffering system having a pH from about pH 2.2 to about pH 6, wherein the water content of the pharmaceutical composition is less than 30%.

Priority: DK20090000874 Applic. Date: 2009-07-17

Inventor: BYMOSE BJARNE [DK]; DE DARKO ELISABETH [DK]; HYLDGAARD JOERGEN [DK]; BROWN MARC BARRY [GB]; LIM SIAN TIONG [GB]; BECK PETRA HELGA [GB]; GRIFFITH HANNAH MARY TALBOT [GB]


Publication No.: WO2011006510A1  Published: 20/Jan/2011

Title: LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES

Applicant/Assignee: TECHNICAL UNIVERSITY OF DENMARK, RIGSHOSPITALET

Application No.: DK2010/050192   Filing Date: 16/Jul/2010

Abstract:The present invention relates to a novel composition and method for loading delivery systems such as liposome compositions with radionuclides useful in targeted diagnostic and/or therapy of target site, such as cancerous tissue and, in general, pathological conditions associated with leaky blood vessels. The composition and methods of the invention find particular use in diagnosing and imaging cancerous tissue and, in general, pathological conditions associated with leaky blood vessels in a subject. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. One specific aspect of the invention is directed to a method of producing nanoparticles with desired targeting properties for diagnostic and/or radio-therapeutic applications.

Priority: DK20090000879 Applic. Date: 2009-07-17; US20100300782P Applic. Date: 2010-02-02; EP20100152394 Applic. Date: 2010-02-02

Inventor: PETERSEN ANNCATRINE LUISA [DK]; HEDENGRAN RASMUSSEN PALLE [DK]; ROSAGER HENRIKSEN JONAS [DK]; KJAER ANDREAS [DK]; ANDRESEN THOMAS LARS [DK]


Publication No.: WO2011006596A2  Published: 20/Jan/2011

Title: AQUEOUS SOLUTION AND GELATINIZED COMPOSITION COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR AND CORRESPONDING METHODS AND USE

Applicant/Assignee: RATIOPHARM GMBH

Application No.: EP2010/004058   Filing Date: 05/Jul/2010

Abstract:The invention relates to aqueous solutions and gelatinized compositions of a phosphodiesterase-5 inhibitor, preferably tadalafil, to methods for producing the same and to corresponding medicaments, and to the use of gelatin to improve the solubility of a phosphodiesterase-5 inhibitor in water.

Priority: DE200910033396 Applic. Date: 2009-07-16

Inventor: RIMKUS KATRIN [DE]; HOLFINGER KONSTANTIN [DE]


Publication No.: WO2011007148A1  Published: 20/Jan/2011

Title: IMPROVED CONJUGATION METHOD

Applicant/Assignee: POLYTHERICS LIMITED

Application No.: GB2010/001356   Filing Date: 15/Jul/2010

Abstract:A process for the conjugation of a polymer to a protein, which comprises reacting a polymeric conjugating agent with said protein, in an aqueous medium, in the presence of an amphipathic sugar polymer. The process is particularly useful when conjugating PEG to proteins, particularly to proteins which have previously proved difficult to PEGylate in acceptable yields, for example INF-ss.

Priority: GB20090012485 Applic. Date: 2009-07-17

Inventor: CHOI JI-WON [GB]; GODWIN ANTHONY [GB]; PAWLISZ ESTERA [GB]


Publication No.: WO2011007153A1  Published: 20/Jan/2011

Title: IMPROVEMENTS IN AND RELATING TO COLON CLEANSING COMPOSITIONS

Applicant/Assignee: NORGINE BV

Application No.: GB2010/001362   Filing Date: 16/Jul/2010

Abstract:The invention provides a dry composition for admixture with water, wherein the composition is optionally presented in two or more parts and comprises, per litre of solution to be made, the following components: (a) 85 to 115 g polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500

(b) 6 to 9 g sodium sulphate

(c) 2 to 3 g sodium chloride

(d) 0.5 to 1.5 g potassium chloride

(e) 5 to 15 g of an organic acid component

and (f) orange flavouring. Also provided are solutions, kits, unit doses and methods that comprise or use the compositions.

Priority: GB20090012487 Applic. Date: 2009-07-17; US20100305814P Applic. Date: 2010-02-18

Inventor: ATTWELL MARK [GB]; COCKETT ALASTAIR [GB]; COX IAN [GB]; GRANGER JANET [GB]; OZA PANKAJ [GB]; PADFIELD DAWN [GB]; PADFIELD NICK [GB]


Publication No.: WO2011007208A1  Published: 20/Jan/2011

Title: COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

Applicant/Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Application No.: IB2009/054210   Filing Date: 16/Jul/2009

Abstract:The present invention relates to a pharmaceutical composition comprising: a) at least one iron uptake inhibitor, and b) at least one vitamin D and/or at least one analog thereof and/or at least one vitamin D receptor modulator, and optionally a pharmaceutically acceptable carrier.

Priority:

Inventor: CRUZ MOURA IVAN [FR]


Publication No.: WO2011007327A2  Published: 20/Jan/2011

Title: SUSPENSION FOR THERAPEUTIC USE AND DEVICE FOR DELIVERING SAID SUSPENSION

Applicant/Assignee: KONINKLIJKE PHILIPS ELECTRONICS N.V

Application No.: IB2010/053229   Filing Date: 15/Jul/2010

Abstract:The invention provides a suspension for therapeutic use comprising a fluid dispersion medium, particles that are dispersed in the fluid dispersion medium, and a gelling agent, wherein the particles comprise an amorphous and chemically inert matrix in which a drug is dispersed, and wherein the gelling agent is present in an amount in the range of from 0.01-10 % by weight, based on total suspension. Further, a drug delivery device is provided which comprises a reservoir comprising the suspension and a means for releasing a discrete amount of the suspension from the drug delivery device. In addition, the invention relates to a method for preparing the suspension and the use of the suspension and the drug delivery device for the treatment and/or prevention of a disease.

Priority: EP20090165668 Applic. Date: 2009-07-16

Inventor: VAN BRUGGEN MICHEL PAUL BARBARA [NL]; DE LAAT ANTONIUS WILHELMUS MARIA [NL]


Publication No.: WO2011007454A1  Published: 20/Jan/2011

Title: CHITOSAN HYDROGEL DERIVATIVES AS A COATING AGENT WITH BROAD SPECTRUM OF ANTIMICROBIAL ACTIVITIES

Applicant/Assignee: MENICON CO., LTD, NANYANG TECHNOLOGICAL UNIVERSITY

Application No.: JP2009/063013   Filing Date: 13/Jul/2009

Abstract:The present invention relates to water soluble quaternized chitosan derivatives which from hydrogel matrix with broad antimicrobial properties for the protection and coating of medical device. In order to achieve hydrogel formation, quaternized chitosan can be grafted with polymerizable groups, especially photocrosslinkable groups, such as methacrylates, PEG derivatives and be converted into hydrogels through a thermal or UV polymerization process. Hydrogels are hydrated cross-linked polymeric systems that contain water in an equilibrium state forming cushion water shield. The present invention is widely used in many medical devices for example biomedical devices such as contact lenses, bio-implants. This invention describes the formation of novel hydrogels based on quaternized ammonium chitosan derivatives which has been grafted with photocrosslinkable groups, hence providing hydrogels as antimicrobial water shield coating agent.

Priority:

Inventor: BEE ENG MARY CHAN [SG]; YIN FUN POON [SG]; LAMRANI MOUAD [FR]; HAMAGUCHI SHINICHI [JP]


Publication No.: WO2011007794A1  Published: 20/Jan/2011

Title: ZEOLITE AND SERICITE-CONTAINING COMPOSITION FOR MEDICAL OR MEDICAL ASSISTING USES

Applicant/Assignee: RAPAS CORPORATION

Application No.: JP2010/061879   Filing Date: 14/Jul/2010

Abstract:The present invention is directed to improve the usefulness of zeolite and sericite in various medical fields. To achieve this purpose, a composition for medical or medical assisting uses, which contains zeolite and sericite, is provided based on, as the most important characteristic, the finding that zeolite and sericite can exert a synergistic effect when used in combination. It is confirmed that the aforesaid composition containing zeolite and sericite exerts an advantageous synergistic effect in the following cases. When externally applied, the aforesaid composition is particularly efficacious in, for example, treating skin itching, sore and pain caused by burn injury, skin diseases, miliaria, etc., atopic dermatitis, cut, scratch, nail slipping, inflammatory diseases, sunburn inflammation, muscle fragmentation, muscular pain, contusion, bruise, sprain, athlete's foot, urticaria and cancerous pain, as a substitute for ice in cooling, as an additive to hair dyes and perming agents for preventing itching and sore, and so on. When orally administered, the aforesaid composition is particularly efficacious in, for example, healing bronchitis, asthma, stomach ulcer, duodenal ulcer, gastritis, stomatitis, chronic gastritis, periodontal disease, chronic liver disease, pollen allergy, oral dysodia, cancer, etc., overcoming fatigue and exhaustion, and so on.

Priority: JP20090168531 Applic. Date: 2009-07-17; JP20090235118 Applic. Date: 2009-10-09; JP20090270208 Applic. Date: 2009-11-27

Inventor: ISHIDUKA HIROKO [JP]


Publication No.: WO2011007795A1  Published: 20/Jan/2011

Title: COMPOSITION FOR INHIBITING THE EXPRESSION OF TARGET GENE

Applicant/Assignee: KYOWA HAKKO KIRIN CO., LTD

Application No.: JP2010/061884   Filing Date: 14/Jul/2010

Abstract:Disclosed are: a composition comprising a double-stranded nucleic acid molecule and a liposome in which the double-stranded nucleic acid molecule is encapsulated

and others. In the composition, the double-stranded nucleic acid molecule comprises an antisense strand and a sense strand, wherein the antisense strand is a polynucleotide which contains a nucleotide sequence complementary to a sequence composed of contiguous 17 nucleotides contained in mRNA for a target gene and which has a length of 17 to 30 nucleotides, the sense strand is a polynucleotide which contains a nucleotide sequence complementary to a sequence lying between the 1st nucleotide and the 17th nucleotide numbered from the 5'-terminal toward the 3'-terminal in the antisense strand and which has a length of 17 to 30 nucleotides, each of sugars respectively bound to a nucleotide located at a specific position in the antisense strand and a nucleotide located at a specific position in the sense strand is a deoxyribose or a ribose in which a hydroxy group at position-2' is substituted by a modifying group, and the deoxyribose and the ribose are contained at a specific ratio. In the composition, the liposome has a lipid bilayer membrane comprising a lipid derivative, fatty acid derivative or aliphatic hydrocarbon derivative of a water-soluble substance as a component.

Priority: JP20090165320 Applic. Date: 2009-07-14; JP20100022534 Applic. Date: 2010-02-03

Inventor: SHINOHARA FUMIKAZU; YOSHIDA TETSUO; SUGISHITA HIROKO; NAOI TOMOYUKI; ISHII TOSHIHIKO; ENOKIZONO JUNICHI


Publication No.: WO2011007824A1  Published: 20/Jan/2011

Title: ANTITUMOR COMPOSITION AND METHOD FOR TREATING TUMORS

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: JP2010/061958   Filing Date: 15/Jul/2010

Abstract:Disclosed is an antitumor composition which has an extremely remarkable permeation or accumulation effect with respect to tumors that are present in an ischemic or thick fibrotic environment (for example, intractable cancers such as pancreatic cancer, and diffuse or undifferentiated gastric cancer). Specifically disclosed is an antitumor composition which contains an antitumor agent and a polymer that forms a coordination complex together with the antitumor agent. The coordination complexes form micelles having an average size with a diameter of 40 nm or less.

Priority: US20090225716P Applic. Date: 2009-07-15

Inventor: KATAOKA KAZUNORI [JP]; NISHIYAMA NOBUHIRO [JP]; CABRAL HORACIO [JP]; KANO MITSUNOBU [JP]


Publication No.: WO2011007838A1  Published: 20/Jan/2011

Title: BENZIMIDAZOLE-BASED INJECTION SOLUTION

Applicant/Assignee: NIPRO CORPORATION

Application No.: JP2010/061992   Filing Date: 15/Jul/2010

Abstract:Disclosed is a benzimidazole-based injection solution which does not cause hemolysis or local irritation when used as an injection solution. Specifically disclosed is a method for producing a benzimidazole-based injection solution, which comprises a step of preparing a benzimidazole-based solution by mixing a benzimidazole-based compound or a salt thereof and ammonia water in an aqueous solvent that contains no nonaqueous solvent, and a step of freeze-drying the solution. By this method, a benzimidazole-based injection solution which does not cause hemolysis or local irritation when used as an injection solution can be obtained. Since a benzimidazole-based compound or a salt thereof is sufficiently dissolved in an aqueous solvent that contains no nonaqueous solvent and is highly stable in the solvent, a high-quality benzimidazole-based injection solution can be obtained. In addition, the benzimidazole-based injection solution obtained by the method has excellent storage stability.

Priority: JP20090168587 Applic. Date: 2009-07-17

Inventor: NISHIYAMA KANAME [JP]; SHIROUCHI YUTAKA [JP]


Publication No.: WO2011008183A1  Published: 20/Jan/2011

Title: TRIMETAZIDINE DIHYDROCHLORIDE-CONTAINING MEDICATION IN THE FORM OF AN EXTENDED-RELEASE MATRIX TABLET (VARIANTS) AND METHODS FOR PREPARING SAME (VARIANTS)

Applicant/Assignee:

Application No.: UA2010/000026   Filing Date: 14/May/2010

Abstract:The invention pertains to the field of medicine and relates to a trimetazidine dihydrochloride-containing medication in the form of a 12-hour extended-release matrix tablet containing: 45.4 to 46.4 wt. % of hydrophilic substances, including 9 to 25 wt. % of trimetazidine dihydrochloride

52.2 to 54.0 wt. % of non-soluble substances, including 26.0 to 27.0 wt. % of a methacrylic acid polymer

and adjuvants. The invention also relates to a trimetazidine dihydrochloride-containing medication in the form of a 24-hour extended-release matrix tablet containing: 33.0 to 34.7 wt. % of hydrophilic substances, including 13.6 to 16.7 wt. % of trimetazidine dihydrochloride

52.2 to 54.0 wt. % of non-soluble substances, including 26.0 to 27.0 wt. % of a methacrylic acid polymer

and adjuvants. The invention also relates to methods for producing said trimetazidine dihydrochloride-containing medication in the form of a 12-hour or 24-hour extended-release matrix tablet.

Priority: UA20090007425 Applic. Date: 2009-07-15

Inventor: PRYKHODKO ROMAN NICOLAEVICH [UA]; SHTEINGART MARK VOLFOVICH [UA]


Publication No.: WO2011008770A2  Published: 20/Jan/2011

Title: METHODS FOR INHIBITING YELLOW COLOR AND PEROXIDE FORMATION IN A COMPOSITION

Applicant/Assignee: BIOGEN IDEC MA INC

Application No.: US2010/041842   Filing Date: 13/Jul/2010

Abstract:The present invention is related to methods for preventing or retarding (i.e., inhibiting) yellow color or peroxide formation in a composition. The present invention is also related to methods of reducing or decreasing the amount of yellow color or peroxide in a composition. More specifically, the present invention relates to the use of an antioxidant, an oxygen scavenger, pH, a chelating agent, and/or at least two factors in the methods of the invention. The present invention is also related to methods for predicting the rate of yellow color or peroxide formation in a composition.

Priority: US20090225455P Applic. Date: 2009-07-14

Inventor: LUCAS KARIN [US]; MALONEY KEVIN [US]


Publication No.: WO2011008823A2  Published: 20/Jan/2011

Title: PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD BRAIN BARRIER

Applicant/Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

Application No.: US2010/041924   Filing Date: 14/Jul/2010

Abstract:The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.

Priority: US20090225412P Applic. Date: 2009-07-14

Inventor: CURRAN GEOFFRY L [US]; SARKAR GOBINDA [US]; PODUSLO JOSEPH F [US]; JENKINS ROBERT B [US]; LOWE VAL J [US]; MAHLUM ERIC W [US]


Publication No.: WO2011008985A2  Published: 20/Jan/2011

Title: METHODS AND COMPOSITIONS FOR IMPROVED DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS

Applicant/Assignee: GEORGIA TECH RESEARCH CORPORATION, EMORY UNIVERSITY

Application No.: US2010/042175   Filing Date: 15/Jul/2010

Abstract:Among other things, this disclosure provides for compounds having a targeting moiety linked to a therapeutic moiety and/or a diagnostic moiety

the synthetic methods for making the compounds

pharmaceutical compositions comprising the compounds

and, methods for treating or diagnosing disorders. Some of the compounds include a linker which can be cleaved under physiological conditions, including linkers comprising an amide or disulfide bond. Examples of targeting moieties are derivatives of DNA binding agents, which may comprise derivatives of Hoechst 33258. Examples of therapeutic moieties are compounds useful for treating a cancer, which may comprise derivatives of nucleotides and nucleosides such as gemcitabine. This abstract is intended to be used as a scanning tool for the purposes of searching in the particular art and is not intended to limiting of the present disclosure.

Priority: US20090225649P Applic. Date: 2009-07-15

Inventor: MURTHY NIREN [US]; DAVIS MICHAEL E [US]; KIM DONGIN [US]; DASARI MADHURI [US]; LEE SUNGMUN [US]; LEE SEUNGJUN [US]; SY JAY [US]; GOODMAN MARK [US]


Publication No.: WO2011008992A2  Published: 20/Jan/2011

Title: PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/042184   Filing Date: 15/Jul/2010

Abstract:Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety

A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates

B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids

X is a linker

and M is a macromolecular carrier.

Priority: US20090225872P Applic. Date: 2009-07-15

Inventor: TSIEN ROGER [US]; AGUILERA TODD [US]; OLSON EMILIA [US]; JIANG TAO [US]; NGUYEN QUYEN [US]


Publication No.: WO2011009106A2  Published: 20/Jan/2011

Title: METHODS AND COMPOSITIONS FOR IN VITRO AND IN VIVO CHONDROGENESIS

Applicant/Assignee: BIOTIME, INC

Application No.: US2010/042369   Filing Date: 16/Jul/2010

Abstract:Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy.

Priority: US20090226237P Applic. Date: 2009-07-16; US20090243939P Applic. Date: 2009-09-18; US20100349088P Applic. Date: 2010-05-27; US20100365308P Applic. Date: 2010-07-16

Inventor: WEST MICHAEL D [US]; STERNBERG HAL [US]; CHAPMAN KAREN B [US]


Publication No.: WO2011009539A1  Published: 27/Jan/2011

Title: e-POLYLYSINE CONJUGATES AND USE THEREOF

Applicant/Assignee: MERCK PATENT GMBH

Application No.: EP2010/004198   Filing Date: 09/Jul/2010

Abstract:The present invention relates to e-polylysine conjugates, in particular conjugates of e-polylysine with compounds carrying carboxyl groups, and to the preparation and to the use thereof for targeting the kidneys.

Priority: EP20090009393 Applic. Date: 2009-07-20

Inventor: KUEBELBECK ARMIN [DE]; LARBIG GREGOR [DE]; MIER WALTER [DE]; BEIJER BARBRO [DE]; HABERKORN UWE [DE]


Publication No.: WO2011009624A1  Published: 27/Jan/2011

Title: DELIVERY SYSTEM AND CONJUGATES FOR COMPOUND DELIVERY VIA NATURALLY OCCURRING INTRACELLULAR TRANSPORT ROUTES

Applicant/Assignee: CENIX BIOSCIENCE GMBH

Application No.: EP2010/004512   Filing Date: 22/Jul/2010

Abstract:The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell. The present invention further relates to a pharmaceutical composition comprising said conjugate and to its use. The present invention also relates to a method of delivering a compound to a cell or an organism, preferably a patient. The conjugates comprise: (a) at least one module that mediates cell targeting and facilitates cellular uptake, (b) at least one module that facilitates transport to the endoplasmic reticulum (ER), (c) at least one module that mediates translocation from the ER to the cytosol, and (d) at least one compound to be delivered wherein the modules (a) to (c) and the compound (d) are linked to each other in any arrangement.

Priority: US20090227669P Applic. Date: 2009-07-22

Inventor: ECHEVERRI CHRISTOPHE J [DE]; SOENNICHSEN BIRTE [DE]; WAEHLER REINHARD [DE]; HELMS MIKE WERNER [DE]


Publication No.: WO2011009797A2  Published: 27/Jan/2011

Title: PLASMA-ADAPTED AND BALANCED GELATIN SOLUTION

Applicant/Assignee: B. BRAUN MELSUNGEN AG

Application No.: EP2010/060210   Filing Date: 15/Jul/2010

Abstract:The invention relates to a pharmaceutical preparation which comprises an aqueous composition which in turn comprises gelatin and/or a physiologically acceptable gelatin derivative. The pharmaceutical preparation can be used in the prophylaxis and therapy of hypovolemia. The invention further relates to uses of the pharmaceutical preparation as a volume substitute and as an erythrocyte-protecting wash solution.

Priority: DE200910034132 Applic. Date: 2009-07-20

Inventor: BOLL MICHAEL [DE]


Publication No.: WO2011009852A2  Published: 27/Jan/2011

Title: PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: NOVARTIS AG

Application No.: EP2010/060470   Filing Date: 20/Jul/2010

Abstract:The present invention relates to pharmaceutics compositions of 2-Methyl-4'- trifluoromethoxy-biphenyl-3-carboxylic acid [6-{cis-2,6-dimethyl-morpholin-4-yl)-pyridlin-3-yl]- amide, to the use of such compositions in therapeutic applications and to methods for manufacturing such compositions.

Priority: US20090227141P Applic. Date: 2009-07-21; US20100295884P Applic. Date: 2010-01-18

Inventor: FRITZE ANDREAS [CH]; CORCELLE KARINE [CH]; GRUBESA MELINDA ENIKOE [CH]


Publication No.: WO2011009956A1  Published: 27/Jan/2011

Title: INJECTABLE AQUEOUS SOLUTION CONTAINING ARTESUNATE

Applicant/Assignee: DAFRA PHARMA N.V

Application No.: EP2010/060757   Filing Date: 23/Jul/2010

Abstract:The present invention relates to pharmaceutical compositions in powder form comprising an anti-malarial agent. Specifically, the present invention relates to pharmaceutical composition in powder form, comprising: a) artesunate

b) a pharmaceutically acceptable hydroxycarbohydrate carrier

c) a phosphate salt

wherein, in aqueous form, the composition has a pH of at least 6, and wherein the ratio between the artesunate and the pharmaceutically acceptable hydroxycarbohydrate carrier is in the range of 1:0.1 to 1:3 by weight. Further, the present invention relates to a unit dose comprising the pharmaceutical compositions. Furthermore, the present invention relates to a unit dose comprising the pharmaceutical compositions for use in the treatment of malaria.

Priority: WO2009EP59596 Applic. Date: 2009-07-24

Inventor: JANSEN FRANS HERWIG [BE]


Publication No.: WO2011009991A2  Published: 27/Jan/2011

Title: DENDRITIC PIC MICELLES WITH BIOACTIVE PROTEINS

Applicant/Assignee: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Application No.: ES2010/070504   Filing Date: 22/Jul/2010

Abstract:Dendritic PIC micelles with bioactive proteins. The invention relates to a Polyion Complex (PIC) polymeric micelle formed by interaction between a bioactive protein and a dendritic block copolymer of opposite charge. The conventional low stability of PIC micelles with bioactive proteins vis-à-vis ionic strength is offset in the present invention by the stability provided by the dendritic block. The overall process for preparing these micelles is facilitated by the simplicity of the dendritic block copolymer synthesis.

Priority: ES20090001645 Applic. Date: 2009-07-24

Inventor: SOUSA HERVES ANA [ES]; FERNANDEZ MEGIA EDUARDO [ES]; RIGUERA VEGA RICARDO [ES]


Publication No.: WO2011010084A2  Published: 27/Jan/2011

Title: CYCLOSPORIN CONJUGATES

Applicant/Assignee: UCL BUSINES PLC

Application No.: GB2010/001369   Filing Date: 19/Jul/2010

Abstract:A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R1 and R1* represents hydrogen and the other represents methyl, R2 represents ethyl or isopropyl, R3 represents hydrogen or methyl, and R4 represents -CH2CH(CH3)CH3, -CH2CH(CH3)CH2CH3, -CH(CH3)CH3 or -CH(CH3)CH2CH3.

Priority: GB20090012584 Applic. Date: 2009-07-20

Inventor: SELWOOD DAVID [GB]; CROMPTON MARTIN [GB]


Publication No.: WO2011010156A1  Published: 27/Jan/2011

Title: FAS (APO-1, CD95) TARGETED PLATFORMS FOR INTRACELLULAR DRUG DELIVERY

Applicant/Assignee: QUEEN MARY & WESTFIELD COLLEGE

Application No.: GB2010/051207   Filing Date: 21/Jul/2010

Abstract:A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.

Priority: GB20090012645 Applic. Date: 2009-07-21; GB20100009891 Applic. Date: 2010-06-14

Inventor: ATEH DAVIDSON DAY [GB]; MARTIN JOANNE ELIZABETH [GB]


Publication No.: WO2011010324A1  Published: 27/Jan/2011

Title: ORAL PHARMACEUTICAL COMPOSITION OF RASAGILINE AND PROCESS FOR PREPARING THEREOF

Applicant/Assignee: ALKEM LABORATORIES LTD

Application No.: IN2010/000309   Filing Date: 14/May/2010

Abstract:The present invention relates to a stable oral pharmaceutical composition comprising rasagiline or its pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier, wherein the carrier is selected from a polyhydric alcohol, disaccharide(s) and polysaccharide(s) or mixtures thereof, and wherein the said composition is free of pentahydric or hexahydric alcohols.

Priority: IN2009MU01704 Applic. Date: 2009-07-23

Inventor: PRASAD ARUN [IN]; PRASAD KRISHNA [IN]; SATHYANARAYANA VEMULA [IN]; RAMPAL ASHOK


Publication No.: WO2011010399A1  Published: 27/Jan/2011

Title: CORNEAL ENDOTHELIAL CELL PROLIFERATION PROMOTER

Applicant/Assignee: SENJU PHARMACEUTICAL CO., LTD

Application No.: JP2009/063624   Filing Date: 24/Jul/2009

Abstract:A corneal endothelial cell proliferation promoter and a therapeutic agent for diseases associated with the damage of a corneal endothelium, both of which are characterized by being administered to the inside of the anterior chamber of the eye. bFGF sustained release gelatin hydrogel particles, each of which comprises a gelatin hydrogel and bFGF supported on the gelatin hydrogel, are prepared. By using the particles, it becomes possible to release bFGF in a sustained manner. Thus, the proliferation of corneal endothelial cells can be promoted continuously and diseases associated with the damage of a corneal endothelium can be treated by administering a preparation comprising the bFGF sustained release gelatin hydrogel particles to the inside of the anterior chamber of the eye.

Priority:

Inventor: TABATA YASUHIKO [JP]; KINOSHITA SHIGERU [JP]; KOIZUMI NORIKO [JP]; SAKAMOTO YUJI [JP]; OKUMURA NAOKI [JP]; TAKAHASHI HIROAKI [JP]


Publication No.: WO2011010456A1  Published: 27/Jan/2011

Title: EXTERNAL PREPARATION CONTAINING NSAIDs AND METHOD FOR PRODUCING THE EXTERNAL PREPARATION

Applicant/Assignee: NEXT21 K.K, THE UNIVERSITY OF TOKYO

Application No.: JP2010/004669   Filing Date: 21/Jul/2010

Abstract:Disclosed is an external preparation containing nonsteroidal anti-inflammatory drugs (NSAIDs), which is suppressed in cytotoxicity induced by the NSAIDs. Also disclosed is a method for producing the external preparation. The present invention is based on the finding that skin disorders induced by nonsteroidal anti-inflammatory drugs (NSAIDs) can be suppressed when the NSAIDs form intermolecular compounds together with trehalose, which is an example of disaccharides. A disaccharide other than trehalose may be used therefor.

Priority: JP20090173609 Applic. Date: 2009-07-24

Inventor: TEI YUICHI [JP]; SASAKI NOBUO [JP]; SUZUKI SHIGEKI [JP]


Publication No.: WO2011010556A1  Published: 27/Jan/2011

Title: TRANSDERMAL PREPARATION

Applicant/Assignee: NIPRO PATCH CO., LTD

Application No.: JP2010/061536   Filing Date: 07/Jul/2010

Abstract:Disclosed is a transdermal preparation which is capable of maintaining adhesive properties for a long time even in cases when a crosslinked adhesive, which is capable of containing a sufficient amount of a medical agent, is used for an adhesive layer. Specifically disclosed is a transdermal preparation which is characterized in that one surface of a supporting body is provided with an adhesive layer that contains at least an adhesive and that the adhesive contains two kinds of acrylic resins Acr-A and Acr-B which are obtained by copolymerizing a combination of specific monomers.

Priority: JP20090172329 Applic. Date: 2009-07-23

Inventor: NAKAJIMA NORIKO [JP]; SHINKAI NORIHIRO [JP]; OKUMURA YUTAKA [JP]; IZAWA MANAMI [JP]


Publication No.: WO2011010605A1  Published: 27/Jan/2011

Title: MICRONEEDLE ARRAY

Applicant/Assignee: HISAMITSU PHARMACEUTICAL CO., INC, TOPPAN PRINTING CO., LTD

Application No.: JP2010/062008   Filing Date: 15/Jul/2010

Abstract:By studying the relation between the crystallinity and the performance of a biodegradable resin, the relation between the weight average molecular weight and the strength of the biodegradable resin, and the relation between the weight average molecular weight and the performance of the biodegradable resin, it is found that a microneedle array which comprises microneedles containing an amorphous polylactic acid that has a weight average molecular weight of 40,000-100,000 can maintain the function and the performance required for a microneedle array.

Priority: JP20090172525 Applic. Date: 2009-07-23

Inventor: TERAHARA TAKAAKI [JP]; TOKUMOTO SEIJI [JP]; TAMURA AKIRA [JP]; YAMADA YUMIKO [JP]


Publication No.: WO2011010645A1  Published: 27/Jan/2011

Title: FENTANYL-CONTAINING ADHESIVE PREPARATION FOR EXTERNAL USE

Applicant/Assignee: TEIKOKU SEIYAKU CO., LTD

Application No.: JP2010/062201   Filing Date: 21/Jul/2010

Abstract:Disclosed is a fentanyl-containing adhesive preparation for external use, wherein an adhesive layer is laminated on a supporting body. The adhesive layer contains a styrene-isoprene-styrene block copolymer, a tackifying resin that is composed of a rosin resin and a terpene resin, and a softening agent that is composed of a polybutene and a liquid paraffin. The adhesive layer also contains fentanyl as an active ingredient. The fentanyl-containing adhesive preparation for external use has excellent skin permeation of fentanyl and high preparation stability, without suffering from crystallization of fentanyl during storage.

Priority: JP20090173135 Applic. Date: 2009-07-24

Inventor: NARUSE MAMORU [JP]; HATTORI KENICHI [JP]; MATSUSHITA KUNIHIKO [JP]


Publication No.: WO2011010691A1  Published: 27/Jan/2011

Title: POLYION COMPLEX COMPRISING PHD2 EXPRESSION INHIBITING SUBSTANCE

Applicant/Assignee: THE UNIVERSITY OF TOKYO

Application No.: JP2010/062344   Filing Date: 22/Jul/2010

Abstract:Disclosed is a safer and more sustainable gene delivery system or the like, which is effective for treatment of ischemic diseases and the like. Specifically disclosed is a pharmaceutical composition which contains, as an active ingredient, a polyanionic substance that inhibits the expression of PHD2, and which contains a polyion complex of the polyanionic substance and a polycationically charged polymer.

Priority: JP20090171562 Applic. Date: 2009-07-22

Inventor: KATAOKA KAZUNORI [JP]; WU SHOURONG [JP]; NISHIYAMA NOBUHIRO [JP]; ITAKA KEIJI [JP]; KOYAMA HIROYUKI [JP]; HASHIMOTO TAKUYA [JP]; TEI YUICHI [JP]


Publication No.: WO2011011347A2  Published: 27/Jan/2011

Title: FUNCTIONALIZATION OF SILK MATERIAL BY AVIDIN-BIOTIN INTERACTION

Applicant/Assignee: TRUSTEES OF TUFTS COLLEGE

Application No.: US2010/042502   Filing Date: 20/Jul/2010

Abstract:The present invention provides for compositions and methods of linking silk fibroin to active agents through the specific interaction between avidin and biotin, providing for functionalization of silk-based protein biomaterials. An avidin- or biotin-modified silk is a biomaterial platform for functionalization with a variety of correspondingly linked active agents, such as antibodies and growth factors. A variety of functionalized silk materials, such as silk hydrogel, silk micro/nanoparticles and silk films, can be prepared by the methods of the present invention. The functionalization strategies of the present invention are relatively easy, fast and feasible, and are thus useful in many biomedical applications.

Priority: US20090227254P Applic. Date: 2009-07-21

Inventor: KAPLAN DAVID L [US]; WANG XIAOQIN [US]; SERBAN MONICA A [US]


Publication No.: WO2011011351A2  Published: 27/Jan/2011

Title: A STABLE PHARMACEUTICAL OMEPRAZOLE FORMULATION FOR ORAL ADMINISTRATION

Applicant/Assignee: VETEGEN, LLC

Application No.: US2010/042508   Filing Date: 20/Jul/2010

Abstract:The present invention is directed to a pharmaceutical solution or syrup formulation for oral administration comprising

omeprazole, a solubilizing agent, a sweetening agent, a flavoring agent, and an antioxidant.

Priority: US20090226890P Applic. Date: 2009-07-20

Inventor: JUVONEN ERIK [US]; MICOLUCCI LOUIS MASSIMO [US]


Publication No.: WO2011011517A2  Published: 27/Jan/2011

Title: IRON PREPARATION SUITABLE FOR PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION THEREOF

Applicant/Assignee: BIOLINK LIFE SCIENCES, INC

Application No.: US2010/042747   Filing Date: 21/Jul/2010

Abstract:New iron preparations comprising stable, unpolymerized iron(III) citrate complex compositions and methods for their preparation are provided. Further, the invention involves the use stable, unpolymerized iron(III) citrate complex compositions of the invention as a food additive, nutritional supplement, dietary supplement, medical food, nutrient, iron fortificant, and source of iron in the fields of nutrition for humans, animals, fish, and birds and of diagnostics. The invention further involves the use of stable, unpolymerized iron(III) citrate complex compositions of the invention as a pharmaceutical and pharmacologically active ingredient for human clinical and veterinary applications.

Priority: US2009-506408 Applic. Date: 2009-07-21

Inventor: NELSON DEANNA JEAN [US]; MOSLEY BRIAN J [US]


Publication No.: WO2011011543A1  Published: 27/Jan/2011

Title: OLIGOMER-OPIOID AGONIST CONJUGATES

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: US2010/042792   Filing Date: 21/Jul/2010

Abstract:The invention provides conjugates wherein the opioid agonists, hydroxycodone (oxycodone) and hydrocodone (dihydrocodeipone) are covalently attached to poly(ethylene glycol) oligomers. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the opioid agonist not attached to the PEG oligomers.

Priority: US20090227399P Applic. Date: 2009-07-21; US2009-558395 Applic. Date: 2009-09-11; US20100350853P Applic. Date: 2010-06-02

Inventor: RIGGS-SAUTHIER JENNIFER [US]; DENG BO-LIANG [US]; RILEY TIMOTHY A [US]


Publication No.: WO2011011658A1  Published: 27/Jan/2011

Title: ADHESIVE COMPLEX COACERVATES AND METHODS OF MAKING AND USING THEREOF

Applicant/Assignee: UNIVERSITY OF UTAH RESEARCH FUNDATION

Application No.: US2010/043009   Filing Date: 23/Jul/2010

Abstract:Adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations andpolyanions in the adhesive complex coacervate are crosslinked with one another bycovalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate. The adhesive complex coacervates have numerous biological applications as bioadhesives and drug delivery devices. In particular, the adhesive complex coacervates described herein are particularly useful in underwater applications and situations where water is present such as, for example, physiological conditions.

Priority: US2009-508280 Applic. Date: 2009-07-23

Inventor: STEWART RUSSELL JOHN [US]; SHAO HUI [US]


Publication No.: WO2011011675A1  Published: 27/Jan/2011

Title: PHARMACEUTICALLY ACCEPTABLE FORMULATIONS/COMPOSITIONS FOR PEPTIDYL DRUGS

Applicant/Assignee: ZELOS THERAPEUTICS, INC

Application No.: US2010/043038   Filing Date: 23/Jul/2010

Abstract:Compositions are disclosed comprising a pharmaceutically effective amount of a peptidyl drug and a bioavailability enhancer in an amount sufficient to increase the bioavailability of the peptidyl drug, wherein the bioavailabilty enhancer comprises a diol or diol ether.

Priority: US20090227972P Applic. Date: 2009-07-23

Inventor: STOGNIEW MARTIN [US]; MERUTKA GENE SCOTT [US]


Publication No.: WO2011011873A1  Published: 03/Feb/2011

Title: STICKY SOFT GEL FOR TREATING POULTRY

Applicant/Assignee:

Application No.: CA2010/001156   Filing Date: 27/Jul/2010

Abstract:The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.

Priority: CA20092674143 Applic. Date: 2009-07-28; US2009-510926 Applic. Date: 2009-07-28

Inventor: LEE ENG-HONG [CA]


Publication No.: WO2011011879A1  Published: 03/Feb/2011

Title: H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE

Applicant/Assignee: NATIONAL RESEARCH COUNCIL OF CANADA

Application No.: CA2010/001173   Filing Date: 30/Jul/2010

Abstract:Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a a1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula (I): wherein R is a a-DDHep-3-a-L-Fuc-3-ss-GlcNAc trisaccharide substituted with an a1,6-glucan linked to an a1,3-DD-heptan, and wherein the last DD-Hep residue of a1,3-DD- heptan is capped with ss-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.

Priority: US20090230315P Applic. Date: 2009-07-31

Inventor: ALTMAN ELEANORA [CA]; MORRISON BLAIR A [CA]; CHANDAN VANDANA [CA]


Publication No.: WO2011011978A1  Published: 03/Feb/2011

Title: NANOSPHERE OR MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF

Applicant/Assignee: XI'AN LIBANG MEDICAL TECHNOLOGY CO., LTD

Application No.: CN2010/001154   Filing Date: 30/Jul/2010

Abstract:A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the production method of the formulations and the use of the carrier are disclosed. The carrier comprises biodegradable methoxy end capping polyethylene glycol-polylactide block copolymers and their derivatives of formula (I) as the main carrier materials: CH3O-[CH2-CH2-O]m-[C(O)-CH(CH3)-O]n-R (I)

Priority: WO2009CN00862 Applic. Date: 2009-07-31

Inventor: HU RENLE [CN]; WANG JIUCHENG [CN]; CHEN TAO [CN]; LIANG HUA [CN]; DING DUOHAO [CN]; JIAO YAQI [CN]


Publication No.: WO2011012162A1  Published: 03/Feb/2011

Title: AQUEOUS CARBONATED MEDIUM CONTAINING AN AMINO(METH)ACRYLATE POLYMER OR COPOLYMER

Applicant/Assignee: EVONIK ROEHM GMBH

Application No.: EP2009/059853   Filing Date: 30/Jul/2009

Abstract:The invention relates to an aqueous medium containing an amino(meth)acrylate polymer or copolymer which is not soluble in demineralised water, characterized in that the medium has a content of an aqueous phase of at least 60 % by weight and a content of up to 40 % by weight of solids comprising the amino(meth)acrylate polymer or copolymer, whereby the aqueous phase is charged by a sufficient amount of carbon dioxide that effects the amino(meth)acrylate polymer or copolymer to be present in solute form in the medium. The aqueous medium may be used beneficially as a coating or binding solution for the spray coating or binding of pharmaceutical compositions or nutraceutical compositions or cosmetical compositions.

Priority:

Inventor: LIZIO ROSARIO [DE]; DAMM MICHAEL [DE]; PETEREIT HANS-ULRICH [DE]


Publication No.: WO2011012312A1  Published: 03/Feb/2011

Title: BLADDER INSTILLATION COMPOSITIONS FOR TREATING BLADDER CANCER

Applicant/Assignee: FRESENIUS KABI DEUTSCHLAND GMBH

Application No.: EP2010/004671   Filing Date: 30/Jul/2010

Abstract:The present invention relates to a bladder instillation composition, comprising at least two different glycosaminoglycanes, or the salts thereof, and at least one cytostaticum, a method for the production thereof, and a kit containing separate solutions of the glycosaminoglycanes and the cytostaticum. The compositions are used for treating bladder cancer and are applied intravesically.

Priority: DE200910035586 Applic. Date: 2009-07-31

Inventor: MUELLER BERND-W [DE]


Publication No.: WO2011012715A1  Published: 03/Feb/2011

Title: BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: EP2010/061155   Filing Date: 30/Jul/2010

Abstract:The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

Priority: EP20090167026 Applic. Date: 2009-07-31; EP20090172339 Applic. Date: 2009-10-06

Inventor: RAU HARALD [DE]; HERSEL ULRICH [DE]; KRUSCH MATHIAS [DE]; VETTER DIRK [DE]; VOIGT TOBIAS [DE]


Publication No.: WO2011012718A1  Published: 03/Feb/2011

Title: PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: EP2010/061159   Filing Date: 30/Jul/2010

Abstract:The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an insulin linker conjugate D-L, wherein D represents the insulin moiety

and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the insulin by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by insulin.

Priority: EP20090167027 Applic. Date: 2009-07-31; EP20090174525 Applic. Date: 2009-10-29; EP20090179336 Applic. Date: 2009-12-15; EP20090179818 Applic. Date: 2009-12-18

Inventor: RAU HARALD [DE]; CLEEMANN FELIX [DE]; HERSEL ULRICH [DE]; KADEN-VAGT SILVIA [DE]; LESSMANN TORBEN [DE]; WEGGE THOMAS [DE]


Publication No.: WO2011012719A1  Published: 03/Feb/2011

Title: LONG ACTING INSULIN COMPOSITION

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: EP2010/061160   Filing Date: 30/Jul/2010

Abstract:The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.

Priority: EP20090167017 Applic. Date: 2009-07-31; EP20090179337 Applic. Date: 2009-12-15; EP20090179827 Applic. Date: 2009-12-18

Inventor: SPROGOEE KENNETT [US]; CLEEMANN FELIX [DE]; HERSEL ULRICH [DE]; KADEN-VAGT SILVIA [DE]; LESMANN TORBEN [DE]; RAU HARALD [DE]; WEGGE THOMAS [DE]


Publication No.: WO2011012721A1  Published: 03/Feb/2011

Title: CARRIER LINKED PRAMIPEXOLE PRODRUGS

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: EP2010/061162   Filing Date: 30/Jul/2010

Abstract:The present invention relates to a carrier linked pramipexole prodrug or a pharmaceutical acceptable salt thereof, wherein pramipexole is bound via a linker to a polymeric carrier. The invention also relates to pharmaceutical compositions comprising said polymeric pramipexole prodrug and their use as medicaments.

Priority: EP20090167028 Applic. Date: 2009-07-31; EP20090172341 Applic. Date: 2009-10-06; EP20090180522 Applic. Date: 2009-12-23

Inventor: RAU HARALD [DE]; BARON JULIA [DE]; HERSEL ULRICH [DE]


Publication No.: WO2011012722A1  Published: 03/Feb/2011

Title: PRODRUGS CONTAINING AN AROMATIC AMINE CONNECTED BY AN AMIDO BOND TO A LINKER

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: EP2010/061163   Filing Date: 30/Jul/2010

Abstract:The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein an aromatic amine containing biologically active moiety is connected (bound) by an amido bound to a linker. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.

Priority: EP20090167029 Applic. Date: 2009-07-31

Inventor: RAU HARALD [DE]; BARON JULIA [DE]; HERSEL ULRICH [DE]; KRUSCH MATHIAS [DE]


Publication No.: WO2011012723A1  Published: 03/Feb/2011

Title: INJECTABLE SUSTAINED RELEASE COMPOSITIONS COMPRISING A PRAMIPEXOLE PRODRUG

Applicant/Assignee: ASCENDIS PHARMA AS

Application No.: EP2010/061164   Filing Date: 30/Jul/2010

Abstract:The present invention relates to an injectable slow release pharmaceutical composition containing a carrier linked pramipexole prodrug. The invention also relates to their use as medicaments.

Priority: EP20090167030 Applic. Date: 2009-07-31; EP20090172340 Applic. Date: 2009-10-06; EP20090180526 Applic. Date: 2009-12-23

Inventor: SPROGOEE KENNETT [US]; BARON JULIA [DE]; HERSEL ULRICH [DE]; MAITRE GUILLAUME [DE]; RAU HARALD [DE]; WEGGE THOMAS [DE]


Publication No.: WO2011012729A1  Published: 03/Feb/2011

Title: USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER I, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Application No.: EP2010/061229   Filing Date: 02/Aug/2010

Abstract:The invention relates to the use of oligomers having constrained dipeptide or tripeptide motifs as agents for the vectorization of active ingredients.

Priority: FR20090055427 Applic. Date: 2009-07-31

Inventor: AMBLARD MURIEL [FR]; MARTINEZ JEAN [FR]; VEZENKOV LUBOMIR [FR]; HERNANDEZ JEAN-FRANCOIS [FR]; GARCIA MARCEL [FR]; MAYNADIER MARIE [FR]


Publication No.: WO2011012774A1  Published: 03/Feb/2011

Title: NOVEL FORM OF OSTEOGENIC PROTEIN ADMINISTRATION

Applicant/Assignee: ADOCIA

Application No.: FR2009/001331   Filing Date: 19/Nov/2009

Abstract:The invention relates to osteogenic compositions consisting of a coprecipitate that contains at least one insoluble calcium salt and at least one osteogenic protein, said coprecipitate being divided. The invention also relates to the kits enabling the implementation of the invention. The invention also relates to the method for preparing the divided coprecipitate containing at least one insoluble calcium salt and at least one complex between an osteogenic protein and a polysaccharide. The invention also relates to the formulations, pharmaceuticals, and medical devices including said coprecipitate.

Priority: FR20090003802 Applic. Date: 2009-07-31; US20090213938P Applic. Date: 2009-07-31

Inventor: SOULA GERARD [FR]; SOULA REMI [FR]; SOULA OLIVIER [FR]


Publication No.: WO2011012816A2  Published: 03/Feb/2011

Title: PHARMACEUTICAL FORMULATION

Applicant/Assignee: SANOFI-AVENTIS

Application No.: FR2010/051611   Filing Date: 29/Jul/2010

Abstract:The invention relates to a pharmaceutical formulation including, as an active principle, the compound of formula (I) or a salt of said compound with a pharmaceutically acceptable acid.

Priority: FR20090003742 Applic. Date: 2009-07-30

Inventor: BURNOUF JEAN-PIERRE [FR]; BENARD TSIALA [FR]


Publication No.: WO2011012850A2  Published: 03/Feb/2011

Title: GLYCOPOLYSIALYLATION OF NON-BLOOD COAGULATION PROTEINS

Applicant/Assignee: LIPOXEN TECHNOLOGIES LIMITED, BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: GB2010/001422   Filing Date: 26/Jul/2010

Abstract:A water soluble polymer, in particular polysialic acid (PSA) or a modified PSA (mPSA), is conjugated to an oxidized carbohydrate moiety of a glycoprotein other than a blood coagulation protein or to a ganglioside or drug delivery system by contacting the oxidized carbohydrate moiety with the water soluble polymer, wherein said water soluble polymer contains an aminooxy group and an oxime linkage is formed between the oxidized carbohydrate moiety and the aminooxy group on the water soluble polymer or wherein said water soluble polymer contains a hydrazide group and a hydrazone linkage is formed between the oxidized carbohydrate moiety and the hydrazide group on the water soluble polymer. Conjugates of aminooxy- or hydrazide-water soluble polymer, such as PSA and mPSA, are thus obtained in which the PSA or mPSA is attached via a carbohydrate moiety.

Priority: US20090228828P Applic. Date: 2009-07-27; US20100347136P Applic. Date: 2010-05-21

Inventor: JAIN SANJAY [GB]; GREGORIADIS GREGORY [GB]; DWIVEDI ARCHANA [GB]; NATH SRIJIT [GB]; SIEKMANN JUERGEN [AT]; HAIDER STEFAN [AT]; ROTTENSTEINER HANSPETER [AT]; TURECEK PETER [AT]


Publication No.: WO2011012866A1  Published: 03/Feb/2011

Title: SOLUTIONS COMPRISING POLYETHYLENE GLYCOL AND ELECTROLYTES

Applicant/Assignee: NORGINE BV

Application No.: GB2010/001455   Filing Date: 30/Jul/2010

Abstract:The invention provides a solution in water comprising the following components at the following concentrations: (a) N x (70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500

(b) N x (1.6 to 4.0) g/L sodium chloride

(c) N x (0.2 to 0.6) g/L potassium chloride

(d) N x (0.6 to 2.2) g/L sodium bicarbonate

(e) N x an amount of preservative

(f) optionally N x an amount of flavouring

and (g) optionally N x an amount of sweetener where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.

Priority: GB20090013295 Applic. Date: 2009-07-30

Inventor: SELDON CHRIS [GB]; PADFIELD DAWN [GB]; MORRISSEY FRANCES [GB]


Publication No.: WO2011012989A1  Published: 03/Feb/2011

Title: S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY

Applicant/Assignee: MSI METHYLATION SCIENCES INC

Application No.: IB2010/001877   Filing Date: 29/Jul/2010

Abstract:The invention relates to compositions and methods to enhance the absorption of S- adenosylmethionine (SAMe) and to methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. The enhanced bioavailability formulations may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia

as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease.

Priority: US20090229194P Applic. Date: 2009-07-28

Inventor: MACDONALD I DAVID [CA]; HARRISON NANCY [CA]; TAKACS-COX ANIKO [CA]; PURAC ADMIR [CA]; BLAZEK-WELSH ALMIRA [CA]


Publication No.: WO2011013128A2  Published: 03/Feb/2011

Title: VECTORS FOR DELIVERY OF NEUROTHERAPEUTICS TO THE CENTRAL NERVOUS SYSTEM

Applicant/Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD

Application No.: IL2010/000612   Filing Date: 29/Jul/2010

Abstract:The present invention provides novel BBB transport vectors which are capable of delivering BBB-non-transportable neurotherapeutics through the BBB and releasing them in the brain in a slow and continuous fashion, while maintaining their therapeutic effect.

Priority: US20090230162P Applic. Date: 2009-07-31

Inventor: FRIDKIN MATITYAHU [IL]; SHECHTER YORAM [IL]


Publication No.: WO2011013130A2  Published: 03/Feb/2011

Title: CELL-TARGETING NANOPARTICLES COMPRISING POLYNUCLEOTIDE AGENTS AND USES THEREOF

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: IL2010/000614   Filing Date: 29/Jul/2010

Abstract:A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome

and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.

Priority: GB20090013442 Applic. Date: 2009-07-31

Inventor: PEER DAN [IL]


Publication No.: WO2011013359A1  Published: 03/Feb/2011

Title: MEDICINAL COMPOSITION FOR IONTOPHORESIS

Applicant/Assignee: TEIKOKU SEIYAKU CO.,LTD

Application No.: JP2010/004779   Filing Date: 28/Jul/2010

Abstract:Disclosed is a medicinal composition for iontophoresis, in which a medicinal agent has excellent stability, and which can be prepared and filled readily in the production process and can be produced at low cost. The medicinal composition for iontophoresis is characterized by comprising a nonionic synthetic polymer, betamethasone sodium phosphate, and a solvent. A preferred embodiment of the medicinal composition is characterized in that the nonionic synthetic polymer substance is polyvinyl alcohol (PVA). A preferred embodiment of the medicinal composition is characterized in that the content of polyvinyl alcohol (PVA) is 0.5 to 30 wt%.

Priority: JP20090179895 Applic. Date: 2009-07-31

Inventor: HASUI AKIHIRO [JP]; MIYAGI TAKAMITSU [JP]


Publication No.: WO2011013494A1  Published: 03/Feb/2011

Title: AQUEOUS COMPOSITION

Applicant/Assignee: ARCH CHEMICALS JAPAN, INC

Application No.: JP2010/061578   Filing Date: 08/Jul/2010

Abstract:Disclosed is an aqueous composition which is prevented from the occurrence of remarkable white turbidity and precipitation even when a polyvalent anionic compound and a polycationic antibacterial agent are contained as components. The aqueous composition additionally contains a phosphoric acid ester of a polyoxyethylene alkyl ether and/or a salt thereof. It is more preferred to add a phosphoric acid ester of a polyoxyethylene alkyl ether or a salt thereof which has a linear alkyl group having a predetermined number or more of carbon atoms and contains a polyoxyethylene in a predetermined repeating number or more. It is also more preferred to add the phosphoric acid ester of the polyoxyethylene alkyl ether or the salt thereof at a predetermined ratio or more relative to the amount of the polycationic antibacterial agent.

Priority: JP20090177172 Applic. Date: 2009-07-30

Inventor: YONEDA RYU [JP]; NEW MAYUMI [JP]; SAKATA KAZUHIKO [JP]


Publication No.: WO2011013546A1  Published: 03/Feb/2011

Title: WATER-SOLUBLE POLYMER COMPOSITION, COMPOSITION FOR FORMING PLASTER LAYER OF SKIN PATCH, AND SKIN PATCH

Applicant/Assignee: SUMITOMO SEIKA CHEMICALS CO., LTD

Application No.: JP2010/062220   Filing Date: 21/Jul/2010

Abstract:Disclosed are a water-soluble polymer composition which comprises a water-soluble poly(meth)acrylic acid polymer and a gelation rate retarding agent, and a composition for forming plaster layer of skin patch which is obtained by adding a polyvalent metal compound to said water-soluble polymer composition. When a polyvalent metal compound is added, the aforesaid water-soluble polymer composition shows an appropriate induction period before the start of the gel hardening. When the water-soluble polymer composition is used for forming a plaster layer of a skin patch, therefore, added components can be uniformly mixed and the procedure for coating to a support can be facilitated.

Priority: JP20090177281 Applic. Date: 2009-07-30

Inventor: MIURA KAZUYUKI [JP]


Publication No.: WO2011013592A1  Published: 03/Feb/2011

Title: COATED PREPARATION

Applicant/Assignee: IDEMITSU KOSAN CO., LTD

Application No.: JP2010/062454   Filing Date: 23/Jul/2010

Abstract:Disclosed is a coated preparation which is produced by causing a cashew nut shell oil, anacardic acid or cardanol to be adsorbed onto an oil absorbent, granulating the resulting product, and coating the surfaces of the resulting granules with a hydrogenated oil or a coating agent. The coated preparation of the cashew nut shell oil enables the easy handling of the cashew nut shell oil, can prevent from the occurrence of rash that is usually caused by cashew nut shell oils, and is suitable for the release of the cashew nut shell oil into the rumen.

Priority: JP20090177490 Applic. Date: 2009-07-30

Inventor: MOCHIZUKI MASAMI [JP]; NAGASHIMA KYO [JP]


Publication No.: WO2011013639A1  Published: 03/Feb/2011

Title: TABLET

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: JP2010/062568   Filing Date: 27/Jul/2010

Abstract:Disclosed is a high-dose tablet which contains 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof as a pharmaceutically active ingredient. Specifically disclosed is a tablet which contains the compound (A) or a salt thereof, and a fluidizer, with the content of the compound (A) being 35-50% by weight.

Priority: JP20090175695 Applic. Date: 2009-07-28

Inventor: MURAKAWA YUSUKE [GB]; OKABE TAKAYUKI [JP]


Publication No.: WO2011013698A1  Published: 03/Feb/2011

Title: CARRIER PEPTIDE FRAGMENT AND USE THEREOF

Applicant/Assignee: TOAGOSEI CO.,LTD

Application No.: JP2010/062691   Filing Date: 28/Jul/2010

Abstract:A foreign substance introduction method, which comprises the steps of: preparing a foreign substance introduction construct comprising a carrier peptide fragment and a foreign substance of interest bound to the N-terminal side and/or the C-terminal side of the carrier peptide fragment

supplying the foreign substance introduction construct to a sample containing eukaryotic cells of interest

and incubating the sample into which the foreign substance introduction construct has been supplied to thereby introduce the construct into the eukaryotic cells in the sample, wherein the carrier peptide fragment comprises an amino acid sequence: WRRQARFK (SEQ ID NO:1) or an amino acid sequence produced by substituting, deleting and/or adding (inserting) one, two or three amino acid residues in the preceding amino acid sequence.

Priority: JP20090177101 Applic. Date: 2009-07-29

Inventor: KOBAYASHI NAHOKO [JP]; YOSHIDA TETSUHIKO [JP]; NIWA MIKIO [JP]; TANAKA KENICHI [JP]


Publication No.: WO2011013699A1  Published: 03/Feb/2011

Title: CARRIER PEPTIDE FRAGMENT AND USE THEREOF

Applicant/Assignee: TOAGOSEI CO.,LTD

Application No.: JP2010/062692   Filing Date: 28/Jul/2010

Abstract:A foreign substance introduction method, which comprises the steps of: preparing a foreign substance introduction construct comprising a carrier peptide fragment and a foreign substance of interest bound to the N-terminal side and/or the C-terminal side of the carrier peptide fragment

supplying the foreign substance introduction construct to a sample containing eukaryotic cells of interest

and incubating the sample into which the foreign substance introduction construct has been supplied to thereby introduce the construct into the eukaryotic cells in the sample, wherein the carrier peptide fragment comprises an amino acid sequence selected from those depicted in SEQ ID No:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 or an amino acid sequence produced by substituting, deleting and/or adding (inserting) one, two or three amino acid residues in the selected amino acid sequence.

Priority: JP20090177102 Applic. Date: 2009-07-29

Inventor: YOSHIDA TETSUHIKO [JP]; KOBAYASHI NAHOKO [JP]; NIWA MIKIO [JP]; TANAKA KENICHI [JP]


Publication No.: WO2011013700A1  Published: 03/Feb/2011

Title: CARRIER PEPTIDE FRAGMENT AND USE THEREOF

Applicant/Assignee: TOAGOSEI CO.,LTD

Application No.: JP2010/062693   Filing Date: 28/Jul/2010

Abstract:A foreign substance introduction method, which comprises the steps of: preparing a foreign substance introduction construct comprising a carrier peptide fragment and a foreign substance of interest bound to the N-terminal side and/or the C-terminal side of the carrier peptide fragment

supplying the foreign substance introduction construct to a sample containing eukaryotic cells of interest

and incubating the sample into which the foreign substance introduction construct has been supplied to thereby introduce the construct into the eukaryotic cells in the sample, wherein the carrier peptide fragment comprises an amino acid sequence: KKRTLRKNDRKKR (SEQ ID NO:1) or an amino acid sequence produced by substituting, deleting and/or adding (inserting) one, two or three amino acid residues in the preceding amino acid sequence.

Priority: JP20090177103 Applic. Date: 2009-07-29

Inventor: YOSHIDA TETSUHIKO [JP]; KOBAYASHI NAHOKO [JP]; NIWA MIKIO [JP]


Publication No.: WO2011013791A1  Published: 03/Feb/2011

Title: KIDNEY-TARGETING DRUG DELIVERY AGENT COMPRISING GENETICALLY MODIFIED GELATIN

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: JP2010/062886   Filing Date: 30/Jul/2010

Abstract:Disclosed is a kidney-targeting drug delivery agent which comprises a bioabsorbable material, can be accumulated in the kidney, particularly organelles in the kidney such as tubular epithelial cells, transiently within a short period, and does not remain in the kidney for a so long period after the accumulation. The kidney-targeting drug delivery agent comprises a gelatin-like protein.

Priority: JP20090177582 Applic. Date: 2009-07-30

Inventor: NAKAMURA KENTARO [JP]; TABATA YASUHIKO [JP]


Publication No.: WO2011013794A1  Published: 03/Feb/2011

Title: WATER-BASED COMPOSITION FOR EYE DROP

Applicant/Assignee: WAKAMOTO PHARMACEUTICAL CO.,LTD

Application No.: JP2010/062891   Filing Date: 30/Jul/2010

Abstract:Disclosed is a water-based composition for eye drop which comprises a ss-blocker typified by timolol or carteolol or an a-blocker such as bunazosin together with boric acid or a pharmaceutically acceptable salt thereof but contains no preservative. It is unnecessary to add a preservative, which is used in the existing eye drops, to the aforesaid composition. Thus, it is expected that the composition exerts little effect on eye tissues even in prolonged use. Moreover, the eye drop is free from microbial contamination in using and, therefore, the drug solution can be used up after opening. Therefore, it is not required to discard a container after each administration as in disposable containers and a large space is not required for preservation, which brings about economical advantages.

Priority: JP20090177626 Applic. Date: 2009-07-30; JP20090177727 Applic. Date: 2009-07-30

Inventor: NAKAYA SEIGO [JP]; OHYAMA YUKAKO [JP]; SUZUKI HIDEKAZU [JP]


Publication No.: WO2011014588A2  Published: 03/Feb/2011

Title: DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS

Applicant/Assignee: AMIRA PHARMACEUTICALS, INC

Application No.: US2010/043599   Filing Date: 28/Jul/2010

Abstract:Described herein are topical formulations for use in the treatment or prevention of dermatological diseases, disorders, or conditions in a mammal. Topical formulations disclosed herein include a DP2 receptor antagonist compound formulated for dermal administration

Priority: US20090230585P Applic. Date: 2009-07-31

Inventor: HUTCHINSON JOHN HOWARD [US]


Publication No.: WO2011014960A1  Published: 10/Feb/2011

Title: PROCESS FOR PREPARATION OF OVER-THE-COUNTER GELATIN OR PECTIN-BASED DRUG DELIVERY

Applicant/Assignee: 7267207 CANADA LIMITED CORPORATION

Application No.: CA2010/001217   Filing Date: 05/Aug/2010

Abstract:Disclosed herein is a process producing a therapeutic comestible gummie product, the process comprises providing a sugar and/or sugar alcohol, water and heating to at least 80 DEG C to produce a first mixture. A gelling agent and water is also provided and heat to at least 80 DEG C to produce a second mixture. Combining the first and second mixtures to produce a slurry. The slurry is heated to at least 112 DEG C to produce a gummie base. The gummie base is cooled to an optimal temperature of below 90 DEG C for the addition of an active drug and the active drug is substantially uniformly mixed with the gummie base. In some embodiments the active is drug is mixed with an ingestible oil and added to the cooling slurry. The gummie base and active drug mixture is then poured into molding trays and allowed to cure. Also disclosed herein by way the process of the present disclosure is therapeutic comestible gummie product. Furthermore, the present disclosure comprises a therapeutic comestible gummie product comprising ibuprofen and/or other active drug(s).

Priority: US20090231627P Applic. Date: 2009-08-05

Inventor: LOWTHER STUART A [CA]; PLANTE REAL [CA]; PILON BRADLEY H [CA]; TARNOPOLSKY MARK A [CA]


Publication No.: WO2011015634A2  Published: 10/Feb/2011

Title: CONTROLLED RELEASE FORMULATIONS OF LIPOCALIN MUTEINS

Applicant/Assignee: PIERIS AG

Application No.: EP2010/061436   Filing Date: 05/Aug/2010

Abstract:The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation.

Finally, the invention is directed to the use of the formulations of the invention for the controlled delivery of the lipocalin mutein, for extending the in vivo half-life of the lipocalin mutein, for increasing the bioavailability of the lipocalin mutein, or for decreasing the immunogenicity of the lipocalin mutein upon administration to a subject as well as methods for the treatment of a disease or disorder comprising the administration of the formulations of the invention to a subject in need thereof.

Priority: US20090231365P Applic. Date: 2009-08-05

Inventor: HOHLBAUM ANDREAS [DE]; HUELSMEYER MARTIN [DE]; GILLE HENDRIK [DE]; MANTRIPRAGADA SANKARAM BHIMA [US]; CAMPBELL KATHLEEN MARIE [US]


Publication No.: WO2011015649A1  Published: 10/Feb/2011

Title: GROWTH HORMONES WITH PROLONGED IN-VIVO EFFICACY

Applicant/Assignee: NOVO NORDISK HEALTH CARE AG

Application No.: EP2010/061473   Filing Date: 06/Aug/2010

Abstract:The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin.

Priority: EP20090167350 Applic. Date: 2009-08-06; US20090232967P Applic. Date: 2009-08-11

Inventor: JOHANSEN NILS LANGELAND [DK]; ANDERSEN HENRIK SUNE [DK]; BUCHARDT JENS [DK]; BEHRENS CARSTEN [DK]; NOERSKOV-LAURITSEN LEIF [DK]; SU JING [DK]


Publication No.: WO2011016043A2  Published: 10/Feb/2011

Title: ANTIBIOTIC DRUG DELIVERY AND POTENTIATION

Applicant/Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD

Application No.: IL2010/000638   Filing Date: 05/Aug/2010

Abstract:Disclosed are compositions-of-matter comprising polymer-mediated cochleates, which are formed from a calcium-free mixture of a wide variety of phospholipids that are atypical for forming cochleates. Further disclosed are compositions-of-matter comprising these cochleates which co-encapsulate another bioactive agent. The polymer mediating the formation of these cochleates exhibits a plurality of positively charged amino acid residues and ?-amino-fatty acid moieties, and may further exhibit antimicrobial, anticancerous and drug-potentiating activity. Further disclosed are pharmaceutical compositions and methods using the compositions-of-matter disclosed herein, and processes of preparing same.

Priority: US20090231709P Applic. Date: 2009-08-06

Inventor: MOR AMRAM [IL]; EPAND RICHARD M [CA]; EPAND RAQUEL F [CA]; PAPAHADJOPOULOS-STERNBERG BRIGITTE [US]


Publication No.: WO2011016049A2  Published: 10/Feb/2011

Title: A STABLE COMPOSITION OF READY-TO-USE GEMCITABINE INJECTION

Applicant/Assignee: ASTRON RESEARCH LIMITED

Application No.: IN2010/000501   Filing Date: 29/Jul/2010

Abstract:The present invention relates to non aqueous pharmaceutical preparations containing gemcitabine or its pharmaceutically, acceptable salts in the form of ready-to-use solutions wherein the concentration of Gemcitabine is in the range of about 16 mg/ml to about 200 mg/ml and a pH of about 3.5 to 10.0. Further, a method for the preparation of non- aqueous Gemcitabine solution of the present invention is also disclosed.

Priority: IN2009MU01766 Applic. Date: 2009-07-31

Inventor: MUKESH BOTHRA [IN]; BHAVESH PATEL [IN]; ASHISH SEHGAL [IN]; JAYANTA KUMAR MANDAL [IN]


Publication No.: WO2011016435A1  Published: 10/Feb/2011

Title: METHOD FOR PRODUCING FREEZE-DRIED COMPOSITION CONTAINING POLYLACTIC ACID PARTICLES

Applicant/Assignee: SENJU PHARMACEUTICAL CO., LTD

Application No.: JP2010/063055   Filing Date: 03/Aug/2010

Abstract:Provided are a method for preventing the formation of coarse particles in the process of freeze-drying an aqueous suspension of fine polylactic acid particles, and a method for producing polylactic acid particles for use as an agent for rendering the transparent tissue of the eye visible. The method for suppressing the formation of coarse particles when an aqueous suspension of fine polylactic acid particles is freeze-dried includes: (a) a step in which an aqueous suspension of fine polylactic acid particles containing a dispersing agent and from 3.5% to 10% mannitol is prepared by (i) adding, while stirring, a solution of polylactic acid dissolved in a water miscible organic solvent to a dispersing agent aqueous solution and then adding mannitol, or (ii) adding, while stirring, the solution of polylactic acid dissolved in said solvent to a dispersing agent/mannitol aqueous solution containing a dispersing agent and mannitol

and (b) a step in which said suspension is freeze-dried in a glass container. The method for producing polylactic acid particles for use as an agent for rendering transparent tissue visible includes the steps (a) and (b).

Priority: JP20090181970 Applic. Date: 2009-08-04

Inventor: MATSUHISA KEIICHI [JP]


Publication No.: WO2011016436A1  Published: 10/Feb/2011

Title: METHOD FOR PRODUCING FREEZE-DRIED COMPOSITION CONTAINING FINE POLYLACTIC ACID PARTICLES

Applicant/Assignee: SENJU PHARMACEUTICAL CO., LTD

Application No.: JP2010/063056   Filing Date: 03/Aug/2010

Abstract:Provided are a method for preventing the formation of coarse particles in the process of freeze-drying an aqueous suspension of fine polylactic acid particles, and a method for producing polylactic acid particles for use as an agent for rendering visible transparent tissue of the eye. The method for suppressing the formation of coarse particles when an aqueous suspension of fine polylactic acid particles is freeze-dried includes: (a) a step in which an aqueous suspension of fine polylactic acid particles containing dispersing agent and excipient is prepared by (i) adding, while stirring, a solution of polylactic acid dissolved in a water miscible organic solvent to a dispersing agent aqueous solution and then adding excipient, or (ii) adding, while stirring, the solution of polylactic acid dissolved in said solvent to an aqueous solution containing dispersing agent and excipient

and (b) a step in which said suspension is freeze-dried in a glass container, wherein the glass container is placed in the chamber of a freeze dryer and the rate of cooling in the chamber when said suspension is frozen is adjusted to 0.1 to 1 DEG C/minute.

Priority: JP20090181971 Applic. Date: 2009-08-04

Inventor: MATSUHISA KEIICHI [JP]


Publication No.: WO2011016487A1  Published: 10/Feb/2011

Title: INDIGOCARMINE PREPARATION

Applicant/Assignee: NAGASE MEDICALS CO., LTD, MYLAN SEIYAKU LTD

Application No.: JP2010/063188   Filing Date: 04/Aug/2010

Abstract:Disclosed is a storage-stabilized indigocarmine preparation which is characterized by containing indigocarmine and at least one kind of reducing agent that is selected from the group consisting of ascorbic acid, isoascorbic acid, L-cysteine and tannic acid.

Priority: JP20090182821 Applic. Date: 2009-08-05

Inventor: UMEKAWA TOMOMICHI [JP]; TAKEDA TOMOHARU [JP]; YOSHIOKA YU [JP]


Publication No.: WO2011016527A1  Published: 10/Feb/2011

Title: HYDROXYL RADICAL GENERATOR, ANTIVIRAL MATERIAL USING HYDROXYL RADICAL GENERATOR, AND METHOD FOR GENERATING HYDROXYL RADICALS

Applicant/Assignee: MOCHIGASE CO., LTD

Application No.: JP2010/063311   Filing Date: 05/Aug/2010

Abstract:Disclosed are: a hydroxyl radical generator which is capable of efficiently generating hydroxyl radicals

an antiviral material using the hydroxyl radical generator

and a method for generating hydroxyl radicals. Specifically disclosed is a hydroxyl radical generator which is composed of a mixture that contains a titanium oxide powder and a powder or solution of an additive that is compose of at least one substance selected from the group consisting of a partial hydrate of dolomite, silver oxide, aluminum hydroxide, aluminum oxide, magnesium hydroxide, calcium hydroxide, potassium hydroxide and sodium hydroxide. The mixture contains 99-1% by weight of the titanium oxide and 1-99% by weight of the additive.

Priority: JP20090185309 Applic. Date: 2009-08-07

Inventor: YAMAMOTO NORIO [JP]


Publication No.: WO2011016562A1  Published: 10/Feb/2011

Title: OPHTHALMIC COMPOSITION FOR SILICONE HYDROGEL CONTACT LENS

Applicant/Assignee: ROHTO PHARMACEUTICAL CO., LTD

Application No.: JP2010/063419   Filing Date: 06/Aug/2010

Abstract:Disclosed is an ophthalmic composition for a silicone hydrogel contact lens, which can prevent the deformation of a silicone hydrogel contact lens caused by the action of polyoxyethylene hydrogenated castor oil. Specifically disclosed is an ophthalmic composition for a silicone hydrogel contact lens, which contains (A) polyoxyethylene hydrogenated castor oil and additionally contains (B) at least one compound selected from the group consisting of chlorhexidine compounds and cyclodextrin compounds.

Priority: JP20090185269 Applic. Date: 2009-08-07

Inventor: MATSUMOTO ERI [JP]; NAKATA ATSUKO [JP]


Publication No.: WO2011017055A2  Published: 10/Feb/2011

Title: BLOOD COAGULATION PROTEIN CONJUGATES

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: US2010/043242   Filing Date: 26/Jul/2010

Abstract:The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.

Priority: US20090228828P Applic. Date: 2009-07-27; US20100347136P Applic. Date: 2010-05-21

Inventor: SIEKMANN JUERGEN [AT]; HAIDER STEFAN [AT]; ROTTENSTEINER HANSPETER [AT]; TURECEK PETER [AT]


Publication No.: WO2011017101A2  Published: 10/Feb/2011

Title: METHOD FOR PRODUCING PROTEIN-CARBOHYDRATE VACCINES REDUCED IN FREE CARBOHYDRATE

Applicant/Assignee: FINA BIOSOLUTIONS, LLC

Application No.: US2010/043387   Filing Date: 27/Jul/2010

Abstract:This invention is directed to processes for reducing the level of free carbohydrate from a solution of protein-linked carbohydrate (conjugate) and non-linked carbohydrate. In this process, the conjugate is adsorbed to a hydrophobic membrane while the carbohydrate is not. The conjugate is then desorbed from the membrane, yielding a solution that is substantially reduced in free carbohydrate.

Priority: US20090228784P Applic. Date: 2009-07-27

Inventor: LEES ANDREW [US]


Publication No.: WO2011017249A1  Published: 10/Feb/2011

Title: ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF

Applicant/Assignee: MEDAREX, INC

Application No.: US2010/044078   Filing Date: 02/Aug/2010

Abstract:Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:

Priority: US20090230932P Applic. Date: 2009-08-03; US20090232883P Applic. Date: 2009-08-11

Inventor: CHENG HENG [US]; CONG QIANG [US]; GANGWAR SANJEEV [US]; ZHANG QIAN [US]


Publication No.: WO2011017346A2  Published: 10/Feb/2011

Title: FAST-ACTING NAPROXEN COMPOSITION WITH REDUCED GASTROINTESTINAL EFFECTS

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: US2010/044279   Filing Date: 03/Aug/2010

Abstract:The present invention relates to pharmaceutical formulations containing Naproxen and a delivery agent.

Priority: US20090230964P Applic. Date: 2009-08-03

Inventor: NOVINSKI MICHAEL [US]; OSINSKI PATRICK [US]; HART NICHOLAS [US]


Publication No.: WO2011017382A2  Published: 10/Feb/2011

Title: NANOFIBERS AND MORPHOLOGY SHIFTING MICELLES

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/044321   Filing Date: 03/Aug/2010

Abstract:The invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.

Priority: US20090230924P Applic. Date: 2009-08-03; US20100316325P Applic. Date: 2010-03-22

Inventor: CHIEN MIAO-PING [US]; GIANNESCHI NATHAN C [US]


Publication No.: WO2011017835A1  Published: 17/Feb/2011

Title: PREPARATION METHOD OF PROTEIN OR PEPTIDE NANOPARTICLES FOR IN VIVO DRUG DELIVERY BY UNFOLDING AND REFOLDING

Applicant/Assignee: NANJING UNIVERSITY, NANJING EFFECT PHARM DRUG DEVELOPMENT CORPORATION

Application No.: CN2009/073180   Filing Date: 11/Aug/2009

Abstract:Preparation method of protein and peptide nanoparticles for in vivo delivery of pharmacologically active agetnts is disclosed. The method is carried out to encase pharmaceutically active agents into proteins or peptides to form nanoparicles by unfolding and refolding transitions, wherein said unfolding and refolding transitions comprise subjecting proteins or peptides to unfolding solution or external stress and then refolding them in refolding solution. The produced particles comprise 1-25% by weight of pharmacologically active agents.

Priority:

Inventor: HU YIQIAO [CN]; WU JINHUI [CN]; DING DAWEI [CN]; GONG GUANGMING [CN]; TANG XIAOLEI [CN]; TONG CHUNHUI [CN]; ZHU YAN [CN]


Publication No.: WO2011018227A2  Published: 17/Feb/2011

Title: PEPTIDE LIBRARIES

Applicant/Assignee: MEDICAL RESEARCH COUNCIL

Application No.: EP2010/004948   Filing Date: 12/Aug/2010

Abstract:The invention relates to a method for altering the conformational diversity of a first repertoire of polypeptide ligands, comprising a plurality of polypeptides comprising at least two reactive groups separated by a loop sequence covalently linked to a molecular scaffold which forms covalent bonds with said reactive groups, to produce a second repertoire of polypeptide ligands, comprising assembling said second repertoire from the polypeptides and structural scaffold of said first repertoire, incorporating one of the following alterations: (a) altering at least one reactive group

or (b) altering the nature of the molecular scaffold

or (c) altering the bond between at least one reactive group and the molecular scaffold

or (d) any combination of (a), (b) or (c).

Priority: GB20090014110 Applic. Date: 2009-08-12

Inventor: WINTER PAUL GREGORY [GB]; HEINIS CHRISTIAN [GB]; BERNARD ELISE [GB]; LOAKES DAVID [GB]; TEUFEL DANIEL PAUL [GB]


Publication No.: WO2011018480A1  Published: 17/Feb/2011

Title: PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE PARENTERALLY ADMINISTERED

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: EP2010/061701   Filing Date: 11/Aug/2010

Abstract:The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.

Priority: FR20090055612 Applic. Date: 2009-08-11

Inventor: LEVERD ELIE [FR]; VAN HOOGEVEST PETER [CH]; KUNG ELSA [CH]; LEIGH MATHEW [CH]


Publication No.: WO2011018541A2  Published: 17/Feb/2011

Title: HYDROGELS BASED ON POLOXAMERS WITH A STAR STRUCTURE FOR THE CONTROLLED RELEASE OF ACTIVE SUBSTANCES

Applicant/Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CISC), UNIVERSIDAD COMPLUTENSE DE MADRID (UCM)

Application No.: ES2010/070538   Filing Date: 04/Aug/2010

Abstract:The invention relates to a compound based on poloxamers and a hydrogel comprising said compounds, and to the use of said hydrogels as vehicles for administering active substances or as adjuvants in pharmaceutical compositions, especially those administered in an ocular topical manner.

Priority: ES20090030587 Applic. Date: 2009-08-10

Inventor: PARRA RUIZ FRANCISCO JESUS [ES]; VAZQUEZ LASA BLANCA [ES]; SAN ROMAN DEL BARRIO JULIO [ES]; RODRIGUEZ ALONSO LUCENA [ES]; HERRERO VANRELL MARIA DEL ROCIO [ES]


Publication No.: WO2011018800A2  Published: 17/Feb/2011

Title: A NOVEL IN-SITU GEL FORMING SOLUTION FOR OCULAR DRUG DELIVERY

Applicant/Assignee: FDC LIMITED

Application No.: IN2010/000536   Filing Date: 13/Aug/2010

Abstract:Disclosed herein is a novel in-situ gel forming system for ocular drug delivery comprises a combination of natural polysaccharide having thixotropic behavior, thermoreversible polymer and a vehicle alongwith one or more optional components selected from active pharmaceutical ingredient(s), buffer, preservative with or without stabilizer, pH modifier(s) and tonicity modifiers.

Priority: IN2009MU01874 Applic. Date: 2009-08-13

Inventor: CHANDAVARKAR NANDAN MOHAN [IN]; JINDAL KOUR CHAND [IN]; MALAYANDI RAJKUMAR [IN]


Publication No.: WO2011018801A2  Published: 17/Feb/2011

Title: SOLID ORAL DOSAGE FORM OF ZIPRASIDONE

Applicant/Assignee: GENEPHARM INDIA PVT LTD

Application No.: IN2010/000537   Filing Date: 12/Aug/2010

Abstract:A solid oral dosage form comprising ziprasidone or its pharmaceutically acceptable salt and cationic ion exchange resin and the process of its preparation.

Priority: IN2009MU01863 Applic. Date: 2009-08-12

Inventor: MURPANI DEEPAK [IN]; ALEXAKI PANDORA [GR]


Publication No.: WO2011018858A1  Published: 17/Feb/2011

Title: NOVEL MASTITIS VACCINE

Applicant/Assignee: NAI INC

Application No.: JP2009/064601   Filing Date: 14/Aug/2009

Abstract:Disclosed is a novel mastitis vaccine. More specifically disclosed is a novel mastitis vaccine, which can efficiently induce humoral or cellular transmucosal immune responses mainly including the production of IgA antibodies. A liposome containing a membrane-fusogenic lipid (methylglutaryl-modified polyglycidol) is used as a vaccine carrier. The mastitis vaccine comprises a vaccine carrier comprising a liposome containing methylglutaryl-modified polyglycidol and an immunogen contained in the vaccine carrier.

Priority:

Inventor: WATARAI SHINOBU [JP]; KONO KENJI [JP]


Publication No.: WO2011019043A1  Published: 17/Feb/2011

Title: TABLET THAT DISINTEGRATES RAPIDLY IN THE MOUTH AND THAT CONTAINS TWO OR MORE TYPES OF PARTICLES

Applicant/Assignee: DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/063599   Filing Date: 11/Aug/2010

Abstract:The disclosed tablet that disintegrates rapidly in the mouth is for a drug having an unpleasant flavour, and is characterised by being hard enough so as to not interfere with handling between production and consumption and in particular remains hard after becoming moist. The tablet is small so the unpleasant flavour is not tasted, feels pleasant to take, has excellent disintegration properties in the mouth and elution properties in the alimentary canal and contains two or more types of particles.

Priority: JP20090186643 Applic. Date: 2009-08-11

Inventor: FUJIWARA KEIICHI [JP]


Publication No.: WO2011019045A1  Published: 17/Feb/2011

Title: DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET

Applicant/Assignee: FUJI CHEMICAL INDUSTRY CO., LTD, DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/063601   Filing Date: 11/Aug/2010

Abstract:There has been a need for an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity and can sustain a sufficient hardness even under humid conditions after opening. Disclosed are a disintegrating particle composition which is prepared by dispersing, in the presence of water, mannitol, xylitol, an inorganic excipient, a disintegrating agent and carmellose and drying, and an orally rapidly disintegrating tablet which comprises said disintegrating particle composition, an active substance and a disintegrating agent. The disintegrating tablet has a good texture and taste, an appropriate hardness and good disintegrating properties and can sustain a sufficient hardness under humid conditions.

Priority: JP20090186646 Applic. Date: 2009-08-11

Inventor: FUJIWARA KEIICHI [JP]; FUKAMI TADASHI [JP]; KOIZUMI HARUKA [JP]


Publication No.: WO2011019046A1  Published: 17/Feb/2011

Title: DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET

Applicant/Assignee: FUJI CHEMICAL INDUSTRY CO., LTD, DAINIPPON SUMITOMO PHARMA CO., LTD

Application No.: JP2010/063602   Filing Date: 11/Aug/2010

Abstract:Disclosed is an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity. The orally rapidly disintegrating tablet, which has a good texture and taste, an appropriate hardness, and good disintegrating properties, can be produced by using a composition, which is prepared by dispersing, by spray-drying, an inorganic excipient and starch(es) in complex particles composed of mannitol and xylitol, in an orally rapidly disintegrating tablet.

Priority: JP20090186648 Applic. Date: 2009-08-11

Inventor: FUJIWARA KEIICHI [JP]; FUKAMI TADASHI [JP]; KOIZUMI HARUKA [JP]


Publication No.: WO2011019317A1  Published: 17/Feb/2011

Title: COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTION OF THE NAIL

Applicant/Assignee: MOBERG DERMA AB

Application No.: SE2010/050886   Filing Date: 13/Aug/2010

Abstract:A stable antifungal composition for topical application on a nail comprising a diol component, an organic acid component, a volatile vehicle, an antifungal agent and a keratolytic agent

the active compound and the keratolytic agent are soluble in the composition in the absence of said volatile vehicle, and wherein at least one in the group selected from the antifungal agent and the keratolytic agent is present in solid state in the composition in the presence of said volatile vehicle. Preferred ingredients include propylene glycol, lactic acid, ethyl acetate, urea and terbinafine or naftifine.

Priority: US20090233557P Applic. Date: 2009-08-13

Inventor: LINDAHL AAKE [SE]


Publication No.: WO2011019323A1  Published: 17/Feb/2011

Title: PARTICULATE HYALURONIC ACID FORMULATIONS FOR CELLULAR DELIVERY OF BIOACTIVE AGENTS

Applicant/Assignee: AGENCY FOR SCIENCE TECHNOLOGY AND RESEARCH

Application No.: SG2010/000297   Filing Date: 11/Aug/2010

Abstract:There is presently provided a suspension of immiscible particles in a solution, wherein the particles comprise an agglomeration of a bioactive agent

and a plurality of conjugates of a hyaluronic acid and a flavonoid wherein the particles are on average from about 15 nm to about 300 nm in diameter and wherein the bioactive agent is releasably retained in the particles by the flavonoid. There is also provided a therapeutic formulation comprising such a suspension and methods for using the suspension and therapeutic formulation, including for delivery of a bioactive agent to a cell and for treating a disease, including cancer.

Priority: SG20090005341 Applic. Date: 2009-08-11

Inventor: KURISAWA MOTOICHI [SG]; NG SHENGYONG [SG]; CHUNG JOO EUN [SG]


Publication No.: WO2011019685A2  Published: 17/Feb/2011

Title: SECOND GENERATION FATTY ACID COMPOSITIONS, FORMULATIONS, AND METHODS OF USE AND SYNTHESIS THEREOF

Applicant/Assignee: DRACOPHARMA, INC

Application No.: US2010/044962   Filing Date: 10/Aug/2010

Abstract:An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The composition may include at least one omega-3 fatty acid amide, and/or at least one omega-3 fatty acid plus ethanolamine, and at least one tocotrienol. The composition may include 5Z,8Z,l lZ,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100 - 900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10 - 500 mg per dosage form. The at least one tocotrienol includes at least one of a-tocotrienol, ss- tocotrienol, ?-tocotrienol, or d-tocotrienol and is preferably substantially tocopherol- free.

The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg d-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.

Priority: US20090288587P Applic. Date: 2009-12-21; US2010-852620 Applic. Date: 2010-08-09; US20090232554P Applic. Date: 2009-08-10

Inventor: QUAY STEVEN C [US]


Publication No.: WO2011019940A2  Published: 17/Feb/2011

Title: DEUTERATED WATER AND RIBOFLAVIN SOLUTION FOR EXTENDING SINGLET OXYGEN LIFETIMES IN TREATMENT OF OCULAR TISSUE AND METHOD FOR USE

Applicant/Assignee: SEROS MEDICAL, LLC

Application No.: US2010/045356   Filing Date: 12/Aug/2010

Abstract:A solution of deuterated water containing a riboflavin-based photosensitizer is provided in order to extend lifetimes of UVA/Rf photo-generated intra-stromal singlet oxygen, in combination with UVA delivery profiles of pulsing, fractionation, and optionally auxiliary stromal/Rf hyper-oxygenation in order to accelerate protein cross-linking density rates in ocular tissue. A 100% deuterated water solution with 0.1% riboflavin in solution increases singlet oxygen lifetimes by at least an order of magnitude without inducing endothelial cell apoptosis, thereby also permitting use of some combination of lower percentages of deuterated water, lower concentrations of riboflavin or lower dosages of UVA on intact (un-debrided) epithelium for equivalent cross-link densities compared to current acceptable corneal cross-linking procedures.

Lower concentrations of deuterated water with regular water, for example, yields shorter singlet oxygen lifetimes in approximately linear proportion to concentration, which are considered acceptable in therapies known or being developed in the art of corneal cross-linking.

Priority: US20090233315P Applic. Date: 2009-08-12

Inventor: HEREKAR SATISH V [US]


Publication No.: WO2011020047A1  Published: 17/Feb/2011

Title: USE OF IL-15 TO INCREASE THYMIC OUTPUT AND TO TREAT LYMPHOPENIA

Applicant/Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFHE

Application No.: US2010/045511   Filing Date: 13/Aug/2010

Abstract:The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15.

Priority: US20090234152P Applic. Date: 2009-08-14; US20090234155P Applic. Date: 2009-08-14

Inventor: PAVLAKIS GEORGE N [US]; FELBER BARBARA K [US]; VALENTIN ANTONIO [US]; BERGAMASCHI CRISTINA [US]


Publication No.: WO2011020054A1  Published: 17/Feb/2011

Title: METHOD FOR MODULATING THE PHARMACODYNAMIC EFFECT OF ORALLY ADMINISTERED GUANYLATE CYCLASE RECEPTOR AGONISTS

Applicant/Assignee: IRONWOOD PHARMACEUTICALS INC

Application No.: US2010/045518   Filing Date: 13/Aug/2010

Abstract:A method of modulating the pharmacodynamic effect of a GC-C receptor agonist polypeptide formulation in a subject in need of such treatment is disclosed, The method comprises administering the GC-C receptor agonist polypeptide formulation to the subject before the ingestion of food.

Priority: US20090233740P Applic. Date: 2009-08-13

Inventor: JOHNSTON JEFFREY [US]; KURTZ CAROLINE [US]


Publication No.: WO2011020079A1  Published: 17/Feb/2011

Title: ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS OF USE

Applicant/Assignee: CALMUNE CORPORATION

Application No.: US2010/045549   Filing Date: 13/Aug/2010

Abstract:Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.

Priority: US20090274395P Applic. Date: 2009-08-13

Inventor: WILLIAMSON ROBERT ANTHONY [US]; WADIA JEHANGIR [US]; PASCUAL GABRIEL [US]; KEOGH ELISSA [US]


Publication No.: WO2011020107A2  Published: 17/Feb/2011

Title: COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF BREAST CANCER

Applicant/Assignee: GEORGETOWN UNIVERSITY

Application No.: US2010/045645   Filing Date: 16/Aug/2010

Abstract:Disclosed herein are compositions and methods relating to detecting breast cancer. Further provided are methods and compositions for treating breast cancer.

Priority: US20090234163P Applic. Date: 2009-08-14

Inventor: PAIGE MIKELL A [US]; TIMOFEEVA OLGA [US]


Publication No.: WO2011020188A1  Published: 24/Feb/2011

Title: PEPTIDE SEQUENCES AND PEPTIDE-MEDIATED SIRNA DELIVERY

Applicant/Assignee: UNIVERSITY OF WATERLOO

Application No.: CA2010/001275   Filing Date: 20/Aug/2010

Abstract:Peptides and a complex comprising a peptide and a cargo molecule, wherein the peptide and the cargo molecule are coupled by a non-covalent molecular association Peptides of the invention are designed according to five separate design criteria Certain members of these groups w ere found to facilitate the delivery en of siRNA molecules into eukariotic cells and siRNA mediated silencing of cellular targets

Priority: US20090235934P Applic. Date: 2009-08-21

Inventor: CHEN PU [CA]; MOUSA JAFARI [CA]; JIANG JOHN X [CA]; FUNG SHAN-YU [CA]; YONG HONG [CA]


Publication No.: WO2011020189A1  Published: 24/Feb/2011

Title: FORMS OF DEXLANSOPRAZOLE AND PROCESSES FOR THE PREPARATION THEREOF

Applicant/Assignee: APOTEX PHARMACHEM INC

Application No.: CA2010/001276   Filing Date: 19/Aug/2010

Abstract:Provided is dexlansoprazole propylene glycolate hydrate. Polymorphic forms thereof are also provided. The dexlansoprazole propylene glycolate hydrate maybe such that the propylene glycol component is present in approximately equal proportions of (R) absolute configuration and (S) absolute configuration, or present in predominantly (R) absolute configuration, or predominantly (S) absolute configuration. Salts of dexlansoprazole are also provided. In particular, crystalline dexlansoprazole isopropylammonium salt and crystalline MTBE solvate of dexlansoprazole t-butylammonium salt are provided. Pharmaceutical formulations comprising dexlansoprazole propylene glycolate hydrate are also provided. Furthermore, processes for preparation of dexlansoprazole propylene glycolate hydrate are provided.

Priority: US20090235205P Applic. Date: 2009-08-19; US20090243359P Applic. Date: 2009-09-17

Inventor: WANG FAN [CA]; KELLS KEVIN W [CA]; MILNES KAARINA [CA]; MCPHAIL CAMERON L [CA]


Publication No.: WO2011020294A1  Published: 24/Feb/2011

Title: MAGNETIC NANOPARTICLES HAVING NOVEL CORE-SHELL STRUCTURE AND PH RESPONSIVENESS, AND USE THEREOF

Applicant/Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA

Application No.: CN2010/001243   Filing Date: 17/Aug/2010

Abstract:A class of magnetic composite nanoparticles of multilayer core-shell structure having Fe3O4 nanoparticles encapsulated by a triblock copolymer, and use of the composite nanoparticles as drug carriers are provided. The first block of the triblock copolymer is methoxypolyethylene glycol

the second block is a random copolymer of acrylic acid and acrylate, or a random copolymer of methacrylic acid and methacrylate

and the third block is polyglycerol monoacrylate or polyglycerol monomethacrylate. The third block polymer is combined with the surface of Fe3O4 nanoparticles. The drugs having amino group or amine group, such as adriacin can be loaded on a polyanion layer which is outer sublayer of the composite nanoparticles. The loaded drugs will not be released under neutral condition and will be released when pH is under 5.5.

Priority: CN20091166438 Applic. Date: 2009-08-17

Inventor: LIU KELIANG [CN]; YAN HUSHENG [CN]; GUO MIAO [CN]; YAN YU [CN]


Publication No.: WO2011020526A1  Published: 24/Feb/2011

Title: TABLETTING OF ERYTHRITOL AND ISOMALT

Applicant/Assignee: CARGILL, INCORPORATED

Application No.: EP2010/004223   Filing Date: 12/Jul/2010

Abstract:Erythritol is granulated together with from 10% w/w to 50% w/w isomalt. Chewable tablets are prepared and the corresponding process is described.

Priority: EP20090010597 Applic. Date: 2009-08-18

Inventor: BOGHMANS CATHERINE PATRICIA L [BE]; MEEUS LIESBETH MARIA FERNANDE [BE]


Publication No.: WO2011020783A2  Published: 24/Feb/2011

Title: TARGETED IMMUNOCONJUGATES

Applicant/Assignee: ROCHE GLYCART AG

Application No.: EP2010/061810   Filing Date: 13/Aug/2010

Abstract:The present invention relates to immunoconjugates. In particular embodiments, the present invention relates to immunoconjugates comprising at least one single-chain effector moiety and two or more antigen binding moieties. In addition, the present invention relates to nucleic acid molecules encoding such immunoconjugates, vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.

Priority: US20090234584P Applic. Date: 2009-08-17; EP20100162410 Applic. Date: 2010-05-10

Inventor: HOSSE RALF [CH]; MOESSNER EKKEHARD [CH]; SILACCI-MELKKO MICHELA [CH]; UMANA PABLO [CH]


Publication No.: WO2011020866A2  Published: 24/Feb/2011

Title: ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS

Applicant/Assignee: CSL BEHRING GMBH

Application No.: EP2010/062069   Filing Date: 18/Aug/2010

Abstract:The present invention relates to pharmaceutical preparations comprising albumin- fused coagulation factors for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders and to a method for increasing the in- vivo recovery after non-intravenous administration of a coagulation factor by fusing it to albumin.

Priority: EP20090010699 Applic. Date: 2009-08-20; US20090237006P Applic. Date: 2009-08-26

Inventor: KRONTHALER ULRICH [DE]


Publication No.: WO2011020933A2  Published: 24/Feb/2011

Title: LIPOSOMES COVERED WITH THE EXTRACELLULAR DOMAIN OF THE APO2L/TRAIL PROTEIN

Applicant/Assignee: UNIVERSIDAD DE ZARAGOZA, UNIVERSIDAD DEL PAIS VACO / EUSKAL HERRIKO UNIBERTSITATEA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Application No.: ES2010/000354   Filing Date: 12/Aug/2010

Abstract:The invention relates to the field of biotechnology and medicine. The invention specifically relates to a compound comprising a liposome covered or decorated at least with the extracellular domain of the APO2L/TRAIL protein, and to the use thereof for developing a medicament preferably for the treatment of a cancer or inflammatory or autoimmune diseases, such as rheumatoid arthritis.

Priority: ES20090030618 Applic. Date: 2009-08-21

Inventor: ANEL BERNAL LUIS ALBERTO [ES]; MARTINEZ LORENZO MARIA JOSE [ES]; MARTINEZ LOSTAO LUIS [ES]; ALAVA MARTINEZ DE CONTRASTA MARIA ANGELES [ES]; LARRAD MUR LUIS [ES]; NAVAL IRABERRI JAVIER [ES]; PINEIRO ANTON ANDRES [ES]; BASANEZ ASUA GORKA [ES]


Publication No.: WO2011021390A1  Published: 24/Feb/2011

Title: BISPHOSPHONIC ACID DERIVATIVE AND COMPOUND THEREOF LABELED WITH RADIOACTIVE METAL NUCLIDE

Applicant/Assignee: FUJIFILM RI PHARMA CO., LTD

Application No.: JP2010/005111   Filing Date: 19/Aug/2010

Abstract:Disclosed is a radioactive bone diagnostic agent which gives a high ratio of radioactivity accumulation in bone to that in blood from an early stage of administration of the agent and is capable of capturing an image in a short time after administration. Also disclosed is a bisphosphonic acid derivative represented by chemical formula (II) or a salt thereof. In formula (II), X represents -(CH2)mCO-, Y represents -(CH2)n-, R represents H, OH, or a halogen atom, m and n are independent of each other and m represents an integer of 1 to 3, and n represents an integer of 0 to 4.

Priority: JP20090190714 Applic. Date: 2009-08-20

Inventor: DOZONO HIROYUKI [JP]


Publication No.: WO2011021594A1  Published: 24/Feb/2011

Title: SUSTAINED DRUG DELIVERY SYSTEM

Applicant/Assignee: TOHOKU UNIVERSITY

Application No.: JP2010/063793   Filing Date: 10/Aug/2010

Abstract:Disclosed is a drug delivery system for delivering a drug at a sustained constant rate for a long period, which can be transplanted into an affected part safely and in a simple manner and can deliver a drug to the affected part for a long period. Specifically disclosed is a sustained drug delivery system characterized in that an implant is transplanted into a body, wherein the implant is a PEG capsule comprising a box-shaped PEG and a porous PEG sheet, and wherein the box-shaped PEG has, encapsulated therein, a solution of a therapeutic drug, a collagen impregnated with the therapeutic drug, or a PEG pellet containing the collagen impregnated with the therapeutic drug, and the PEG capsule has such a structure that the box-shaped PEG is covered with the porous PEG sheet so that the drug contained in the PEG capsule can be released through the porous PEG sheet in a sustained manner.

Priority: JP20090189462 Applic. Date: 2009-08-18

Inventor: ABE TOSHIAKI [JP]; NAGAI NOBUHIRO [JP]; KAJI HIROKAZU [JP]; KAWASHIMA TAKEAKI [JP]; NISHIZAWA MATSUHIKO [JP]; NISHIDA KOJI [JP]


Publication No.: WO2011021597A1  Published: 24/Feb/2011

Title: QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION

Applicant/Assignee: EISAI R&D MANAGEMENT CO., LTD

Application No.: JP2010/063804   Filing Date: 16/Aug/2010

Abstract:Disclosed is a pharmaceutical composition which contains: a compound represented by formula (I), a pharmacologically acceptable salt thereof, or a solvate of the compound or salt

and a basic substance. The pharmaceutical composition has excellent dissolvability, is stable even after long-term storage, and is useful as a prophylactic/therapeutic agent for tumors. (In the formula, R1 represents a hydrogen atom, a C1-6 alkyl group or a C3-8 cycloalkyl group

and R2 represents a hydrogen atom or a methoxy group.)

Priority: JP20090190145 Applic. Date: 2009-08-19

Inventor: BANDO MASASHI [JP]


Publication No.: WO2011021804A2  Published: 24/Feb/2011

Title: SENSITIVE POLYMER CAPSULE AND METHOD FOR PREPARING SAME

Applicant/Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION

Application No.: KR2010/005256   Filing Date: 11/Aug/2010

Abstract:Proposed is a polymer capsule obtained by polymerizing the compound expressed in chemical formula 1, or by polymerizing the compound expressed in chemical formula 1 and the compound expressed in chemical formula 2. The detailed structures of the compounds of chemical formula 1 and chemical formula 2 are described in the detailed description of the invention.

Priority: KR20090075739 Applic. Date: 2009-08-17

Inventor: KIM KI MOON [KR]; LEE JIYEONG [KR]; KIM DONGWOO [KR]; KIM EUNJU [KR]; JUNG HYUNTAE [KR]


Publication No.: WO2011022056A2  Published: 24/Feb/2011

Title: PEPTIDE MODULATORS OF THE dPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Applicant/Assignee: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC

Application No.: US2010/002268   Filing Date: 18/Aug/2010

Abstract:The present invention provides isolated or synthetic peptides derived from the d subunit of mammalian F1 Fo ATP synthase (dF1 Fo) protein for the purposes of tissue protection and improved energy production following acute injury from ischemia/reperfusion or other toxic insults, or in chronic diseases such as diabetes and cancer. The major focus of the patent protection will be 2 peptides comprising an amino acid sequence having at least 75% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 and pharmaceutical compositions thereof. However, additional peptide sequences within the dF1Fo protein may also have efficacies in these disease states and we therefore include all peptides shown in the Figures of this application (combined with the HIV-Tat protein transduction, COIV mitochondrial targeting and Flag domains) for their efficacies in these conditions.

Priority: US20090274431P Applic. Date: 2009-08-18; US20100396375P Applic. Date: 2010-05-26

Inventor: JOHNSON JOHN A [US]; NGUYEN TIFFANY TUYEN M [US]; OGBI MOURAD [US]


Publication No.: WO2011022291A2  Published: 24/Feb/2011

Title: PHOTOREGULATED REVERSIBLE HYDROGELS FOR DELIVERY AND RELEASING OF DRUGS AND OTHER THERAPEUTICAL REAGENTS

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC

Application No.: US2010/045314   Filing Date: 12/Aug/2010

Abstract:A novel hydrogel delivery systems useful for encapsulating and releasing pharmaceuticals or chemicals is disclosed where water soluble polymers containing crosslinker repeating units that associate or dissociate with complementary crosslinking repeating units or separate linkers to reversibly crosslink the hydrogel. In an exemplary embodiment, a DNA crosslinked hydrogel displays photoreversibility. An exemplary hydrogel delivery system comprises DNA polymer conjugates, wherein complementary DNA sequences are crosslinked with polymer chains and hybridization of the DNA sequences is controlled by photoresponsive moieties. Such hydrogcls can be used to release drug molecules and/or other therapeutic reagents. The exemplary hydrogel employs photosensitive azobenzene moieties that are incorporated into the DNA crosslinker units.

The azobenzene moieties respond to different wavelengths of light so that the state of azobenzene isomerization is induced by the proportion of visible and UV light irradiated. The isomer state of the azobenzene dictates whether the complementary DNA sequences hybridize to cross link the DNA polymer conjugates. Thus, irradiation of light (visible or UV) can transform the hydrogel network between a sol and any of multiple gel states to regulate the degree of crosslinking between complementary DNA sequences and, therefore, provide a profile of release of a hydrogel encapsulated pharmaceutical or other chemical.

Priority: US20090235040P Applic. Date: 2009-08-19

Inventor: TAN WEIHONG [US]; KANG HUAIZHI [CN]


Publication No.: WO2011022467A2  Published: 24/Feb/2011

Title: CONTROLLED-RELEASE FORMULATIONS OF ANABASEINE COMPOUNDS AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODYCORPORATE

Application No.: US2010/045867   Filing Date: 18/Aug/2010

Abstract:The subject invention pertains to controlled-release dosage forms of anabaseine compounds, such as 3-(2,4-dimethoxybenzylidene)-anabaseine (also known as DMXBA or GTS-21) or a pharmaceutically acceptable salt thereof, methods of use, and methods for producing controlled-release dosage forms.

Priority: US20090235876P Applic. Date: 2009-08-21

Inventor: KEM WILLIAM READE [US]; SOTI FERENC [US]; FREEDMAN ROBERT [US]; JOHNSON LYNN [US]


Publication No.: WO2011022652A1  Published: 24/Feb/2011

Title: TOPICAL GELS

Applicant/Assignee: NOVAN, INC

Application No.: US2010/046173   Filing Date: 20/Aug/2010

Abstract:Provided according to some embodiments of the invention are topical gels that may release nitric oxide. Also provided are methods of using such topical gels in the treatment of wounds and other skin ailments. The topical gels comprise diazeniutndiolate-functionalized polysiloxane macromolecules.

Priority: US20090235933P Applic. Date: 2009-08-21

Inventor: STASKO NATHAN [US]; BAUMAN SUSANNE [US]; JOSHI PRANAV R [US]


Publication No.: WO2011022737A2  Published: 24/Feb/2011

Title: TABLET MANUFACTURE

Applicant/Assignee: WAXTABS (PTY) LTD

Application No.: ZA2010/000045   Filing Date: 16/Aug/2010

Abstract:A method of making a tablet wherein a measured volume of a settable fluent wax or polymer matrix is placed in an upwardly facing mould cavity under controlled conditions to ensure that an upper surface of a resulting bead, in the cavity, has a shape and size which are substantially the same as the shape and size of a lower surface of the bead is determined by the mould cavity.

Priority: ZA20090005684 Applic. Date: 2009-08-17; ZA20090008736 Applic. Date: 2009-12-08; ZA20100002780 Applic. Date: 2010-04-20

Inventor: LIEBENBERG POON [ZA]


Publication No.: WO2011022861A1  Published: 03/Mar/2011

Title: FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF

Applicant/Assignee: XI'AN LIBANG PHARMACEUTICAL TECHNOLOGY CO., LTD

Application No.: CN2009/000990   Filing Date: 31/Aug/2009

Abstract:Fulvestrant nanosphere/microsphere and preparative method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere /microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, liquid drying method and/or spray drying method, and has the features of high medicine carrying quantity and high envelop rate, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere/microsphere is used to treat metastatic advanced breast cancer in post-menopausal woman.

Priority:

Inventor: HU RENLE [CN]; WANG JIUCHENG [CN]; JIAO YAQI [CN]; LIANG HUA [CN]; DING DUOHAO [CN]


Publication No.: WO2011023213A1  Published: 03/Mar/2011

Title: MODIFIED CHEMODENERVATING AGENTS

Applicant/Assignee: MERZ PHARMA GMBH & CO. KGAA

Application No.: EP2009/006273   Filing Date: 28/Aug/2009

Abstract:The present invention relates to chemodenervating agents that are modified to carry different functional modulators via specific linker groups. In one embodiment said chemodenervating agent is botulinum toxin. Claimed by this invention is a modified polypeptide wherein the polypeptide is represented by formula I: NT[-NHm(-W)n ]1 k wherein NT represents a biologically active neurotoxic component or fragment thereof, which is still capable of cleaving proteins of the SNARE complex and of binding to the native HC domain receptor as well as to translocate the light chain

NHm represents an amino group of NT

W represents a residue comprising at least one moiety that is negative charged at physiological pH

m represents an integer of 0, 1 or 2

n represents an integer of 1, 2 or 3 and (m + n) = 2 or 3

k represents an integer of 1 to 1000 wherein for k > 1, each set of m, W and n can be equal or different from each other

i represents a positive charge if (m + n) is 3,wherein if (m+n) is 2 then i represents no charge.

Priority:

Inventor: TAYLOR HAROLD V [DE]; GUTCAITS ALEKSANDRS [LT]; EISELE KARL-HEINZ [DE]; WEIL TANJA [SG]


Publication No.: WO2011023367A2  Published: 03/Mar/2011

Title: BISPHOSPHONATE-PRODRUGS

Applicant/Assignee: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH

Application No.: EP2010/005187   Filing Date: 24/Aug/2010

Abstract:The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.

Priority: EP20090010871 Applic. Date: 2009-08-25

Inventor: KRATZ FELIX [DE]


Publication No.: WO2011024110A2  Published: 03/Mar/2011

Title: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS

Applicant/Assignee: RINAT NEUROSCIENCE CORPORATION

Application No.: IB2010/053754   Filing Date: 19/Aug/2010

Abstract:Glucagon-like peptide-1 receptor (GLP-1R) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. GLP-1R agonists include, e.g., naturally-occurring agonists, such as exendin-4, as well as GLP-1R agonist peptides linked to antibodies.

Priority: US20090237654P Applic. Date: 2009-08-27

Inventor: CHOU JOYCE CHING TSU [US]; LIN CHIA-YANG [US]; LONG HUA [US]


Publication No.: WO2011024354A1  Published: 03/Mar/2011

Title: TRANSDERMAL COMPOSITION OF PHOSPHATIDYLCHOLINE AND METHOD FOR PRODUCING SAME

Applicant/Assignee: MEDRX CO., LTD

Application No.: JP2010/003447   Filing Date: 21/May/2010

Abstract:Disclosed is a transdermal composition, which uses high-purity phosphatidylcholine that is most susceptible to oxidation and the like, and which exhibits high stability and high migration into the skin. Specifically, a transdermal composition having good stability and migration into the skin is able to be obtained by preparing a transdermal composition (a colloidal dispersion liquid of phosphatidylcholine) that contains high-purity phosphatidylcholine, carnitine, a polyhydric alcohol and water. Since the transdermal composition does not contain an oleaginous base (an oil component), the transdermal composition has skin compatibility and is thus useful as a therapeutic agent or a cosmetic preparation. In addition, phosphatidylcholine and carnitine have an effect of achieving good migration into the skin and are capable of promoting systemic or local lipid metabolism in subcutaneous adipose tissues. Consequently, the transdermal composition is able to provide a transdermal preparation that is capable of promoting lipolysis in subcutaneous adipose tissues.

Priority: JP20090193858 Applic. Date: 2009-08-25

Inventor: YAMASAKI KEIKO [JP]; TANIMOTO TAKAHIRO [JP]


Publication No.: WO2011024620A1  Published: 03/Mar/2011

Title: ANTIMYCOTIC PHARMACEUTICAL COMPOSITION

Applicant/Assignee: POLA PHARMA INC, NIHON NOHYAKU CO., LTD

Application No.: JP2010/063230   Filing Date: 29/Jul/2010

Abstract:A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof

and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1=R2=a chlorine atom: where R1 and R2 each independently represents a hydrogen atom or a halogen atom, and at least one of R1 and R2 represents a halogen atom. The present invention provides a preparation excellent in solubilization stability for a compound represented by the general formula (1) and/or a salt thereof in low-temperature or high-temperature storage.

Priority: JP20090194835 Applic. Date: 2009-08-25

Inventor: KOBAYASHI HIROKAZU [JP]; KUBOTA NOBUO [JP]


Publication No.: WO2011024942A1  Published: 03/Mar/2011

Title: MATRIX METALLOPROTEASE-2 (MMP-2) INHIBITOR

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: JP2010/064568   Filing Date: 27/Aug/2010

Abstract:For the purpose of developing novel use applications of resveratrol, an inhibitory activity of resveratrol on matrix metalloprotease-2 (MMP-2) is found. A preparation for exhibiting the inhibitory activity of resveratrol on matrix metalloprotease-2 (MMP-2) effectively is provided. Thus, disclosed is a matrix metallo protease-2 (MMP-2)inhibitor comprising resveratrol as an active ingredient.

Priority: JP20090197544 Applic. Date: 2009-08-28

Inventor: MURAGUCHI TAICHI [JP]; AIMI MAKIKO [JP]; KUBO TOSHIAKI [JP]


Publication No.: WO2011025035A1  Published: 03/Mar/2011

Title: COATING COMPOSITION

Applicant/Assignee: NISSHIN KASEI CO., LTD

Application No.: JP2010/064815   Filing Date: 31/Aug/2010

Abstract:Disclosed is a coating composition which has increased coating speed and improved productivity, while maintaining excellent moisture prevention performance of coating compositions that are mainly composed of a polyvinyl alcohol polymer. Specifically disclosed is a coating composition which is characterized by containing (A) a polymer or copolymer that is obtained by polymerizing or copolymerizing at least one polymerizable vinyl monomer in the presence of a polyvinyl alcohol and/or a derivative thereof, and (B) a cellulose polymer.

Priority: JP20090200248 Applic. Date: 2009-08-31

Inventor: YOSHINO HIROYUKI [JP]; MORIUCHI TOSHIAKI [JP]; KOJO AKANE [JP]; HAYASHI YUSUKE [JP]


Publication No.: WO2011025036A1  Published: 03/Mar/2011

Title: PARTICLE COMPOSITION AND MEDICINAL COMPOSITION COMPRISING SAME

Applicant/Assignee: NANOCARRIER CO., LTD

Application No.: JP2010/064816   Filing Date: 31/Aug/2010

Abstract:A particle composition comprising block copolymer units, which are arranged radially with hydrophobic polymer chain segments facing inward and hydrophilic polymer chain segments facing outward, and a charged lipid which is charged oppositely to the charge of a drug to be encapsulated, wherein said charged lipid is arranged in a state of being attracted to the hydrophobic polymer chain segment side. In this particle composition, a drug is held within the particles due to the electrostatic binding to the charged lipid, while the outer circumferential face of the particles is prevented from becoming electrically charged so as to attract a substance charged oppositely to the charged lipid.

Priority: JP20090200681 Applic. Date: 2009-08-31

Inventor: KATO YASUKI [JP]; ISHII ATSUSHI [JP]


Publication No.: WO2011025158A2  Published: 03/Mar/2011

Title: COACERVATE HAVING AN IONIC POLYMER MIXED WITH THE ADHESIVE PROTEIN OF A MUSSEL OR OF A SPECIES OF THE VARIOME THEREOF

Applicant/Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION

Application No.: KR2010/005178   Filing Date: 06/Aug/2010

Abstract:The present invention relates to a coacervate including the adhesive protein of a mussel and an ionic polymer, and particularly, to a coacervate prepared by mixing the adhesive protein of a mussel and an ionic polymer, and to a novel use thereof. The coacervate prepared by mixing the adhesive protein of a mussel and an ionic polymer according to the present invention can be effectively used as an adhesive due to the excellent adhesive force thereof on a variety of substrates such as cells or metals, and especially as the adhesive force can be maintained in the presence of water or even in water. In addition, the coacervate can be effectively used as an active ingredient of a composition for delivering bioactive materials, due to the activity thereof in enabling the encapsulation of bioactive materials.

Priority: KR20090078666 Applic. Date: 2009-08-25; KR20100075716 Applic. Date: 2010-08-05; KR20100075717 Applic. Date: 2010-08-05

Inventor: CHA HYUNG-JOON [KR]; CHOI YOO-SEONG [KR]; KANG DONG-GYUN [KR]; HWANG DONG-SOO [KR]; SONG YOUNG-HOON [KR]; LIM SEONG-HYE [KR]; CHOI BONG-HYUK [KR]


Publication No.: WO2011025881A1  Published: 03/Mar/2011

Title: FILM COATING COMPOSITION FROM SOLID POWDER COMPOUNDS

Applicant/Assignee: HERCULES INCORPORATED

Application No.: US2010/046811   Filing Date: 26/Aug/2010

Abstract:The present invention relates to a film coating composition used for film coating pharmaceutical tablets, nutritional supplements, confectionary forms and the like. The film coating composition comprises a water soluble film former such as hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, starches, modified starches and the like and one or more hydrophobic compounds, such as metal salt of higher fatty acids, higher fatty alcohol natural wax either from vegetable, animal origin or synthetic wax. Optionally, the film coating composition may include plasticizers, colorants, such as pigments and/or flow aids.

Priority: US20090237720P Applic. Date: 2009-08-28

Inventor: DURIG THOMAS [CH]; TEWARI DIVYA [IN]


Publication No.: WO2011026003A2  Published: 03/Mar/2011

Title: A XYLITOL CONTAINING COMESTIBLE PRODUCT

Applicant/Assignee: HERSHEY FOODS CORPORATION

Application No.: US2010/047071   Filing Date: 30/Aug/2010

Abstract:The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the xylitol in a slurry and (b) then shaping the extruded slurry and cooling the product to form a solid. The present invention additionally is directed to a product produced therefrom.

Priority: US20090238017P Applic. Date: 2009-08-28

Inventor: KUMIEGA STEVEN M [US]; CARROLL THOMAS J [US]; BOLDT ASHLEY L [US]; GIBSON PAULA M [US]; HUZINEC ROBERT J [US]; BROWN BURTON DOUGLAS [US]; STUMPF DAVID M [US]


Publication No.: WO2011026041A2  Published: 03/Mar/2011

Title: SDF-1 DELIVERY FOR TREATING ISCHEMIC TISSUE

Applicant/Assignee: THE CLEVELAND CLINIC FOUNDATION

Application No.: US2010/047175   Filing Date: 30/Aug/2010

Abstract:

Priority: US20090237775P Applic. Date: 2009-08-28; US20100334216P Applic. Date: 2010-05-13

Inventor: PENN MARC S [US]; ARAS RAHUL [US]; PASTORE JOSEPH [US]; MILLER TIMOTHY R [US]


Publication No.: WO2011026076A2  Published: 03/Mar/2011

Title: TOPICAL FORMULATIONS COMPRISING A STEROID

Applicant/Assignee: DR. REDDY'S LABORATORIES LTD, DR. REDDY'S LABORATORIES, INC

Application No.: US2010/047240   Filing Date: 31/Aug/2010

Abstract:The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Priority: IN2009CH02111 Applic. Date: 2009-08-31; US20090256554P Applic. Date: 2009-10-30

Inventor: UBAIDULLA UDHUMANSHA [IN]; KANDAVILLI SATEESH [IN]; VAIRALE AJAY SUNIL [IN]; WAYNE JEFFREY A [CA]; NALAMOTHU VIJENDRA [US]; MEGHAL MISTRY [IN]; PAKUNLU REFIKA ISIL [US]


Publication No.: WO2011026122A2  Published: 03/Mar/2011

Title: B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF

Applicant/Assignee: AMPLIMMUNE, INC

Application No.: US2010/047366   Filing Date: 31/Aug/2010

Abstract:Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-lss, TNF-a, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs

or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

Priority: US20090238605P Applic. Date: 2009-08-31; US20090254930P Applic. Date: 2009-10-26; US20090266854P Applic. Date: 2009-12-04; US20090286537P Applic. Date: 2009-12-15; US20100378361P Applic. Date: 2010-08-30

Inventor: LANGERMANN SOLOMON [US]; LIU LINDA [US]; PODOJIL JOSEPH R [US]; MILLER STEPHEN D [US]; MARSHALL SHANNON [US]


Publication No.: WO2011026125A2  Published: 03/Mar/2011

Title: GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN

Applicant/Assignee: DEPOMED, INC

Application No.: US2010/047369   Filing Date: 31/Aug/2010

Abstract:Gastric retentive dosage forms for extended release of acetaminophen or for both immediate and extended release of acetaminophen are described. The dosage forms allow effective pain relief upon once- or twice-daily dosing Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

Priority: US20090238374P Applic. Date: 2009-08-31

Inventor: HOU SUI YUEN EDDIE [US]; VARGAS THADD [US]


Publication No.: WO2011026132A2  Published: 03/Mar/2011

Title: METHODS AND COMPOSITIONS FOR THE INHIBITION OF TRANSPLANT REJECTION

Applicant/Assignee: 1/3ACAMPLIMMUNE, INC, AMPLIMMUNE, INC

Application No.: US2010/047384   Filing Date: 31/Aug/2010

Abstract:Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. ThI, ThI 7 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation.

Priority: US20090238605P Applic. Date: 2009-08-31; US20090254930P Applic. Date: 2009-10-26; US20090266854P Applic. Date: 2009-12-04; US20090286537P Applic. Date: 2009-12-15; US20100378361P Applic. Date: 2010-08-30

Inventor: LANGERMANN SOLOMON [US]; LIU LINDA [US]


Publication No.: WO2011026234A1  Published: 10/Mar/2011

Title: CLARITHROMYCIN EXTENDED-RELEASE TABLET

Applicant/Assignee:

Application No.: CA2010/001373   Filing Date: 02/Sep/2010

Abstract:The present application relates to an extended-release tablet for oral administration of Clarithromycin The tablet comprises a water soluble diluent and an acidic compound wherein the acidic compound is used to increase the dissolution rate of Clarithromycin The tablet is free from pohmers or ma\ comprise pohmer that is insufficient to function as a release controlling agent.

Priority: US20090239210P Applic. Date: 2009-09-02

Inventor: SHERMAN BERNARD CHARLES [CA]


Publication No.: WO2011026351A1  Published: 10/Mar/2011

Title: A CYANOVIRIN N MUTANT, MODIFIED DERIVATIVE AND USES THEREOF

Applicant/Assignee: JINAN UNIVERSITY

Application No.: CN2010/073124   Filing Date: 24/May/2010

Abstract:A cyanovirin N (CVN) mutant, its PEG modified derivative and their uses in preparing drugs. The said cyanovirin N mutant is composed of sequence A and sequence B: sequence A is a linker peptide with hydrophilicity and flexibility, sequence B is a codon optimized sequence of cyanovirin N. The cyanoviein N mutant is modified by PEG to obtain derivative. The mutant and the derivative both exhibit good anti-HIV activities, and have prospect of being used in preparing drugs for anti-HIV and other viral microorganism.

Priority: CN20091192063 Applic. Date: 2009-09-04

Inventor: XIONG SHENG [CN]; CHEN WEI [CN]; QIAN CHUIWEN [CN]; WANG YIFEI [CN]; KITAZATO KAIO [CN]


Publication No.: WO2011026447A1  Published: 10/Mar/2011

Title: NEW ANTIBIOTIC CONTAINING SIMULACRUM ANTIBODY, PREPARATION METHOD AND APPLICATION THEREOF

Applicant/Assignee: PROTEIN DESIGN LAB, LTD

Application No.: CN2010/077351   Filing Date: 27/Sep/2010

Abstract:The invention provides a new antibiotic containing simulacrum antibody. The antibiotic consists of colicin E1, Ia, Ib, A, B, N, or aqueous channel-forming structural domain and the simulacrum antibody which is covalently linked to the carboxyl terminal of the peptide chain of said colicin or aqueous channel-forming structural domain. The simulacrum antibody is formed by the carboxyl terminal of the heavy chain variable (VH) complementarity determining region (CDR) 1 of immunoglobulin connected with the amino terminal of the VH framework region (FR) 2 where the carboxyl terminal is further connected with the amino terminal of the light chain variable (VL) CDR, and the immunoglobulin specifically recognizes the bacterial porin. The antibiotic is useful for preparing antibacterial agents such as anti-Neisseria meningitides, anti-vancomycin-resistant Enterococcus, anti-methicillin-resistant Staphylococcus aureus or anti-multiple drug resistant Pseudomonas aeruginosa.

Priority: CN20091092128 Applic. Date: 2009-09-02

Inventor: QIU XIAOQING [CN]


Publication No.: WO2011026641A1  Published: 10/Mar/2011

Title: DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS

Applicant/Assignee: CUREVAC GMBH

Application No.: EP2010/005438   Filing Date: 03/Sep/2010

Abstract:The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.

Priority: US2009-553559 Applic. Date: 2009-09-03

Inventor: BAUMHOF PATRICK [DE]; SCHLAKE THOMAS [DE]


Publication No.: WO2011026824A2  Published: 10/Mar/2011

Title: NOVEL DIAGNOSTIC AGENTS FOR THE NON-INVASIVE IN VIVO IMAGING OF AMINOPEPTIDASE N (APN/CD13)

Applicant/Assignee: UNIVERSITAETSKLINIKUM MUENSTER

Application No.: EP2010/062669   Filing Date: 31/Aug/2010

Abstract:The present invention relates to aminopeptidase N (APN) inhibitor conjugates of formula I wherein W is a -CO- or an -SO2- group and at least one of R1 or R2 represents (OCH2- CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and the other represents an alkoxy group or OH, and wherein R3, R3'and R3'' is independently selected from an alkoxy group or (OCH2-CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and R4 is selected from the group comprising: wherein R is an alkyl group. Furthermore, the present invention relates to a diagnostic and/or pharmaceutical composition comprising the conjugate of the invention.

The present invention also relates to the conjugate or composition of the invention for use in the diagnosis or treatment of APN-associated diseases like for example angiogenesis in cancer, rheumatoid arthritis, leukemia and diabetic nephropathy, as well as to the use of the conjugate or of the composition of the invention in the diagnosis or treatment of angiogenesis in cancer, rheumatoid arthritis, leukemia and diabetic nephropathy. In a further aspect, the present invention relates to kits comprising the conjugate or composition of the invention. The conjugate or pharmaceutical/diagnostic composition of the invention can also be used in in vivo or in vitro imaging studies of aminopeptidase N.

Priority: EP20090169131 Applic. Date: 2009-09-01

Inventor: BREMER CHRISTOPH [DE]; HOELTKE CARSTEN [DE]


Publication No.: WO2011026898A2  Published: 10/Mar/2011

Title: DRUG ACTIVATION SYSTEM

Applicant/Assignee: BANGOR UNIVERSITY

Application No.: EP2010/062871   Filing Date: 02/Sep/2010

Abstract:The present invention discloses a drug activator carrier comprising: a) particles having a metallic or metallic oxide core prepared from a paramagnetic material, said metallic core being coated with a coating material selected from polymer, metal or metal oxide

b) a biological material, having reductase activity, bound onto the metal coating the particles of step a), and wherein said biological material is capable of activating non-toxic pro-drugs into active and toxic drugs suitable for treating a disease

said drug activator carrier allowing targeted delivery of the toxic drug.

Priority: GB20090015249 Applic. Date: 2009-09-02

Inventor: GWENIN CHRISTOPHER [GB]; KALAJI MAHER [US]; ROBERTS VANESSA [GB]


Publication No.: WO2011027152A1  Published: 10/Mar/2011

Title: STABLE FORMULATION OF FACTOR VIII

Applicant/Assignee: ARECOR LIMITED

Application No.: GB2010/051441   Filing Date: 02/Sep/2010

Abstract:The invention relates inter alia to a composition which is storage-stable at 25 DEG C for a minimum of 18 weeks comprising a therapeutically effective amount of Factor VIII and an aqueous medium having a Factor VIII potency after 18 weeks of storage at 25 DEG C of at least 90% of the Factor VIII potency of a Control Composition.

Priority: GB20090015480 Applic. Date: 2009-09-04; US20090239934P Applic. Date: 2009-09-04

Inventor: JEZEK JAN [GB]; DERHAM BARRY KINGSTON [GB]


Publication No.: WO2011027174A2  Published: 10/Mar/2011

Title: COMPOSITION

Applicant/Assignee: ROBERT GORDON UNIVERSITY

Application No.: GB2010/051477   Filing Date: 06/Sep/2010

Abstract:A polymer having a structure according to the following formula (I): wherein: A represents a hydrophilic group

B represents a hydrophobic aromatic group such as 5-dimethylamino-1-naphthalenesulfonyl (Dansyl), 9-fluorenylmethoxy carbonyl (Fmoc) and naphthalene (Naphth)

D and E independently represent amine groups

F represents an amine group, the amine group being substituted with a B group and an A group, or the amine group being a quaternary ammonium moiety

wherein W, X, Y and Z each independently have values greater than or equal to (1), especially in the range of (1) to (10).

Priority: GB20090015449 Applic. Date: 2009-09-04

Inventor: KONG THOO LIN PAUL [GB]; CHENG WOEI PING [GB]; HOSKINS CLARE [GB]


Publication No.: WO2011027248A1  Published: 10/Mar/2011

Title: ORAL LIQUID FORMULATION COMPRISING SALBUTAMOL AND GUAIFENESIN

Applicant/Assignee:

Application No.: IB2010/053600   Filing Date: 10/Aug/2010

Abstract:The present invention provides an improved pharmaceutical composition which comprises an aqueous dispersion of one or more cellulose derivatives containing salbutamol and/or one or more of its physiologically acceptable salts and guaiphenesin. The pH of the formulation has been maintained at around 4.5 with citrate buffer for better stability of salbutamol. The liquid formulation of the present invention is found to be stable over its shelf life as confirmed by accelerated studies. The present invention is also directed to an innovative process of formulating an oral liquid dosage form containing Salbutamol sulphate and Guaiphenesin as APIs, and possessing good stability coupled with palatability. The invention is useful as a treatment of Asthma, and used as bronchodilator and expectorant in certain respiratory conditions.

Priority: IN2009MU01812 Applic. Date: 2009-09-03

Inventor: VANANGAMUDI SULUR SUBRAMANIAM [IN]; SRINIVASRAO DEVENASETTI [IN]; CHULLIEL NEELAKANDAN NARAYANAN [IN]; SENTHILKUMAR KUPPUSAMY [IN]


Publication No.: WO2011027365A2  Published: 10/Mar/2011

Title: OPHTHALMIC COMPOSITIONS CONTAINING DORZOLAMIDE, TIMOLOL AND BRIMONIDINE

Applicant/Assignee: MICRO LABS LIMITED

Application No.: IN2010/000591   Filing Date: 03/Sep/2010

Abstract:The present invention is related to ophthalmic composition comprising Timolol, Dorzolamide and Brimonidine. More specifically, the present invention is related to a stable ophthalmic composition comprising Timolol, Dorzolamide and Brimonidine and hydroxyethyl cellulose.

Priority: IN2009CH02151 Applic. Date: 2009-09-07

Inventor: KSHIRSAGAR RAJESH [IN]; KADAM CHANDRASHEKAR [IN]; MHASKE AJAY [IN]; MUDDA SM [IN]


Publication No.: WO2011027605A1  Published: 10/Mar/2011

Title: LIQUID COMPOSITION TO BE FILLED IN SOFT CAPSULES

Applicant/Assignee: RIKEN VITAMIN CO., LTD

Application No.: JP2010/060007   Filing Date: 14/Jun/2010

Abstract:Disclosed is a liquid composition which is intended to be filled in soft capsules and comprises an edible oil or fat and a poorly oil-soluble component dispersed in the edible oil or fat. The liquid composition is characterized by containing a reactive monoglyceride and a triglycerin fatty acid ester having a monoester content of 50% or more. In the liquid composition, beeswax is not used, but the level of the dispersion stability of the poorly oil-soluble component is equivalent to or higher than those in conventional preparations in which beeswax is used.

Priority: JP20090205731 Applic. Date: 2009-09-07

Inventor: IIZUKA MASAO [JP]


Publication No.: WO2011027728A1  Published: 10/Mar/2011

Title: COATING AGENT COMPRISING HYDROXYALKYL CELLULOSE

Applicant/Assignee: NIPPON SODA CO., LTD

Application No.: JP2010/064686   Filing Date: 30/Aug/2010

Abstract:Disclosed is a coating agent comprising a hydroxyalkyl cellulose that has a comprised amount of a hydroxyalkyl group in the range of 40 to 50 mass% in the hydroxyalkyl cellulose, preferably a coating agent comprising a hydroxyalkyl cellulose that has a comprised amount of a hydroxyalkyl group in the range of 40 to 50 mass% and a viscosity in the range of 3.0 to 5.9 mPas in a 2% aqueous solution at 20 DEG C. Also disclosed is a solid preparation coated with said coating agent.

Priority: JP20090202247 Applic. Date: 2009-09-02

Inventor: MASUE YUSUKE [JP]


Publication No.: WO2011027729A1  Published: 10/Mar/2011

Title: HYDROXYPROPYL CELLULOSE PARTICLES

Applicant/Assignee: NIPPON SODA CO., LTD

Application No.: JP2010/064690   Filing Date: 30/Aug/2010

Abstract:Hydroxypropyl cellulose particles containing particles each having a particle size of larger than 150 [mu]m and not larger than 355 [mu]m in an amount of 50 to 100 wt%.

Priority: JP20090202246 Applic. Date: 2009-09-02

Inventor: MASUE YUSUKE [JP]


Publication No.: WO2011027778A1  Published: 10/Mar/2011

Title: COMPOSITION FOR TOPICAL ADMINISTRATION TO EYES FOR USE IN TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA

Applicant/Assignee: R-TECH UENO, LTD, SUCAMPO AG (USA) INC

Application No.: JP2010/064919   Filing Date: 01/Sep/2010

Abstract:Disclosed is a composition for topical administration to eyes, which is intended to be used for the treatment of ocular hypertension and glaucoma, and which contains latanoprost as an active ingredient and additionally contains (a) a polyol and/or a sugar alcohol, (b) a nonionic surfactant and (c) an edetic acid compound. In the composition, the amount of a preservative agent used can be significantly reduced compared to those in conventional compositions, and therefore the occurrence of adverse side effects caused by the preservative agent can be prevented. The composition can be stored stably at room temperature for a long period.

Priority: US20090238859P Applic. Date: 2009-09-01

Inventor: UENO RYUJI [US]; HARADA YASUHIRO [JP]; KAWASAKI JUNICHI [JP]; HAYASHI TADASHI [JP]


Publication No.: WO2011027786A1  Published: 10/Mar/2011

Title: TRANSDERMALLY ABSORBABLE PREPARATION

Applicant/Assignee: NIPRO PATCH CO., LTD

Application No.: JP2010/064937   Filing Date: 01/Sep/2010

Abstract:Disclosed is a transdermally absorbable preparation, in which an adhesive agent produced by crosslinking at least one copolymer is contained in an adhesive layer and the curing period in the production of the adhesive layer can be shortened. The transdermally absorbable preparation comprises a support and an adhesive layer arranged on the support and containing an adhesive agent and a medicinal component. The transdermally absorbable preparation is characterized in that the adhesive agent comprises a resin mixture comprising 100 parts by mass of a specific acrylic copolymer (A) and 0.1 to 30 parts by mass of a specific acrylic copolymer (B) or 0.05 to 2 part(s) by mass of a polyamine compound, and the adhesive layer additionally contains an organic acid.

Priority: JP20090206183 Applic. Date: 2009-09-07

Inventor: KAWAMURA NAOHISA [JP]; SUGAYA CHIE [JP]


Publication No.: WO2011028016A2  Published: 10/Mar/2011

Title: PHARMACEUTICAL PREPARATION COMPRISING BETA-ADRENERGIC BLOCKERS AND ANGIOTENSIN II RECEPTOR BLOCKERS

Applicant/Assignee: HANALL BIOPHARMA CO., LTD

Application No.: KR2010/005918   Filing Date: 01/Sep/2010

Abstract:The present invention relates to a pharmaceutical preparation comprising: an immediate-release compartment including beta-adrenergic blockers as pharmacologically active ingredients

and an extended-release compartment including angiotensin II receptor blockers as pharmacologically active ingredients. The preparation of the present invention exhibits uniform anti-tension effects and effects of preventing complications, and particularly, maintains the blood pressure at a constant level in the dangerous time period in which complications might occur, and thus can be effectively used for a hypertension patient suffering from complications and for a patient requiring the blood pressure thereof to be inhibited during sleep, and effectively reduces side effects caused by the interaction between drugs.

Priority: KR20090083612 Applic. Date: 2009-09-04

Inventor: KIM SUNG WUK [KR]; JUN SUNG SOO [KR]; KOO JA SEONG [KR]; KIM JIN WOOK [KR]; LEE NAYOUNG [KR]


Publication No.: WO2011028110A1  Published: 10/Mar/2011

Title: COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS

Applicant/Assignee: ZACCO NETHERLANDS B.V

Application No.: NL2010/050549   Filing Date: 01/Sep/2010

Abstract:The invention relates to a composition for topical application. The invention further relates to various uses for the treatment of skin conditions, including acne, warts, corns and calluses, psoriasis, keratosis pilaris and conditions in general involving keratinized skin. The invention further relates to an applicator device and kit of parts comprising such a composition. The composition comprises at least one physiologically acceptable C1 -C4 alkyl ester of a carboxylic acid as a carrier, and an effective amount of salicylic acid, and/or a physiologically acceptable ester of salt thereof.

Priority: NL20092003419 Applic. Date: 2009-09-01

Inventor: CLAPPOSEN MIRIAM [NL]


Publication No.: WO2011028334A2  Published: 10/Mar/2011

Title: SYNTHESIS AND ISOLATION OF DENDRIMER SYSTEMS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: US2010/043109   Filing Date: 23/Jul/2010

Abstract:The present invention relates to novel methods of synthesis and isolation of dendrimer systems. In particular, the present invention is directed to novel dendrimer conjugates with defined and limited numbers of ligand conjugates and high levels of structural uniformity, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)).

Priority: US20090237172P Applic. Date: 2009-08-26

Inventor: BAKER JR JAMES R [US]; BANASZAK HOLL MARK M [US]; MULLEN DOUGLAS GURNETT [US]; ORR BRADFORD G [US]; DESAI ANKUR [US]; SANDER LEONARD M [US]; WADDELL JACK NEEL [US]


Publication No.: WO2011028485A2  Published: 10/Mar/2011

Title: TUMORICIDAL, BACTERICIDAL, OR VIRICIDAL MACROPHAGE ACTIVATION

Applicant/Assignee:

Application No.: US2010/046356   Filing Date: 23/Aug/2010

Abstract:The activation of macrophages and methods for treating cancer, bacterial pathogens and viral pathogens are disclosed. In particular, Gc protein is converted to Gc-macrophage activating factor (GcMAF), in vivo or ex vivo. The GcMAF activates macrophages which can then target cancer cells, bacterial pathogens and/or viral pathogens. Alternatively, macrophages are activated by contacting them, in vivo or ex vivo, with GcMAF. Optionally, nagalase is inactivated in a patient receiving the present macrophage activating treatment by contacting the patient's blood with a Nagalase-binding ligand immobilized on an inert medium.

Priority: US20090236088P Applic. Date: 2009-08-22

Inventor: KNEZEVICH CHARLES [US]; SILVETZ ROBERT [US]


Publication No.: WO2011028629A1  Published: 10/Mar/2011

Title: PHARMACEUTICAL FORMULATIONS AND METHODS OF USE

Applicant/Assignee: NUVO RESEARCH INC

Application No.: US2010/046875   Filing Date: 26/Aug/2010

Abstract:In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient

an ester

a non-ionic surfactant

a polar solvent

water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster.

Priority: US20090237252P Applic. Date: 2009-08-26

Inventor: BUYUKTIMKIN NADIR [US]; BUYUKTIMKIN SERVET [US]; SINGH JAGAT [CA]; NEWSAM JOHN M [US]; KING-SMITH DOMINIC [US]; KISAK EDWARD [US]; GALER BRADLEY S [US]; DESAI TEJAS [CA]; RILEY CHRISTOPHER [US]


Publication No.: WO2011028718A1  Published: 10/Mar/2011

Title: KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/047346   Filing Date: 31/Aug/2010

Abstract:The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Priority: US2009-552057 Applic. Date: 2009-09-01

Inventor: FARNES ELDON QUINN [US]; ATTAR MAYSSA [US]; SCHIFFMAN RHETT M [US]; CHANG CHIN-MING [US]; GRAHAM RICHARD S [US]; WELTY DEVIN [US]


Publication No.: WO2011028875A1  Published: 10/Mar/2011

Title: IMMUNOGENIC CONJUGATES FOR PRODUCING IMMUNE RESPONSES TO DRUGS OF ABUSE AND METHODS OF USE

Applicant/Assignee: WAKE FOREST UNIVERSITY HEALTH SCIENCES

Application No.: US2010/047635   Filing Date: 02/Sep/2010

Abstract:The present invention is based, in part, on flagellin adjuvants that enhance immune responses directed against drugs of abuse. Provided are conjugates comprising a flagellin adjuvant covalently linked to a drug of abuse or an immunologically similar derivative thereof. Also provided are methods of making the conjugates of the invention and use thereof for administration to a subject, e.g., to produce an immune response in the subject against the drug of abuse, to prevent addiction to the drug of abuse in the subject, to reduce the effect of the drug of abuse in the subject, to reduce the level of the drug of abuse in the brain of the subject, and/or to reduce the addiction in the subject to the drug of abuse.

Priority: US20090239617P Applic. Date: 2009-09-03

Inventor: MIZEL STEVEN B [US]


Publication No.: WO2011028962A1  Published: 10/Mar/2011

Title: ANTIBODY COFORMULATIONS

Applicant/Assignee: XOMA TECHNOLOGY LTD

Application No.: US2010/047753   Filing Date: 02/Sep/2010

Abstract:This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0.

Priority: US20090240155P Applic. Date: 2009-09-04

Inventor: BABUKA SUSAN JOYCE [US]; HUANG CHIN-YI [US]; LI MINGXIANG [US]


Publication No.: WO2011029028A2  Published: 10/Mar/2011

Title: TARGETED DELIVERY USING TISSUE-SPECIFIC PEPTIDOMIMETIC LIGANDS

Applicant/Assignee: GRADALIS, INC

Application No.: US2010/047858   Filing Date: 03/Sep/2010

Abstract:Compositions and methods for tissue-specific targeted delivery of therapeutic agents through the use of tissue-specific peptidomimetic ligands are disclosed herein. The ligand comprises a composition of formula A-scaffold-A' and one or more hydrophobic anchors covalently linked to the scaffold. The A and A' compounds linked to the scaffold comprise monovalent peptidomimetic compounds wherein each monovalent peptidomimetic compound is selected from the group consisting of fragments IKs, GKs, IDs, GSs, GTs, VSs, TKs, KTs, ARs, KIs, KEs, AEs, GRs, YSs, IRs, and morpholino.

Priority: US20090239648P Applic. Date: 2009-09-03

Inventor: TEMPLETON NANCY SMYTH [US]


Publication No.: WO2011029867A1  Published: 17/Mar/2011

Title: IMPLANTABLE BIO-RESORBABLE POLYMER

Applicant/Assignee: OCCLUGEL

Application No.: EP2010/063227   Filing Date: 09/Sep/2010

Abstract:The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH2=CR1)CO-K (I) wherein: K represents 0-Z or NH-Z, Z representing (CR2R3)m-CH3, (CH2-CH2-O)m-H, (CH2- CH2-O )m-CH3, (CH2)m-N R4R5 with m representing an integer from 1 to 30

R1, R2, R3, R4 and R5 independently represent H or a C1 -C6 alkyl

and (ii) at least one bio-resorbable block copolymer cross-linker.

Priority: EP20090305830 Applic. Date: 2009-09-10; US20090241183P Applic. Date: 2009-09-10

Inventor: MOINE LAURENCE [FR]; BEDOUET LAURENT [FR]; LAURENT ALEXANDRE [FR]; LABARRE DENIS [FR]; WASSEF MICHEL [FR]; NGUYEN VAN NGA [FR]


Publication No.: WO2011029870A1  Published: 17/Mar/2011

Title: USE OF INTERLEUKIN-1 BETA MUTEIN CONJUGATES IN THE TREATMENT OF DIABETES

Applicant/Assignee: CYTOS BIOTECHNOLOGY AG

Application No.: EP2010/063237   Filing Date: 09/Sep/2010

Abstract:The present invention provides compositions, pharmaceutical compositions and vaccines for the treatment, amelioration and / or prophylaxis of type II diabetes. The compositions, pharmaceutical compositions and vaccines of the invention comprise a virus-like particle of an RNA bacteriophage and an antigen, wherein said antigen comprises an interleukin-1 beta (IL-1ss) mutein. When administered to an animal, preferably to a human, said compositions, pharmaceutical compositions, and vaccines induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against IL-1ss. Thus, the invention provides methods of treating, ameliorating or preventing type II diabetes by way of active immunization against IL-1ss.

Priority: EP20090169989 Applic. Date: 2009-09-10

Inventor: BACHMANN MARTIN [CH]; SPOHN GUNTHER [CH]; MAURER PATRIK [CH]


Publication No.: WO2011029980A1  Published: 17/Mar/2011

Title: THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HPV-INDUCED DISEASES

Applicant/Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L

Application No.: ES2010/070590   Filing Date: 10/Sep/2010

Abstract:The invention relates to immunogenic conjugates comprising an immunogenic region of the E7 protein of human Papillomavirus and the EDA region of fibronectin, as well as to compositions containing these conjugates and dendritic cells obtained by stimulation with said conjugates and compositions. The invention also relates to methods for the treatment of HPV-induced diseases through the use of the aforementioned conjugates, compositions and dendritic cells.

Priority: ES20090001847 Applic. Date: 2009-09-11

Inventor: BERRAONDO LOPEZ PEDRO [ES]; LASARTE SAGASTIBELZA JUAN JOSE [ES]; MANSILLA PUERTA CRISTINA [ES]; PRIETO VALTUENA JESUS MARIA [ES]; SAROBE UGARRIZA PABLO [ES]


Publication No.: WO2011030044A1  Published: 17/Mar/2011

Title: NOVEL POWDERED POLYMER, PREPARATION METHOD THEREOF AND USE OF SAME AS A THICKENER

Applicant/Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC

Application No.: FR2010/051819   Filing Date: 01/Sep/2010

Abstract:The invention relates to a branched or crosslinked anionic polyelectrolyte of at least one monomer having a partially- or totally-salified strong acid function, with at least one neutral monomer and at least one monomer having formula (I), wherein: R represents a linear or branched alkyl radical comprising between 8 and twenty carbon atoms, and n represents a number greater than or equal to 1 and less than or equal to twenty. The invention also relates to the use thereof as a thickener in topical compositions.

Priority: FR20090056224 Applic. Date: 2009-09-11

Inventor: BRAUN OLIVIER [FR]; MALLO PAUL [FR]


Publication No.: WO2011030351A2  Published: 17/Mar/2011

Title: TASTE - MASKED PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: RUBICON RESEARCH PRIVATE LIMITED

Application No.: IN2010/000589   Filing Date: 03/Sep/2010

Abstract:The present invention relates to taste-masked pharmaceutical compositions comprising phosphodiesterase-5 (PDE-5) inhibitors. The taste-masked pharmaceutical compositions for oral administration comprise at least one PDE-5 inhibitor, at least one taste-masking agent

and at least one pharmaceutically acceptable excipient. Further the taste-masked PDE-5 inhibitor compositions are provided in the form of palatable formulations suitable for oral administration such as orally disintegrating tablets, bite-dispersion tablets, chewable tablets, dispersible tablets, effervescent tablets or the like. The invention also further relates to method for masking the objectionable taste of PDE-5 inhibitor.

Priority: IN2009MU02021 Applic. Date: 2009-09-03

Inventor: PILGAONKAR PRATIBHA SUDHIR [IN]; RUSTOMJEE MAHARUKH TEHMASP [IN]; GANDHI ANILKUMAR SURENDRAKUMAR [IN]


Publication No.: WO2011030659A1  Published: 17/Mar/2011

Title: ANTACID AND LAXATIVE TABLET

Applicant/Assignee: KYOWA CHEMICAL INDUSTRY CO.,LTD

Application No.: JP2010/064066   Filing Date: 20/Aug/2010

Abstract:Disclosed is a tablet which can sustain excellent disintegration properties (hereinafter sometimes referred to as "quick disintegration properties"), as a tabletted product, over a long time and has a high shape-retention stability caused by an improvement in the tablet strength. An antacid and laxative tablet comprising magnesium oxide particles as the main ingredient, characterized by: (a) the magnesium oxide particles contained in the tablet having an average secondary particle diameter, measured by the laser diffractive scattering method, of 0.5-10 [mu]m

(b) the amount of the magnesium oxide particles contained therein being 85-96 wt%

(c) the amount of crystalline cellulose contained therein as a binder being 2-8 wt%

(d) the amount of croscarmellose sodium contained therein as disintegrating agent-I being 0.8-2.5 wt%

(e) the amount of insoluble polyvinylpyrrolidone contained therein as disintegrating agent-II being 1-3.5 wt%

and (f) the amount of a lubricant contained therein being of 0.5-2 wt%.

Priority: JP20090206720 Applic. Date: 2009-09-08

Inventor: KITAJIMA HIDEAKI [JP]; HORIE SHIRO [JP]; KUBO TAKAAKI [JP]; KAWANABE NARUHITO [JP]; ANABUKI TOMOTAKA [JP]


Publication No.: WO2011030682A1  Published: 17/Mar/2011

Title: CONSTRUCT COATED WITH VIRUS COAT-CONSTITUTING PROTEIN AND METHOD FOR PRODUCING SAME

Applicant/Assignee: TOKYO INSTITUTE OF TECHNOLOGY

Application No.: JP2010/064667   Filing Date: 30/Aug/2010

Abstract:Disclosed is a construct comprising a virus coat-constituting protein, which is usable as a drug delivery carrier applicable to various drugs. Specifically disclosed is a construct coated with a virus coat-constituting protein which is composed of the virus coat-constituting protein and a construct coated therewith, characterized in that the virus coat-constituting protein adheres to the surface of the construct to thereby form a layer comprising this protein.

Priority: JP20090207632 Applic. Date: 2009-09-09

Inventor: HANDA HIROSHI [JP]; DOI KOJI [JP]; ENOMOTO TERUYA [JP]; KAWANO MASAAKI [JP]


Publication No.: WO2011030946A1  Published: 17/Mar/2011

Title: NANO-HYBRID OF TARGETABLE SIRNA-LAYERED INORGANIC HYDROXIDE, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR TREATING TUMOR COMPRISING THE NANO-HYBRID

Applicant/Assignee: NANOHYBRID CO., LTD

Application No.: KR2009/005221   Filing Date: 14/Sep/2009

Abstract:The present invention relates to a nano-hybrid of siRNA (small interfering RNA) with a targetable layered inorganic hydroxide, which is a potent gene therapeutic agent, manufacturing method thereof, and pharmaceutical composition for treating tumor comprising a nano-hybrid of targetable siRNA-layered inorganic hydroxide. The nano-hybrid of the present invention improves the tumor-specific transfer efficiency due to an in vivo stability of siRNA composing a nano-hybrid with a layered inorganic hydroxide which links to a targetable multifunctional ligand capable of specific binding to a tumor marker, and thus, exercises an antitumor activity of siRNA at a dose of relatively low concentration. Therefore, the nano-hybrid of the present invention can be widely used in a general purpose targetable tumor therapy.

Priority:

Inventor: CHOY JIN-HO [KR]; PARK DAE-HWAN [KR]; CHO JAEYONG [KR]


Publication No.: WO2011030952A1  Published: 17/Mar/2011

Title: AQUEOUS COMPOSITION FOR ENTERIC HARD CAPSULES, PRODUCTION METHOD FOR ENTERIC HARD CAPSULES AND ENTERIC HARD CAPSULES

Applicant/Assignee: SAMSUNG FINE CHEMICALS CO., LTD

Application No.: KR2009/005870   Filing Date: 13/Oct/2009

Abstract:Disclosed are an aqueous composition for enteric hard capsules, a production method for enteric hard capsules and enteric hard capsules. The aqueous composition for the disclosed enteric hard capsules comprises an enteric base material, a capsule-moulding adjuvant and a neutralizing agent. Additionally, the production method for the disclosed enteric hard capsules comprises the steps of: producing an aqueous composition by dissolving an enteric base material, a capsule-moulding adjuvant, a neutralizing agent and other additives in water

pre-heating the aqueous composition to a temperature lower than its gelatinization temperature

immersing a mould pin, which has been heated to a temperature higher than the gelatinization temperature, into the aqueous composition

obtaining a film which has been formed on the mould pin by recovering the mould pin from the aqueous composition

and fixing and then drying the film on the mould pin by maintaining the film at a temperature at or above the gelatinization temperature for a predetermined time.

Priority: KR20090085876 Applic. Date: 2009-09-11

Inventor: SON JIN RYUL [KR]; BAEK HYON HO [KR]; LEE SUNG WAN [KR]; SONG MIN GYU [KR]; CHA JAE UK [KR]; PARK EUN HEE [KR]


Publication No.: WO2011031018A2  Published: 17/Mar/2011

Title: WATER-SOLUBLE DRUG DELIVERY SYSTEM ALLOWING SLOW RELEASE

Applicant/Assignee: HANNAM UNIVERSITY INSTITUTE FOR INDUSTRY-ACADEMIACOOPERATION

Application No.: KR2010/005476   Filing Date: 19/Aug/2010

Abstract:The present invention relates to a drug delivery system allowing slow release of the drug. A drug delivery system according to one embodiment of the present invention comprises an ion complex formed from a drug having a negative charge and a compound comprising multivalent cations. Because of the slow release action, the drug delivery system according to the embodiment is advantageous in that it can not only effectively deliver drugs to local affected areas but can also substantially reduce the frequency of drug therapy and in that it can substantially reduce the inconvenience of patients having to frequently attend hospital in order to treat pathologies and the consequent burden of medical expenses for patients.

Priority: KR20090086596 Applic. Date: 2009-09-14; KR20100079550 Applic. Date: 2010-08-17

Inventor: LEE JIN HO [KR]; LIM SUNG MOOK [KR]; OH SE HEANG [KR]


Publication No.: WO2011031116A2  Published: 17/Mar/2011

Title: PAD FOR HERBAL MEDICINE IN WHICH RELEASE OF MEDICINAL INGREDIENT CAN BE CONTROLLED, AND MANUFACTURING METHOD THEREOF

Applicant/Assignee:

Application No.: KR2010/006250   Filing Date: 14/Sep/2010

Abstract:The present invention relates to a method for manufacturing a pad for herbal medicine in which the release of medicinal ingredients can be controlled, which comprises the following steps of: separating two or more kinds of prescribed medicines or medicinal herbal ingredients prepared according to pharmacological effects, on the basis of the weight ratio of each medicinal ingredient to total weight of the prescribed medicinal ingredients

grinding said medicinal ingredients separated on the basis of weight ratio, wherein finely divided particles are separately ground according to the setting of efficacy release duration

preparing herbal medicine by mixing said ground medicinal ingredients together, and then mixing said ingredients with a binding agent

and adhering the herbal medicines prepared in the step of preparing herb medicine to a base sheet.

The pad for herbal medicine manufactured according to the method allows the persistence of the permeation of the medicine through the skin and the release rate of each medicinal ingredient to be different from each other in accordance with the kind of medicinal ingredient, and thus, the efficacy of the medicinal ingredient layer and the effect in treating disease are maximized.

Priority: KR20090086728 Applic. Date: 2009-09-14

Inventor: KIM HEE GU [KR]


Publication No.: WO2011031176A1  Published: 17/Mar/2011

Title: ORAL SUSPENSION FORMULATIONS OF ESCLICARBAZEPINE ACETATE

Applicant/Assignee: BIAL - PORTELA & C.A., S.A

Application No.: PT2010/000038   Filing Date: 10/Sep/2010

Abstract:An oral suspension formulation comprising eslicarbazepine acetate and a pharmaceutically acceptable liquid vehicle.

Priority: US20090241195P Applic. Date: 2009-09-10

Inventor: VASCONCELOS TEOFILO CARDOSO DE [PT]; SANTOS LIMA RICARDO JORGE DOS [PT]; CAMPOS COSTA RUI CERDEIRA DE [PT]; COSTA BARROCAS PEDRO MIGUEL DA [PT]; CASTRO PEREIRA LIGIA SOFIA DE [PT]


Publication No.: WO2011031284A1  Published: 17/Mar/2011

Title: POLYMERIC CARRIER COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS, METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: PHARMAIN CORPORATION

Application No.: US2010/000809   Filing Date: 17/Mar/2010

Abstract:In part, the present invention is directed to compositions and methods of making compositions comprising a polymeric backbone, a chelating group, a metal ion, and an active agent with a metal binding domain. The compositions can optionally further comprise protective side chains. In part, the present invention is directed to prolonging the blood circulation time of an active agent containing a metal binding domain by using a composition comprising a polymeric backbone with a protective chain, a chelator, and a metal ion.

Priority: US2009-556467 Applic. Date: 2009-09-09

Inventor: BOLOTIN ELIJAH M [US]; CASTILLO GERARDO M [US]; LAI MANSHUN [US]; NISHIMOTO-ASHFIELD AKIKO [US]


Publication No.: WO2011031441A1  Published: 17/Mar/2011

Title: THERAPY WITH A CHIMERIC MOLECULE AND A PRO-APOPTOTIC AGENT

Applicant/Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFHE

Application No.: US2010/046382   Filing Date: 23/Aug/2010

Abstract:The present invention provides compositions comprising a chimeric molecule comprising a cytotoxin that inhibits protein synthesis and an agent that inactivates an anti-apoptotic BCL-2 family member protein and methods of inhibiting the growth of or promoting the apoptosis of an aberrantly proliferating cell population by co-administering the chimeric molecule and the agent that inactivates an anti-apoptotic BCL-2 family member protein.

Priority: US20090238032P Applic. Date: 2009-08-28

Inventor: FITZGERALD DAVID J [US]


Publication No.: WO2011031462A2  Published: 17/Mar/2011

Title: COMPOSITIONS FOR DELIVERY OF INSOLUBLE AGENTS

Applicant/Assignee: LATITUDE PHARMACEUTICALS INCORPORATED

Application No.: US2010/046552   Filing Date: 24/Aug/2010

Abstract:Compositions and methods of making the same for improving the bioavailability of a substantially water-insoluble pharmacologically active agent are described. The composition includes a substantially water-insoluble pharmacologically active agent, and a substantially water-insoluble matrix forming material comprising enzyme digestible or bile soluble nutrients, wherein the substantially water-insoluble pharmacologically active agent is dispersed in a solid matrix and wherein said pharmacologically active agent in said matrix is substantially free of the original crystalline form.

Priority: US20090236865P Applic. Date: 2009-08-25

Inventor: CHEN HAILIANG [US]; CHEN ANDREW XIAN [US]


Publication No.: WO2011031476A2  Published: 17/Mar/2011

Title: COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF POST-OPERATIVE ORGAN OR TISSUE INFLAMMATION

Applicant/Assignee: EMORY UNIVERSITY

Application No.: US2010/046621   Filing Date: 25/Aug/2010

Abstract:Compositions, methods and kits for treatment or prevention of post operative organ or tissue inflammation are provided. The compositions contain an effective amount for local delivery, of an anti-inflammatory agent, alone or in combination with other pharmacologic agents, embedded within a polymeric matrix or gel. The polymeric matrix or gel may be a formed from natural or synthetic precursor components. The compositions are applied locally to an organ or tissue for the treatment or prevention of post inflammation resulting from surgical intervention.

Priority: US20090236726P Applic. Date: 2009-08-25

Inventor: YOO DALE [US]; WHALEN SEAN PATRICK [US]; LANGBERG JONATHAN [US]


Publication No.: WO2011031524A2  Published: 17/Mar/2011

Title: METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: US2010/046821   Filing Date: 26/Aug/2010

Abstract:Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Priority: US2009-549015 Applic. Date: 2009-08-27

Inventor: HIGGINS JOEL C [US]; WOODELL-MAY JENNIFER E [US]; HOEPPNER JACY [US]


Publication No.: WO2011031617A2  Published: 17/Mar/2011

Title: SEAMLESS ALGINATE CAPSULES

Applicant/Assignee: FMC CORPORATION

Application No.: US2010/047652   Filing Date: 02/Sep/2010

Abstract:The present invention is directed to a dried seamless capsule comprising an alginate shell membrane encapsulating fill material, wherein: (i) said alginate shell membrane comprises a polyvalent metal ion alginate having: (a) an average M content of from 50%-62% by weight based on the weight of the M and G content, and (b) a viscosity of 35 to 80 cps when measured as a monovalent metal ion alginate in a 3.5% water solution at 20 ?C using a Brookf?eld LV viscometer at 60 rpm and spindle #1

(ii) said alginate shell membrane encapsulates an oil present in an amount of at least 50% by weight of said fill material

(iii) said dried seamless capsule has a disintegration time of less than 12 minutes in an intestinal buffer after pretreatment for 20 minutes in a solution of 0.1 M NaCl and HCl, pH of 3, at 37 ?C

and (iv) said dried seamless capsule has a dry break force strength of at least 7kg. The present invention is also directed to methods of making and using such dried seamless capsules.

Priority: US20090241263P Applic. Date: 2009-09-10; US20090241266P Applic. Date: 2009-09-10

Inventor: GASEROD OLAV [NO]; LARSEN CHRISTIAN KLEIN [NO]; ANDERSEN PEDER OSCAR [NO]


Publication No.: WO2011031621A2  Published: 17/Mar/2011

Title: HIGH STRENGTH SEAMLESS ALGINATE CAPSULES

Applicant/Assignee: FMC CORPORATION

Application No.: US2010/047662   Filing Date: 02/Sep/2010

Abstract:The invention is directed to a seamless alginate capsule having a film encapsulating a fill material, in which the film comprises alginate, noncrystallizing plasticizer, and glycerol and in which a ratio by weight of noncrystallizing plasticizer to glycerol in the film is between about 1 :1 and about 8:1. The invention is also directed to a method of making the seamless alginate capsules and to capsules made by the method. The capsules have excellent breaking strength and are resistant to oxidation of the fill material.

Priority: US20090241266P Applic. Date: 2009-09-10; US20090241263P Applic. Date: 2009-09-10

Inventor: GASEROD OLAY [NO]; LARSEN CHRISTIAN KLEIN [NO]; ANDERSEN PEDER OSCAR [NO]


Publication No.: WO2011031849A2  Published: 17/Mar/2011

Title: ANIONIC LIPIDS AND LIPID NANOSTRUCTURES AND METHODS OF PRODUCING AND USING SAME

Applicant/Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Application No.: US2010/048254   Filing Date: 09/Sep/2010

Abstract:Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same..

Priority: US2009-556906 Applic. Date: 2009-09-10

Inventor: AWASTHI VIBHUDUTTA [US]; LAGISETTY PALLAVI [US]


Publication No.: WO2011031996A2  Published: 17/Mar/2011

Title: ENGINEERED MICROPARTICLES FOR MACROMOLECULE DELIVERY

Applicant/Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: US2010/048465   Filing Date: 10/Sep/2010

Abstract:A method for making a modified release composition, comprising: selecting a desired active agent and polymer matrix for formulating into a modified release composition

assessing degradation effect on release of the active agent from the composition including plotting polymer molecular weight (Mwr) at onset of active agent release vs. active agent molecular weight (MwA)

predicting performance of multiple potential formulations for the composition based on the degradation assessment and average polymer matrix initial molecular weight (Mwo) to define a library of building blocks

determining the optimal ratio of the building blocks to satisfy a specified release profile

and making a modified release composition based on the optimal ratio determination.

Priority: US20090241259P Applic. Date: 2009-09-10

Inventor: LITTLE STEVEN R [US]; ROTHSTEIN SAM [US]


Publication No.: WO2011032022A1  Published: 17/Mar/2011

Title: IMPROVED PSEUDOMONAS EXOTOXIN A WITH REDUCED IMMUNOGENICITY

Applicant/Assignee: THE GOVERNMENT OF THE UNITED STATES OF AMERICA ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OFHE

Application No.: US2010/048504   Filing Date: 10/Sep/2010

Abstract:The present invention provides improved Pseudomonas Exotoxin A (PE) molecules with high cytotoxicity and reduced immunogenicity, compositions containing the improved (PE), and methods of use.

Priority: US20090241620P Applic. Date: 2009-09-11

Inventor: PASTAN IRA H [US]; BEERS RICHARD [US]; ONDA MASANORI [US]


Publication No.: WO2011032229A1  Published: 24/Mar/2011

Title: A NOVEL EPSILON POLYMORPHIC FORM OF INULIN AND COMPOSITIONS COMPRISING SAME

Applicant/Assignee: VAXINE PTY LTD

Application No.: AU2010/001221   Filing Date: 17/Sep/2010

Abstract:A novel polymorphic form of inulin, designated epsilon inulin (eIN), is described along with methods for the preparation of eIN, compositions comprising eIN and uses thereof. Amongst the uses described is the stimulation of an immune response in a subject for the purposes of preventing or treating an infectious disease, autoimmune disease, immunodeficiency disorder, neoplastic disease, degenerative or ageing disease.

Priority: US20090243975P Applic. Date: 2009-09-18

Inventor: PETROVSKY NIKOLAI [AU]; COOPER PETER [AU]


Publication No.: WO2011032318A1  Published: 24/Mar/2011

Title: STABLE ARTESUNATE-AMODIAQUINE HYDROCHLORIDE COMPLEX TABLET AND PREPARATION METHOD THEREOF

Applicant/Assignee: SHANGHAI FOSUN OMNI PHARMACEUTICAL CO., LTD, GUILIN PHARMACEUTICAL CO., LTD, SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., LTD

Application No.: CN2009/074051   Filing Date: 21/Sep/2009

Abstract:The present invention provides an artesunate-amodiaquine hydrochloride complex tablet consisting of (parts by weight) artesunate (100), amodiaquine hydrochloride (352-353), pH regulator (45-55), filler (75-180), binder (5-35), disintegrant (70-80), glidant (3-13), and lubricant (5.7-10.7). The complex tablet is prepared by preparing artesunate and amodiaquine hydrochloride respectively into granules, and pressing into tablets. Artesunate is prepared into granules by using isopropanol as solvent. Calcium carbonate is used as a pH regulator in the complex tablet. The artesunate-amodiaquine hydrochloride complex tablet of the present invention has good stability, and is easy to produce and suitable for industrial production.

Priority:

Inventor: HE PING [CN]; QIAN XIAOMING [CN]


Publication No.: WO2011032386A1  Published: 24/Mar/2011

Title: OSMOTIC PUMP CONTROLLED RELEASE TABLET AND PREPARATION METHOD THEREOF

Applicant/Assignee: TEAM ACADEMY OF PHARMACEUTICAL SCIENCE

Application No.: CN2010/072316   Filing Date: 29/Apr/2010

Abstract:An osmotic pump controlled release tablet and the preparation method thereof are disclosed. The osmotic pump controlled release tablet is composed of tablet core, semipermeable membrane and optional film coating. The material of said semipermeable membrane is composed of ethyl cellulose and povidone in the ratio of 1:1 (approx.) 1:4 by weight. Said tablet core comprises drug containing layer and push layer. The osmotic pump controlled release table also characterizes in that: (1) the angle?1 formed by the outer curved surface and the side surface of the drug containing layer is 120 -180

and/or (2) the ratio of L1 to r is 0.27-1.0, wherein L1 is the vertical distance from the fixed-point of the outer curved surface to the surface formed by the outer curved surface and the side surface, and r is the radius of the tablet core.

Priority: CN20091177529 Applic. Date: 2009-09-15

Inventor: JIANG QINGWEI [CN]; YI WEIFENG [CN]; LIU QUANZHI [CN]; YANG WENBIN [CN]; ZHENG JUNLI [CN]


Publication No.: WO2011032416A1  Published: 24/Mar/2011

Title: PHARMACEUTICAL COMPOSITION CONTAINING DOPAMINE RECEPTOR AGONIST

Applicant/Assignee: ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD

Application No.: CN2010/074691   Filing Date: 29/Jun/2010

Abstract:A pharmaceutical composition containing dopamine receptor agonist, in specific, a solid oral dosage form containing ropinirole or the pharmaceutically acceptable salts thereof, is disclosed. Said composition contains, in terms of the total weight of the dosage form, 0.1%-20.0% of ropinirole or its salts, 0.5%-20% calcium carboxymethylcellulose, 70.0%-98.0% fillers, 0.0%-5.0% binders, 0.0%-3.0% glidants and 0.1%-1.5% lubricants. The preparation method thereof is to mix ropinirole or its salts, calcium carboxymethylcellulose, fillers, binders, glidants and lubricants, then compress the raw materials mixture to tablets. Alternatively, the preparation method is to make granules by dry granulating or wet granulating followed by drying process, then to compress the result mixture to tablets after lubricant is added to. The present invention can significantly improve the stability and quality of the product, and the storage requirement thereof would be less strict.

Priority: CN20091178687 Applic. Date: 2009-09-19

Inventor: YAN QIPING [CN]; DAI YONG [CN]; LI QIAOXIA [CN]; PENG JUNQING [CN]; HU GONGYUN [CN]


Publication No.: WO2011032907A1  Published: 24/Mar/2011

Title: SOLID PHARMACEUTICAL PREPARATIONS COMPRISING AMPHIPHILIC COPOLYMERS ON THE BASIS OF POLYETHERS IN COMBINATION WITH SURFACTANTS

Applicant/Assignee: BASF SE

Application No.: EP2010/063369   Filing Date: 13/Sep/2010

Abstract:The invention relates to formulations comprising preparations of active substances of low solubility in water in a polymer matrix of polyether copolymers, wherein the polyether copolymers are obtained by radically initiated polymerization of a mixture of 30 to 80% by weight of N-vinyl lactam, 10 to 50% by weight of vinyl acetate, and 10 to 50% by weight of a polyether, and of at least one surfactant in which the active substance of low solubility in water is amorphously present in the polymer matrix.

Priority: EP20090170706 Applic. Date: 2009-09-18

Inventor: KOLTER KARL [DE]; DJURIC DEJAN [DE]; FISCHER STEFAN [DE]


Publication No.: WO2011032916A1  Published: 24/Mar/2011

Title: PELLETS COATED WITH COATINGS CONTAINING ACTIVE SUBSTANCES

Applicant/Assignee: BASF SE

Application No.: EP2010/063393   Filing Date: 13/Sep/2010

Abstract:The invention relates to preparations of active substances of low solubility in water, made of carrier particles having coatings containing active substances, wherein the active substances of low solubility are embedded in coatings made of amphiphilic copolymers.

Priority: EP20090170553 Applic. Date: 2009-09-17

Inventor: KOLTER KARL [DE]; DJURIC DEJAN [DE]; FISCHER STEFAN [DE]; KARL MATTHIAS [DE]


Publication No.: WO2011033019A1  Published: 24/Mar/2011

Title: STABLE NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING AN INSULIN

Applicant/Assignee: NOVO NORDISK A/S

Application No.: EP2010/063610   Filing Date: 16/Sep/2010

Abstract:The invention describes a non-aqueous liquid pharmaceutical composition comprising at least one lipid and at least one insulin. Also described is a method of producing a pharmaceutical composition comprising a lipid and a method of purifying a lipid, a cosolvent, a surfactant or a pharmaceutical composition comprising a lipid.

Priority: EP20090170389 Applic. Date: 2009-09-16

Inventor: NAVER HELLE [DK]; FOEGER FLORIAN ANDERS [AT]; HOEG-JENSEN THOMAS [DK]; FYNBO CHARLOTTE HARKJAER [DK]


Publication No.: WO2011033068A1  Published: 24/Mar/2011

Title: LONG-ACTING Y2 RECEPTOR AGONISTS

Applicant/Assignee: NOVO NORDISK A/S

Application No.: EP2010/063707   Filing Date: 17/Sep/2010

Abstract:The present invention relates to PYY analogues or derivatives thereof comprising at least one alteration selected from the group consisting of substitutions, insertions, deletions and modifications and optionally a serum albumin binding side chain comprising an alkyl chain with at least 14 carbon atoms. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y2 receptor modulation.

Priority: EP20090170670 Applic. Date: 2009-09-18; US20090244511P Applic. Date: 2009-09-22; EP20090175893 Applic. Date: 2009-11-13; US20090261769P Applic. Date: 2009-11-17

Inventor: KOFOED JACOB [DK]; OLSEN JOERGEN [DK]; OESTERGAARD SOEREN [DK]; JOERGENSEN RASMUS [DK]


Publication No.: WO2011033085A1  Published: 24/Mar/2011

Title: RAPIDLY SOLUBLE SOLID PHARMACEUTICAL PREPARATIONS CONTAINING AMPHIPHILIC COPOLYMERS BASED ON POLYETHERS IN COMBINATION WITH HYDROPHILIC POLYMERS

Applicant/Assignee: BASF SE

Application No.: EP2010/063735   Filing Date: 17/Sep/2010

Abstract:The invention relates to dosage forms containing preparations of active substances having a low-solubility in water in a polymer matrix comprising amphiphilic polyether-copolymers and at least one hydrophilic polymer, the active substance having a low-solubility in water being present in the polymer matrix in an amorphous form.

Priority: EP20090170702 Applic. Date: 2009-09-18

Inventor: KOLTER KARL [DE]; DJURIC DEJAN [DE]; FISCHER STEFAN [DE]


Publication No.: WO2011033163A2  Published: 24/Mar/2011

Title: SOD-IMITATING METAL COMPLEXES

Applicant/Assignee: UNIVERSITAT DE VALENCIA

Application No.: ES2010/070607   Filing Date: 20/Sep/2010

Abstract:The present invention comprises a method for synthesizing metal complexes from macrocyclic polyazapyridinophanes, characterized in that said complexes imitate the enzyme superoxide dismutase (SOD). In addition, the present invention relates to the actual macrocyclic polyazapyridinophane metal compounds, to the metal complexes formed therefrom and to the use thereof in therapy for treating diseases in which the etiology is based on endogenous SOD activity anomalies, principally as anti-inflammatories, analgesics and antioxidants that protect against oxidative cell stress.

Priority: ES20090030712 Applic. Date: 2009-09-21

Inventor: GARCIA-ESPANA MONSONIS ENRIQUE [ES]; CLARES GARCIA MA PAZ [ES]; BLASCO LLOPIS SALVADOR [ES]; SOTO SORIANO CONCEPCION [ES]; GONZALEZ GARCIA JORGE [ES]; VERDEJO VIU BEGONA [ES]


Publication No.: WO2011033479A1  Published: 24/Mar/2011

Title: NOVEL ALDEHYDES AND NITRILES FROM ISOPHORONE, AND THE USE THEREOF IN PERFUMERY

Applicant/Assignee: V. MANE FILS

Application No.: IB2010/054213   Filing Date: 17/Sep/2010

Abstract:The invention relates to novel aldehydes and nitriles from isophorone with general formula (I) having a specific fragrance (Formula I) (I), as well as to the use of said compounds in perfumery.

Priority: FR20090056422 Applic. Date: 2009-09-18

Inventor: MURATORE AGNES [FR]; CHANOT JEAN-JACQUES [FR]


Publication No.: WO2011034039A1  Published: 24/Mar/2011

Title: ERADICATING AGENT AND ERADICATION METHOD FOR HELICOBACTER PYLORI

Applicant/Assignee: MEDICAL CARE PROTEOMICS BIOTECHNOLOGY CO., LTD

Application No.: JP2010/065787   Filing Date: 14/Sep/2010

Abstract:Disclosed is an eradicating agent for Helicobacter pylori, which comprises an ammonia- or ammonium ion-adsorbent. Also disclosed is an eradication method for H. pylori, which comprises introducing the aforesaid eradicating agent into the stomach infected with H. pylori. H. pylori can survive in the strongly acidic intragastric environment since this bacterium can produce ammonia from urea and thus neutralize gastric acid. According to the aforesaid eradication method, the eradicating agent comprising an ammonia- or ammonium ion-adsorbent (active carbon, silica gel, alumina, zeolite, a cation exchanger, etc.) is introduced into the stomach to adsorb ammonia or ammonium ion. Thus, the intragastric environment is changed so that H. pylori can hardly survive therein, thereby eradicating H. pylori.

Priority: JP20090214322 Applic. Date: 2009-09-16

Inventor: DEGUCHI KISABURO [JP]; NAGASAWA ATSUSHI [JP]


Publication No.: WO2011034105A1  Published: 24/Mar/2011

Title: MODIFIED ERYTHROPOIETIN TO WHICH WATER-SOLUBLE LONG-CHAIN MOLECULE IS ADDED

Applicant/Assignee: KANEKA CORPORATION

Application No.: JP2010/065976   Filing Date: 15/Sep/2010

Abstract:Disclosed is a pharmaceutical composition which contains erythropoietin as an active ingredient and exerts a hematopoietic effect that lasts for 7 days or more when administered to a human and/or an animal. Specifically disclosed are: a pharmaceutical composition that contains erythropoietin, to which two or more water-soluble long-chain molecules are added, in an amount of not less than 50% of the total erythropoietin

a pharmaceutical composition that contains erythropoietin to which a water-soluble long-chain molecule is added, said water-soluble long-chain molecule having a molecular weight of not less than 30 kDa

and a pharmaceutical composition that contains erythropoietin to which a water-soluble long-chain molecule is added, said water-soluble long-chain molecule having a branched chain.

Priority: JP20090213205 Applic. Date: 2009-09-15

Inventor: TANI NOBUTAKA [JP]; FUJII TOSHIHIDE [JP]; WATANABE HIROYUKI [JP]; MAEDA HIROFUMI [JP]


Publication No.: WO2011034192A1  Published: 24/Mar/2011

Title: LATANOPROST-CONTAINING AQUEOUS EYE DROPS AND METHOD FOR INHIBITING ADSORPTION OF LATANOPROST TO RESIN

Applicant/Assignee: SENJU PHARMACEUTICAL CO., LTD

Application No.: JP2010/066263   Filing Date: 17/Sep/2010

Abstract:Provided is a formulation of latanoprost-containing aqueous eye drops wherein decreases in effective latanoprost concentration due to adsorption to resin are inhibited and the stability of the latanoprost is improved. Also provided is a method for inhibiting adsorption of latanoprost to resin. The provided aqueous eye drops contain latanoprost, a surfactant, and a C3-10 aliphatic mono- or di-carboxylic acid or a salt thereof. The inclusion of a surfactant and either a C3-10 aliphatic mono- or di-carboxylic acid or a salt thereof allows the provision of a method for inhibiting the adsorption to resin of latanoprost in an aqueous solution.

Priority: JP20090216182 Applic. Date: 2009-09-17

Inventor: NAKAJIMA TOMOKO [JP]; ASAYAMA WAKIKO [JP]; TAJIKA TETSUYA [JP]


Publication No.: WO2011034323A2  Published: 24/Mar/2011

Title: TRANSDERMAL DELIVERY SYSTEM, METHOD FOR MANUFACTURING THE SAME, AND TRANSDERMAL DELIVERY METHOD USING THE SYSTEM

Applicant/Assignee: SAMYANG CORPORATION

Application No.: KR2010/006251   Filing Date: 14/Sep/2010

Abstract:Disclosed is a transdermal delivery systemof multiple adhesive layers having a drug-free adhesive layer as an intermediate layer to control drug delivery rate. The transdermal delivery system enhances transdermal delivery rate in the early stage after application on skin and provides sustained control of the drug delivery rate in the intermediate and later stages. Thus, the drug delivery rate effective for treatment can be controlled in a sustained manner.

Priority: US20090242854P Applic. Date: 2009-09-16; KR20090106090 Applic. Date: 2009-11-04

Inventor: LEE HEONHAN [KR]


Publication No.: WO2011034396A2  Published: 24/Mar/2011

Title: SOLID DISPERSION COMPRISING A FIBRATE DRUG, AND METHOD FOR PREPARING THE SOLID DISPERSION

Applicant/Assignee: SAMYANG CORPORATION

Application No.: KR2010/006464   Filing Date: 20/Sep/2010

Abstract:Provided are a solid dispersion and a method for preparing same. The solid dispersion is prepared by hot-melting a fibrate drug, a base material for polymer melt, a surfactant, and a polymer solubilizer. The solid dispersion comprises the fibrate drug which can be used in the treatment of hyperlipidemia and which is provided with improved bioavailability.

Priority: KR20090089048 Applic. Date: 2009-09-21

Inventor: KIM KYUNG-HEE [KR]; LEE HYUN-KI [KR]; PAI CHAUL-MIN [KR]


Publication No.: WO2011034465A1  Published: 24/Mar/2011

Title: A PHARMACEUTICAL COMPOSITION FOR PERORAL ADMINISTRATION OF DIINDOLYLMETHANE

Applicant/Assignee:

Application No.: RU2010/000487   Filing Date: 07/Sep/2010

Abstract:The invention relates to the field of pharmaceuticals. The invention describes block copolymer pharmaceutical compositions containing 3,3'-diindolylmethane (DIM). A pharmaceutical composition for peroral administration comprises 3,3'-diindolylmethane as active ingredient and a target additive, wherein said composition comprises, as target additive, a block copolymer of oxyethylene and oxypropylene, in which the hydrophobic block content is less than 50% by mass, and the molecular mass of the hydrophilic block is 2250 Da or more, given a ratio of active ingredient to the selected block copolymer of 10:1-2:1. The compositions improve the absorption of the active compound in the bloodstream when said active compound is administered perorally.

Priority: RU20090134872 Applic. Date: 2009-09-18

Inventor: KISELEV VSEVOLOD IVANOVICH [RU]; VASILYEVA IRINA GENNADIYEVNA [RU]


Publication No.: WO2011034513A1  Published: 24/Mar/2011

Title: THE GRANULES WITH IMPROVED SOLUBILITY AND STABILITY

Applicant/Assignee:

Application No.: TR2010/000167   Filing Date: 13/Aug/2010

Abstract:The present invention is related to the pharmaceutical compositions with improved solubility and stability properties comprising ramipril alone or in combination with a therapeutic agent such as HCTZ, preparation methods of these compositions and their medical use.

Priority: TR20090006322 Applic. Date: 2009-08-17

Inventor: BILGIC MAHMUT [TR]


Publication No.: WO2011034551A2  Published: 24/Mar/2011

Title: PHARMACEUTICAL FORMULATIONS COMPRISING 9-CIS-RETINYL ESTERS IN A LIPID VEHICLE

Applicant/Assignee: QLT INC

Application No.: US2009/059126   Filing Date: 30/Sep/2009

Abstract:Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.

Priority: US20090242741P Applic. Date: 2009-09-15

Inventor: BOCH RONALD ERWIN [CA]


Publication No.: WO2011034604A2  Published: 24/Mar/2011

Title: STABLE CO-FORMULATION OF HYALURONIDASE AND IMMUNOGLOBULIN, AND METHODS OF USE THEREOF

Applicant/Assignee: BAXTER HEALTHCARE, S.A, BAXTER INTERNATIONAL, INC

Application No.: US2010/002545   Filing Date: 16/Sep/2010

Abstract:Provided herein are stable co-formulations of immunoglobulin and hyaluronidase that are stable to storage in liquid form at room temperature for at least 6 months and at standard refrigerator temperatures for 1-2 years. Such co-formulations can be used in methods of treating IG-treatable diseases or conditions by subcutaneous administration.

Priority: US20090277045P Applic. Date: 2009-09-17

Inventor: TESCHNER WOLFGANG [AT]; SVATOS SONJA [AT]; BRUCKSCHWAIGER LEOPOLD [AT]; WEBER ALFRED [AT]; SCHWARZ HANS-PETER [AT]; LEI LAURA [US]


Publication No.: WO2011035065A1  Published: 24/Mar/2011

Title: MONOCONJUGATED CHITOSANS AS DELIVERY AGENTS FOR SMALL INTERFERING NUCLEIC ACIDS

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: US2010/049179   Filing Date: 16/Sep/2010

Abstract:Conjugates are provided, an exemplary conjugating having a single water-soluble, non-peptidic polymer, such as a poly( ethylene oxide), attached to a chitosan. Complexes of small interfering nucleic acids formed with such conjugates as well as small interfering nucleic acids attached to such conjugates are also provided. Related methods, intermediates, and compositions are also provided.

Priority: US20090243516P Applic. Date: 2009-09-17

Inventor: MCMANUS SAMUEL P [US]; KOZLOWSKI ANTONI [US]; YOUSO PATRICK D [US]


Publication No.: WO2011035279A2  Published: 24/Mar/2011

Title: NANOCARRIERS FOR IMAGING AND THERAPY APPLICATIONS

Applicant/Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Application No.: US2010/049572   Filing Date: 21/Sep/2010

Abstract:Nanocarriers and methods of preparation and use of nanocarriers are presented. In some embodiments, a nanocarrier composition comprises an organic liquid comprising a plurality of nanoparticles dispersed therein

and a coating material disposed around the exterior surface of the organic liquid.. Biological tissue may be imaged or treated by coming into contact with a nanocarrier composition, and, at least in some embodiments, irradiated.

Priority: US20090244088P Applic. Date: 2009-09-21

Inventor: EMELIANOV STANISLAV [US]; WILSON KATHERYNE [US]; HOMAN KIMBERLY [US]


Publication No.: WO2011035321A1  Published: 24/Mar/2011

Title: TREATMENT OF WNT/FRIZZLED-RELATED DISEASES

Applicant/Assignee: DUKE UNIVERSITY

Application No.: US2010/049693   Filing Date: 21/Sep/2010

Abstract:Methods of treating Wnt/Frizzled-related diseases, comprising administering niclosamide compounds are provided. Methods of predicting whether a disease will respond to treatment with a niclosamide compound are also provided.

Priority: US20090244399P Applic. Date: 2009-09-21

Inventor: CHEN WEI [US]; CHEN MINYONG [US]; LYERLY H KIM [US]; BARAK LAWRENCE S [US]; MOOK ROBERT [US]; OSADA TAYUKA [US]; MORSE MICHAEL A [US]


Publication No.: WO2011035988A1  Published: 31/Mar/2011

Title: ANTISEPTIC OINTMENT COMPRISING BENTONITE INTERCALATED WITH SILVER, COPPER OR ZINC FOR EXTERNAL APPLICATION

Applicant/Assignee: CLOSED STOCK COMPANY "INSTITUTE OF APPLIED NANOTECHNOLOGY", FONDAZIONE SALVATORE MAUGERI CLINICA DEL LAVORO EDELLA RIABILITAZIONE I.R.C.C.S, SIB LABORATORIES LIMITED

Application No.: EP2010/061992   Filing Date: 17/Aug/2010

Abstract:The invention concerns antiseptic ointments for external application comprising, as a basis, pharmaceutical Vaseline or a mix of pharmaceutical Vaseline with lanoline, and, as the antiseptic agent, a dispersed bentonite powder intercalated by one or more metal ions selected in the group consisting of Ag+, Cu2+, Zn2+. In addition the ointment contains an etheric vegetable oil. More precisely the active antiseptic agent may be: a dispersed bentonite powder intercalated by ions of Ag+ or by ions of Cu2+ or by a mix of said bentonites. According to an anternative the antiseptic dispersed bentonite powder may be intercalated by ions of Ag+ and Zn2+ or by ions of Cu2+ and Zn2+ or by ions of Ag+, Cu2+ and Zn2+. In any case the total content of metals in the composition of ointment is comprised between 0,05-0,5%. The ointments according to the invention are biologically compatible with various integuments of humans and animals and provide a prolonged antiseptic action at low expenses.

Priority: RU20090135436 Applic. Date: 2009-09-24

Inventor: BARBAKOV VLADIMIR ILYCH [RU]; BEKLEMYSHEV VIACHESLAV IVANOVICH [RU]; BEKLEMYSHEVA EVGENIYA FEDOROVNA [RU]; MAKHONIN IGOR IVANOVICH [RU]; MAUGERI UMBERTO ORAZIO GIUSEPPE [IT]; MESHKOVA IRINA MIHAILOVNA [RU]; SOLODOVNIKOV VLADIMIR ALEKSANDROVICH [RU]


Publication No.: WO2011036191A2  Published: 31/Mar/2011

Title: GOLD -COATED MAGNETIC GLYCONANOPARTICLES FUNCTIONALISED WITH PROTEINS FOR USE AS DIAGNOSTIC AND THERAPEUTIC AGENTS

Applicant/Assignee: ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA ENBIOMATERIALES - CIC BIOMAGUNE

Application No.: EP2010/064012   Filing Date: 23/Sep/2010

Abstract:Gold-coated nanoparticles comprising: a) a magnetic core Of XFe2O4 wherein X is a metal selected from the group consisting of Fe, Mn, and Co

b) carbohydrates covalently coupled through a spacer to the gold-coated nanoparticle, wherein said spacer has a thiol linking it to the nanoparticle

and c) an immunoglobulin-binding protein coupled to the gold-coated nanoparticle through an amphiphilic molecule, comprising a functional group capable of coupling the protein and through a thiol group which is attached to the gold coating of the nanoparticle, where a immunoglobulin-binding protein can be coupled to further bioconjugation with antibodies. Said nanoparticles have been found to be useful as contrast agents by MRI.

Priority: EP20090382185 Applic. Date: 2009-09-25

Inventor: PENADES ULLATE SOLEDAD [ES]; GARCIA MARTIN ISABEL [ES]; GALLO PARAMO JUAN [ES]


Publication No.: WO2011036357A2  Published: 31/Mar/2011

Title: STABLE, LIQUID, READY-TO-USE KETOPROFEN FORMULATION

Applicant/Assignee: MACO PHARMA

Application No.: FR2010/000641   Filing Date: 27/Sep/2010

Abstract:The invention relates to a stable, liquid, ready-to-use ketoprofen formulation for parenteral administration, including ketoprofen dissolved in a solely aqueous solvent to which a buffering agent has been added, said formulation being adjusted to a pH greater than 5.5 and less than 6.5.

Priority: FR20090004622 Applic. Date: 2009-09-28

Inventor: DOULEAU DIDIER [FR]; RENARD JULIEN [FR]


Publication No.: WO2011036400A1  Published: 31/Mar/2011

Title: GALENIC FORM SUITABLE FOR ABSORBING, IN A SPECIFIC MANNER, THE UNDESIRABLE MOLECULES IN THE DIGESTIVE TRACT

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -

Application No.: FR2010/051976   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a galenic form including particles capable of adsorbing, in a specific manner, the undesirable molecules in the digestive tract, to a method for preparing same and to the use thereof mainly for manufacturing a drug intended for preventing or treating undesirable effects associated with an imbalance of the intestinal and/or colic flora as a result, for example, of antibiotic therapy.

Priority: FR20090056542 Applic. Date: 2009-09-23

Inventor: FATTAL ELIAS [FR]; TSAPIS NICOLAS [FR]; REYNAUD FRANCELINE [BR]


Publication No.: WO2011036457A1  Published: 31/Mar/2011

Title: PEPTIDE CLEARING AGENTS

Applicant/Assignee: MOLOGIC LTD

Application No.: GB2010/001796   Filing Date: 23/Sep/2010

Abstract:A peptide clearing agent is provided for clearance of a conjugate of an enzyme and a binding molecule which binds specifically at a target location from a non-target location in a subject. The peptide clearing agent binds the active site of the enzyme. The peptide also binds to the asialoglycoprotein receptor expressed by hepatic cells to facilitate clearance through the liver. The peptide may be glycosylated to facilitate clearance through the liver by binding to hepatic cells expressing an asialoglycoprotein receptor. Typically, the peptide prevents or inhibits enzyme activity upon binding to the enzyme and is not substantially modified by the enzyme activity. The peptide may be based upon the dipeptide amino-naphthoic acid (ANA) - glutamate (GIu) and may comprise the amino acid sequence serine (Ser) - Alanine (Ala) - amino-naphthoic acid (ANA) - glutamate (GIu). In such cases, the enzyme of interest is typically CPG2.

Priority: GB20090016749 Applic. Date: 2009-09-23

Inventor: DAVIS PAUL JAMES [GB]; SCHOUTEN JAMES ALEXANDER [GB]


Publication No.: WO2011036467A1  Published: 31/Mar/2011

Title: PRODUCTS USEFUL IN THE TREATMENT OF HAEMOPHILIA

Applicant/Assignee:

Application No.: GB2010/051420   Filing Date: 26/Aug/2010

Abstract:Factor VIII bound to a lymphotoxin is useful in treating haemophilia A inhibitors. The lymphotoxin may be selected from corticosteroids, vincristine, rituxiMab, or any other agent which causes lymphocyte cell death. The lymphotoxin may be bound to Factor VIII directly, via a linker, via an antibody, or by other suitable methods. The invention allows targeted and safe treatment. Similarly, Factor IX bound to a lymphotoxin is useful in treating haemophilia B inhibitors.

Priority: US20090245341P Applic. Date: 2009-09-24

Inventor: KEENAN RUSSELL DAVID [GB]


Publication No.: WO2011036521A2  Published: 31/Mar/2011

Title: FORMULATIONS COMPRISING TRIPTAN COMPOUNDS

Applicant/Assignee: DR. REDDY'S LABORATORIES LIMITED

Application No.: IB2010/001708   Filing Date: 17/Jun/2010

Abstract:The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Priority: WO2010US38838 Applic. Date: 2010-06-16; US20100292206P Applic. Date: 2010-01-05; US20100292213P Applic. Date: 2010-01-05; US2010-816904 Applic. Date: 2010-06-16; IN2009CH02337 Applic. Date: 2009-09-25; IN2009CH02607 Applic. Date: 2009-10-27

Inventor: GANDHI RAJESH [IN]; MANIKONDA SREEKANTH [IN]; JANA ARUN [IN]; KUNTE SAMEER SHRINIVAS [IN]


Publication No.: WO2011036557A1  Published: 31/Mar/2011

Title: COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES

Applicant/Assignee: THE UNIVERSITY OF BRITISH COLUMBIA

Application No.: IB2010/002518   Filing Date: 22/Sep/2010

Abstract:Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject

Priority: US20090277306P Applic. Date: 2009-09-22; US20100400763P Applic. Date: 2010-07-30; US20100400758P Applic. Date: 2010-07-30; US20090277307P Applic. Date: 2009-09-22

Inventor: LIN PAULO J C [CA]; TAM YUEN YI C [CA]; MASUNA SRINIVASULU [CA]; CIUFOLINI MARCO [CA]; ROBERGE MICHEL [CA]; CULLIS PIETER R [CA]


Publication No.: WO2011036560A2  Published: 31/Mar/2011

Title: GLYCOCONJUGATE COMPOSITIONS AND METHODS FOR TREATMENT OF HIV

Applicant/Assignee: NOVARTIS AG

Application No.: IB2010/002541   Filing Date: 21/Sep/2010

Abstract:Compounds are provided which are glycoconjugate compositions having oligosaccharides bound to multivalent structures for use in vaccines and binding to antibodies.

Priority: US20090277326P Applic. Date: 2009-09-23

Inventor: COSTANTINO PAOLO [IT]; KABANOVA ANNA [IT]


Publication No.: WO2011036599A1  Published: 31/Mar/2011

Title: A DISSOLVABLE FILM STRIP COMPRISING NATURAL COMPONENTS

Applicant/Assignee: YEDITEPE UNIVERSITESI

Application No.: IB2010/054121   Filing Date: 14/Sep/2010

Abstract:The present invention relates to film strips which comprise natural product formulations and can be absorbed from oral mucosa. The said film strip can be used with the aim of preventing and treating diseases in a short time, by being absorbed rapidly when it is applied from the oral mucosa at lower dosages than the dosage forms known.

Priority: TR20090007338 Applic. Date: 2009-09-28

Inventor: YESILADA ERDEM [TR]; DUMAN GULENGUL [TR]


Publication No.: WO2011036676A2  Published: 31/Mar/2011

Title: STABLE COCRYSTALS OF TEMOZOLOMIDE

Applicant/Assignee:

Application No.: IN2010/000613   Filing Date: 14/Sep/2010

Abstract:Disclosed herein are novel pharmaceutical cocrystals of temozolomide using co-crystal coformers selected from aliphatic and aromatic carboxylic acids in fixed stoichiometric ratio. The novel Temozolomide-carboxylic acid cocrystals exhibit improved hydrolytic stability and good aqueous dissolution rate compared to the pure drug.

Priority: IN2009CH02303 Applic. Date: 2009-09-23

Inventor: NANGIA ASHWINI [IN]; NANUBOLU JAGADEESH BABU [IN]; SANPHUI PALASH [IN]


Publication No.: WO2011036677A2  Published: 31/Mar/2011

Title: SUSTAINED RELEASE COMPOSITION OF RANOLAZINE

Applicant/Assignee: LUPIN LIMITED

Application No.: IN2010/000628   Filing Date: 16/Sep/2010

Abstract:The present invention relates to sustained release dosage form of Ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof which comprises a combination of at least two pH-dependent binders and optionally one or more pharmaceutically acceptable excipient(s).

Priority: IN2009MU02250 Applic. Date: 2009-09-25

Inventor: BHASALE KETAN [IN]; NAYAK RAGHAVENDRA [IN]; DAS SUBHASIS [IN]; THOMMANDRU VIJAYA KUMAR [IN]


Publication No.: WO2011036811A1  Published: 31/Mar/2011

Title: TURMERIC PIGMENT COMPOSITION AND METHOD FOR PREPARING SAME

Applicant/Assignee: SAN-EI GEN F.F.I., INC

Application No.: JP2009/066823   Filing Date: 28/Sep/2009

Abstract:Disclosed is a turmeric (Curcuma longa L.) pigment composition. Specifically disclosed is a turmeric pigment composition, by which the aggregation or sedimentation of turmeric pigment over time can be effectively prevented even in the case of adding turmeric pigment to a solvent to give a high content and which exhibits good color development and enables clear and stable coloring in a light color tone that cannot be achieved by the conventional techniques. Also disclosed is a method for preparing the turmeric pigment composition. The turmeric pigment composition is prepared by adding turmeric pigment to an aqueous solution containing ghatti gum and then grinding the turmeric pigment in the solution until the average particle diameter thereof falls 1 [mu]m or below.

Priority:

Inventor: MIUCHI TAKESHI [JP]; NISHINO MASAYUKI [JP]; SASAKI YASUSHI [JP]; MORIMOTO TAKASHI [JP]; TANAKA YOSHIHARU [JP]


Publication No.: WO2011036879A1  Published: 31/Mar/2011

Title: TRANSFERRIN LIPOSOME PREPARATION

Applicant/Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Application No.: JP2010/005752   Filing Date: 22/Sep/2010

Abstract:Disclosed is a transferrin liposome preparation which has an anti-cancer agent encapsulated therein and of which the timing of administration is optimized. Specifically disclosed is a transferrin liposome preparation comprising a liposome having transferrin bound thereto through NGPE and an anti-cancer agent such as L-OHP encapsulated in the liposome. The transferrin liposome preparation is characterized by being used so that the preparation is administered at a time point at which the expression of TfR1 is increased or so administered as to coincide with the circadian expression of C-Myc.

Priority: US20090244553P Applic. Date: 2009-09-22

Inventor: OHDO SHIGEHIRO [JP]; MATSUNAGA NAOYA [JP]; KOYANAGI SATORU [JP]


Publication No.: WO2011037157A1  Published: 31/Mar/2011

Title: EYE DROPS

Applicant/Assignee: SANTEN PHARMACEUTICAL CO., LTD

Application No.: JP2010/066488   Filing Date: 24/Sep/2010

Abstract:The purpose of this invention is to maximize the efficacy of, minimize the incidence of adverse effects from, and improve the storage stability of eye drops that contain: a peptide (SSSR), the amino acid sequence of which is represented by Ser-Ser-Ser-Arg, or a pharmacologically-permitted salt thereof

and a peptide (FGLM), the amino acid sequence of which is represented by Phe-Gly-Leu-Met-NH2, or a pharmacologically-permitted salt thereof. The concentration ratio between the SSSR or pharmacologically-permitted salt thereof and the FGLM or pharmacologically-permitted salt thereof is between 1/15 and 1/50. The concentration of the SSSR or pharmacologically-permitted salt thereof is between 0.001% and 0.3% (w/v) and the concentration of the FGLM or pharmacologically-permitted salt thereof is between 0.015% and 1.5% (w/v). The pH of the eye drops is maintained between 2.5 and 6.5.

Priority: JP20090220235 Applic. Date: 2009-09-25

Inventor: NAKAMURA TAKAHIRO [JP]; NAKADA YUICHIRO [JP]; NAGANO TAKASHI [JP]; NAKAMURA MASATSUGU [JP]


Publication No.: WO2011037252A1  Published: 31/Mar/2011

Title: LIPOSOME PREPARATION CONTAINING SPICAMYCIN DERIVATIVE

Applicant/Assignee: TERUMO KABUSHIKI KAISHA, KYOWA HAKKO KIRIN CO., LTD

Application No.: JP2010/066808   Filing Date: 28/Sep/2010

Abstract:Disclosed is a liposome preparation in which a poorly water-soluble spicamycin derivative (KRN5500) can be retained stably, and which can exhibit excellent accumulation in blood when the constitutional proportions of a phospholipid and other lipids, which are membrane-constituting components, and the length of an acyl chain in the phospholipid are controlled properly and can also release KRN5500 with high efficiency in an affected part. The liposome preparation comprises a liposome and a spicamycin derivative represented by chemical formula (I) and carried on the liposome, wherein the liposome comprises 0 to 50 mol% of cholesterol and 100 to 50 mol% of a phospholipid having an acyl chain that is an acyl chain contained in a saturated C14-C18 fatty acid. (In the formula, R1 represents H

R2 represents OH

and R represents a linear or branched alkyl group having 9 to 15 carbon atoms or a linear alkenyl group having 10 to 17 carbon atoms.)

Priority: JP20090223004 Applic. Date: 2009-09-28

Inventor: YAMASHITA KEIKO [JP]; NOZAWA SHIGENORI [JP]; MIWA ATSUSHI [JP]


Publication No.: WO2011037281A1  Published: 31/Mar/2011

Title: SLOW-RELEASE CILOSTAZOL TABLET HAVING AN IMPROVED ELUTION RATE AND MINIMAL SIDE EFFECTS

Applicant/Assignee: KOREA UNITED PHARM, INC

Application No.: KR2009/005420   Filing Date: 23/Sep/2009

Abstract:The present invention relates to a slow-release tablet of cilostazol which is a pharmacologically active component efficacious in the suppression of blood platelet aggregation and the promotion of vascular relaxation by inhibiting phosphodiesterase types

and, more specifically, provided is a slow-release cilostazol tablet of which the elution time is extended such that it can be taken once a day for expediency of drug-taking, and which minimises the occurrence of headache which is a side effect during the taking of cilostazol preparations of the prior art and therefore improves the convenience of drug-taking for women, the elderly and children. Also provided is a slow-release cilostazol tablet which exhibits a stable elution pattern without any variation in the percentage eluted depending on the pH in the stomach in addition to an effect whereby release of the drug is delayed, by using a release-controlling polymer consisting of a mixture of hydroxypropyl methyl cellulose and a carbomer.

Priority:

Inventor: CHOI YOUN-WOONG [KR]; MIN BYUNG-GU [KR]; CHO SANG-MIN [KR]


Publication No.: WO2011037349A2  Published: 31/Mar/2011

Title: TARGET SPECIFIC DRUG DELIVERY SYSTEM, TARGET NON-SPECIFIC LONG-ACTING DRUG DELIVERY SYSTEM AND METHOD OF CONTROLLING TARGET SPECIFICITY THEREOF

Applicant/Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION

Application No.: KR2010/006270   Filing Date: 14/Sep/2010

Abstract:The present invention relates to a method of controlling the target specificity of drug delivery system including the hyaluronic acid (HA) derivative, a target specific drug delivery system and a target non-specific long-acting drug delivery system. The regulation of the substitution ratio of carboxyl group in HA derivative controls the target specific or target non-specific long-acting property of the drug delivery system including the HA derivative.

Priority: KR20090090113 Applic. Date: 2009-09-23

Inventor: HAHN SEI-KWANG [KR]; YOON SEUNG KYU [KR]; HUR WONHEE [KR]; KIM KI SU [KR]


Publication No.: WO2011037550A2  Published: 31/Mar/2011

Title: DRY POWDER COMBINATION OF TIOTROPIUM

Applicant/Assignee:

Application No.: TR2010/000184   Filing Date: 22/Sep/2010

Abstract:The present invention relates to a pharmaceutical composition containing tiotropium formulated with an effective amount of a cromolyn derivative used for the treatment of respiratory disease by inhalation route.

Priority: TR20090007237 Applic. Date: 2009-09-23

Inventor: MAHMUT BILGIC [TR]


Publication No.: WO2011037589A1  Published: 31/Mar/2011

Title: SCENTED AND/OR FLAVOURED COTTON AND PRODUCTS THEREFROM

Applicant/Assignee:

Application No.: US2009/058610   Filing Date: 28/Sep/2009

Abstract:The invention relates to a scented and/or flavoured and/or colored and/or taste altered cotton and products made therefrom, methods of making the cotton and the cotton products, and methods of using the cotton and cotton products.

Priority:

Inventor: EICHELBERGER JOHN EDWARD [US]; RHEE HYOP SEUNG [US]


Publication No.: WO2011037896A2  Published: 31/Mar/2011

Title: POLYPEPTIDE MODIFICATION

Applicant/Assignee: VYBION, INC

Application No.: US2010/049599   Filing Date: 21/Sep/2010

Abstract:The invention provides methods for the PEGylation of an N-terminal cysteine of a polypeptide such that the thiol group of the cysteine is unreacted in the final PEGylated polypeptide. In one embodiment, the invention comprises a method of PEGylating a polypeptide having an N-terminal cysteine, the method comprising: contacting the polypeptide with a polyethylene glycol (PEG) derivative having a free aldehyde group in a reaction mixture under reducing conditions such that the N-terminal cysteine in the resultant PEGylated polypeptide has a free thiol group.

Priority: US20090245777P Applic. Date: 2009-09-25

Inventor: HENDERSON LEE A [US]; FLETCHER G SCOTT [US]


Publication No.: WO2011037908A1  Published: 31/Mar/2011

Title: INJECTABLE AQUEOUS OPHTHALMIC COMPOSITION AND METHOD OF USE THEREFOR

Applicant/Assignee: ALCON RESEARCH, LTD

Application No.: US2010/049623   Filing Date: 21/Sep/2010

Abstract:The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.

Priority: US20090244916P Applic. Date: 2009-09-23

Inventor: CHOWHAN MASOOD A [US]; HOHMAN THOMAS C [US]; CASTILLO ERNESTO J [US]; HAN WESLEY WEHSIN [US]


Publication No.: WO2011037976A2  Published: 31/Mar/2011

Title: PRAMIPEXOLE PHARMACEUTICAL FORMULATIONS

Applicant/Assignee: DR. REDDY'S LABORATORIES LIMITED, DR. REDDY'S LABORATORIES, INC

Application No.: US2010/049785   Filing Date: 22/Sep/2010

Abstract:Aspects of the present application relate to pharmaceutical formulations comprising pramipexole or pharmaceutically acceptable salts thereof, methods for manufacturing the same, and uses thereof. Further aspects relate to stable extended release formulations for oral administration comprising pramipexole or pharmaceutically acceptable salts thereof and microcrystalline cellulose, methods for manufacturing the same, and uses thereof.

Priority: IN2009CH02286 Applic. Date: 2009-09-22; US20100311534P Applic. Date: 2010-03-08; IN2010CH02570 Applic. Date: 2010-09-03

Inventor: MOVVA SNEHALATHA [IN]; JOSHI HEMANTH PRAKASH [IN]; KHARWADE PRAMOD [IN]; NARAYANAN BADRI VISHWANATHAN [IN]; MOLUGU PRASHANTH REDDY [IN]; VURE PRASAD [IN]; SHAREEF MD AJMAL [IN]; VYSYARAJU NAGESWARA RAO [IN]; SINGH PREM PRAKASH [IN]; YEOLA BHUSHAN SUBHASH [IN]; BHAGWATWAR HARSHAL PRABHAKAR [IN]


Publication No.: WO2011038117A2  Published: 31/Mar/2011

Title: CHEMICALLY AMPLIFIED RESPONSE STRATEGIES FOR MEDICAL SCIENCES

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/049996   Filing Date: 23/Sep/2010

Abstract:Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.

Priority: US20090244886P Applic. Date: 2009-09-23

Inventor: ALMUTAIRI ADAH [US]; FOMINA NADEZDA [US]; SANKARANARAYANAN JAGADIS [US]


Publication No.: WO2011038278A2  Published: 31/Mar/2011

Title: MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: US2010/050276   Filing Date: 24/Sep/2010

Abstract:The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) ("PEG-b-PLA") micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor TM EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailabilty without causing toxicity.

It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations.

Priority: US20090245918P Applic. Date: 2009-09-25; US20100375681P Applic. Date: 2010-08-20

Inventor: KWON GLEN S [US]


Publication No.: WO2011038356A2  Published: 31/Mar/2011

Title: NOVEL LIVER-TARGETING AGENTS AND THEIR SYNTHESIS

Applicant/Assignee: JOHNS HOPKINS UNIVERSITY, INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN

Application No.: US2010/050424   Filing Date: 27/Sep/2010

Abstract:This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in Ne-benzyloxycarbonyl-Na-dicarboxymethyl-L-lysine can be conjugated with three glycosides of ahGalNAc or ahLac in one step. This invention also provides a hexa-lactoside. In particular, the TFA- AH A- Asp was used to conjugate 2 moles of NTA(ahLac)3. This invention also provides a method for adding a spacer between NTA and DTPA. The extended hepatocyte-specific glyco-ligand has higher 111In-radiolabelling yield than those non-extended.

Priority: US20090245711P Applic. Date: 2009-09-25

Inventor: LEE REIKO TAKASAKA [US]; LEE YUAN-CHUAN [US]; WANG MEI-HUI; LIN WUU-JYH

WORLD PATENTS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL ACTIVES PUBLISHED IN 2011
This list includes patent documents published by the World Intellectual Property Organization (WIPO). The list was retrieved by searching the claims section of all patent applications. Salient
search terms included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained
drug release; polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal,
nasal, ocular or buccal administration of medications, etc.
World Patents in Excipients, Delivery and Release of Pharmaceutical
Compositions and Actives Published in 2011
Clck to enlarge and view details
World  Patents Published  in 2012
 
World  Patents Published  in 2011 - Page 2
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..